ࡱ>  )` Rdbjbj{{%%&)&)&)&)&)&)&):)&h&h&h8^htm|:)EZ}L}"}}}gYT,CCCCCCC$iJhLCM&)E"gC&)&)}}}CE&)}&)}CC*&)&)}N} )&h|RLHYE0EB[M [M[M&) ـ(<DžـــCCXـــE:):)$^/dnd:):)^/:):):)&)&)&)&)&)&) Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.q\qge兡N gPlQSShandong Xinhua Pharmaceutical Company Limiteda joint stock company established in the People s Republic of China with limited liability Stock Code: 0719 2014 INTERIM RESULTS ANNOUNCEMENTThe board of directors (the  Board ) and directors (Directors) of Shandong Xinhua Pharmaceutical Company Limited (the Company or Xinhua Pharm) hereby announce the unaudited consolidated results of the Company and its subsidiaries (the Group) for the six months ended 30 June 2014 (the Reporting Period). The following financial information has been prepared in accordance with Hong Kong Generally Accepted Accounting Principles (HKGAAP) and PRC accounting standards. This results announcement (the Announcement) is summarised from the Companys 2014 interim report (the Interim Report) and investors are advised to read the full text of the Interim Report for full information. The Announcement is published in Chinese and English. The Chinese version shall prevail if there are discrepancies between the Chinese version and the English version. I. COMPANY INFORMATIONChinese Name of the Company : q\qge兡N gPlQSEnglish Name of the Company: SHANDONG XINHUA PHARMACEUTICALCOMPANY LIMITEDLegal Representative: Mr. Zhang DaimingCompany Secretaries: Mr. Cao Changqiu, Ms. Guo LeiTelephone Number: 86-533-2196024Facsimile Number: 86-533-2287508E-mail Address of Company Secretaries: cqcao@xhzy.com, H HYPERLINK "mailto:guolei@xhzy.com" guolei@xhzy.comRegistered Address: Chemical Industry Area of Zibo Hi-tech Industry Development Zone, Zibo City, Shandong Province, the Peoples Republic of China (the PRC)Office Address: No. 1 Lutai Ave., Hi-tech Industry Development Zone, Zibo City, Shandong Province, the PRCPostal Code: 255086Website of the Company: H HYPERLINK "" E-mail Address of the Company: H HYPERLINK "mailto:xhzy@xhzy.com" Uxhzy@xhzy.comUPRC newspaper for information disclosure: Securities TimesWebsite designated by the China Securities Regulatory Commission (the CSRC): H HYPERLINK "http://www.cninfo.com.cn" http://www.cninfo.com.cnListing InformationH SharesStock Exchange: The Stock Exchange of Hong Kong Limited (the SEHK)Abbreviated Name: Shandong XinhuaStock Code: 0719A SharesStock Exchange: Shenzhen Stock ExchangeAbbreviated Name: Xinhua PharmStock Code: 000756a!. SUMMARY OF FINANCIAL RESULTS(i) In accordance with PRC accounting standards (Renminbi ( RMB ))ItemAs at 30 June 2014(Unaudited)As at 31 December 2013(the  End of Last Year )(Audited)Change as compared to the End of Last Year (%)Total assets3,931,313,448.52 3,849,353,234.20 2.13 Total equity attributable to equity holders of Company1,787,461,693.61 1,759,529,934.58 1.59 Capital457,312,830.00 457,312,830.00 - Net assets per share attributable to equity holders of Company3.913.85 1.56 Asset-liability ratio (%)53.5253.32Increase 0.2 pointsSix months ended 30 June 2014(Unaudited)Six months ended 30 June 2013(the Same Period Last Year)(Unaudited)Change as compared to the Same Period Last Year (%)Total operating income1,736,816,836.23 1,617,134,270.43 7.40 Operating profit23,569,652.27 (13,046,260.32 )280.66Profit before taxation52,744,363.41 9,280,671.77 468.32 Profit attributable to the equity holders of Company39,986,470.06 4,987,774.39 701.69 Profit attributable to the equity holders of Company after extraordinary items (Note)13,068,682.63 (16,444,797.62)179.47Basic earnings per share 0.090.01 800.00 Diluted earnings per share 0.090.01 800.00 Basic earnings per share after extraordinary loss0.03(0.04)175.00Return on equity of weighted average (%)2.250.29 Increase 1.96 pointsFully diluted return on equity (%)2.240.29Increase 1.95 pointsReturn on equity of weighted average after extraordinary loss (%)0.74(0.95)Increase 1.69 pointsFully diluted return on equity after extraordinary loss (%)0.73(0.97)Increase 1.70 pointsNet cash flow from operating activities119,711,584.975,378,264.182,125.84Net cash flow from operating activities per share 0.260.012,500.00Note:Extraordinary items include:ItemAmount (RMB)Notes (if applicable)Profit or loss from disposal of non-current assets(446,948.98)Loss of disposal of fixed assetsGovernment subsidies recognised in current profit and loss, (excluding those closely related to the Companys normal operations and granted on an ongoing basis under the national policies according to certain fixed quota of amount or volume)33,214,639.11 Received government subsidies reckoned into current termGains (losses) from fair value changes of trading financial assets and trading financial liabilities, and investment income from disposal of trading financial assets, trading financial liabilities and available-for-sale financial assets, except effective hedging activities related to the Companys normal operations2,280,000.00 Disposal profit from available-for-sale financial assetsOther non-operating income or cost except the above items(3,592,978.99)-Non-controlling interests(1,240.79)-Income tax expense(4,535,682.92)-Total26,917,787.43 -(ii) In accordance with HKGAAP (RMB 000)Consolidated Income StatementItemSix months ended 30 June 2014Unaudited Six months ended 30 June 2013Unaudited Revenue1,712,012 1,600,002 Profit before tax52,597 8,719 Income tax expense(10,019)(3,086)Profit for the period42,578 5,633 Includes: Profit attributable to owners of the Company39,861 4,510 Non-controlling interests2,717 1,123 Consolidated Statement of Financial PositionItemAs at 30 June 2014Unaudited As at 31 December 2013Audited Total assets3,930,738 3,858,541 Total liabilities(2,088,518) (2,055,934) Non-controlling interests(39,951) (37,290) Equity attributable to owners of the Company1,802,269 1,765,317 (iii) Reconciliation of accounts prepared in accordance with PRC accounting standards and HKGAAP (RMB) (Unaudited)ItemProfit attributable to the equity holders of CompanyTotal equity attributable to equity holders of Companythe Reporting PeriodSame Period Last YearAs at 30 June 2014As at 1 January 2014Prepared under PRC accounting standards39,986,470.064,987,774.391,787,461,693.611,759,529,934.58HKGAAP adjustments:Provision for education fund(147,000.00)(562,000.00)6,662,000.00 6,809,000.00 Deferred taxation21,529.94 84,225.61 (1,000,693.61)(1,021,934.58)Dividends payable--9,146,000.00-Total of the difference between the PRC accounting standards and HKGAAP(125,470.06)(477,774.39)14,807,306.39 5,787,065.42 Prepared under HKGAAP39,861,000.00 4,510,000.00 1,802,269,000.00 1,765,317,000.00 Explanation of the difference between the PRC accounting standards and HKGAAP:1. Education fees are set out as per the actual expenses, without the need of provision under HKGAAP. As at 30 June 2014 provision made for the balance of education fees under the PRC accounting standards was RMB6,662,000 with an amount in education fees of RMB147,000.00 for this period.2. Education fees also led to the difference in the Companys deferred income tax, with the difference in accumulated deferred income tax of RMB1,000,693.61 and that in deferred income tax of the current period of RMB21,529.94.3. Dividends payable are set out as per the actual expenses, without the need of provision under HKGAAP. As at 30 June 2014 provision made for the dividends payable under the PRC accounting standards was RMB9,146,000.III. CHANGES IN SHARE CAPITAL STRUCTURE AND INFORMATION ON SHAREHOLDERS1. Share Capital structure30 Jun 20141 Jan 2014Class of sharesNumber of shares (share)% of the total share capitalNumber of shares (share)% of the total share capital1. Total number of conditional tradable shares009610Stated-owned shares0000Domestic legal person shares0000Conditional tradable senior management A shares009610Others00002. Total number of unconditional tradable shares457,312,830100.00457,311,869100.00Renminbi ordinary shares (A shares)307,312,83067.20307,311,86967.20Overseas listed foreign shares (H shares)150,000,00032.80150,000,00032.803. Total number of shares457,312,830100.00457,312,830100.002. As at 30 June 2014, the Company had on record a total of 35,296 shareholders, including 54 holders of H Shares and 35,242 holders of A Shares.3. As at 30 June 2014, the ten largest shareholders of the Company were as follows: Unit: shareName of ShareholderTypes of shareholdersNumber of shares held% of the total share capitalNumber of conditional tradable shares heldNumber of shares being charged or frozenShandong Xinhua Pharmaceutical Group Company Limited (SXPGC)State-owned shareholder, A shares166,115,72036.3200HKSCC (Nominees) LimitedListed H shares148,571,99832.4900Qingdao Haowei Investment Development Company LimitedDomestic general legal person shares5,120,0001.1200Zhou JichangDomestic person1,005,0000.2200China Construction Bank- Bosera Yufu CSI300 Index FundFund855,4590.1900Dacheng Value Growth FundFund848,2000.1900Liu ShidaDomestic person654,2000.1400CITIC Trust- CITIC, robust hierarchical collection of securities investment trust plan 1309CTrust520,0000.1100Meng JieDomestic person496,7000.1100Taikang Life-Dividend-Personal dividend-019L-FH002Insurance495,7190.11004. As at 30 June 2014, the ten largest shareholders of the unconditional tradable shares of the Company were as follows:Name of ShareholderNumber of unconditional listed shares (share)Class of sharesSXPGC166,115,720A SharesHKSCC (Nominees) Limited148,571,998H SharesQingdao Haowei Investment Development Company Limited5,120,000A SharesZhou Jichang1,005,000A SharesChina Construction Bank- Bosera Yufu CSI300 Index Fund855,459A SharesDacheng Value Growth Fund848,200A SharesLiu Shida654,200A SharesCITIC Trust- CITIC, robust hierarchical collection of securities investment trust plan 1309C520,000A SharesMeng Jie496,700A SharesTaikang Life-Dividend-Personal dividend-019L-FH002495,719 A SharesNote:1. The Directors are not aware as to whether there is any association amongst the ten largest shareholders of the Company, nor the persons acting in concert as defined in the Rules for the information Disclosure of Changes in the Shareholding of Listed Companies (CSRC Rules) issued by the CSRC. In addition, the Directors do not know whether there is any association amongst the shareholders of H Shares of the Company or persons acting in concert as defined in the CSRC Rules. The Directors do not know whether there is any association amongst the ten largest shareholders of unconditional tradable shares of the Company, or any association between ten largest shareholders of unconditional tradable shares and the ten largest shareholders of the Company or if there are any persons acting in concert as defined in the CSRC Rules.2. The only domestic shareholder with more than 5% of the total issued shares of the Company is SXPGC.3. There was no change of controlling shareholder of the Company during the Reporting Period.4. Save as disclosed above and so far as the Directors are aware, as at 30 June 2014 no other person (other than the Directors, supervisors of the Company (the Supervisors), chief executives or members of senior management of the Company (the Senior Officers)) had an interest or short position in the Companys shares or underlying shares (as the case may be) which would fall to be disclosed to the Company and the SEHK under the provisions of Divisions 2 and 3 of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong (SFO) and as recorded in the register required to be kept under section 336 of the SFO), or was otherwise a substantial shareholder (as defined in the Rules Governing the Listing of Securities on the SEHK (the Listing Rules)) of the Company.IV. DIRECTORS, SUPERVISORS AND SENIOR OFFICERSThe number of shares held by the Directors, Supervisors and Senior Officers of the Company were as follows:NamePositionNumber of Shares (share) as at 1 January 2014Change in number of SharesNumber of Shares (share) as at 30 June 2014Directors:Mr. Zhang DaimingChairmanNilNilNilMr. Ren FulongNon-executive DirectorNilNilNilMr. Du DepingExecutive Director, General ManagerNilNilNilMr. Xu LieNon-executive Director NilNilNilMr. Zhao BinNon-executive Director NilNilNilMr. Zhu BaoquanIndependent non-executive DirectorNilNilNilMr. Liu HongweiIndependent non-executive Director (has been appointed with effect from 18 March 2014)NilNilNilMr. Chan Chung Kik, LewisIndependent non-executive Director (has been appointed with effect from 30 May 2014)NilNilNilMr. Zhao SongguoFormer Executive Director, Deputy generalmanager & Financial Controller (resigned with effect from 4 April 2014)NilNilNilMr. Bai HuiliangFormer independent non-executive Director (resigned with effect from 18 March 2014)NilNilNilMr. Kwong Chi Kit, VictorFormer independent non-executive Director (resigned with effect from 5 March 2014)NilNilNilSupervisors:Mr. Li TianzhongChairman of Supervisory CommitteeNilNilNilMr. Zhang YueshunIndependent SupervisorNilNilNilMr. Tao ZhichaoIndependent SupervisorNilNilNilMs. Hu YanhuaEmployee SupervisorNilNilNilSenior Officers:Mr. Wang XiaolongDeputy General Manager (has been appointed with effect from 28 March 2014)NilNilNilMr. Dou XuejieDeputy General ManagerNilNilNilMr. Du DeqingDeputy General Manager NilNilNilMr. He TongqingDeputy General Manager NilNilNilMr. Hou NingFinancial Controller (has been appointed with effect from 4 April 2014)NilNilNilMr. Cao ChangqiuCompany Secretary961-961NilMs. Guo LeiCompany SecretaryNilNilNilTotal961-961NilAll shares held by the Directors, Supervisors and Senior Officers are A shares. One Senior Officer sold unconditional A shares of the Company by SZSE trading system through auction during this Reporting period.So far as the Directors, Senior Officers and Supervisors are aware, save as disclosed above, as at 30 June 2014, no Director, Senior Officer or Supervisor had any interest or short position in the shares, underlying shares and / or debentures (as the case may be) of the Company or any of its associated corporations (as defined in Part XV of the SFO) which was required to be notified to the Company and the SEHK pursuant to Divisions 7 and 8 of Part XV of the SFO (including any interest or short position which any such Director, Senior Officer or Supervisor is taken or deemed to have under such provisions of the SFO) or which was required to be entered in the register required to be kept by the Company pursuant to Section 352 of the SFO or which was otherwise required to be notified to the Company and the SEHK pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers as contained in Appendix 10 to the Listing Rules.CHANGES OF DIRECTORS, SUPERVISORS AND SENIOR OFFICERSDuring this Reporting Period, details in relation to the changes of Directors, Supervisors and Senior Officers can be referred to the table above.V. CHAIRMANS STATEMENTI am pleased to report the operating results of the Company for the six months ended 30 June 2014.For the six months ended 30 June 2014, pursuant to the PRC accounting standards, the operating income of the Group was RMB1,736,817,000 and net profit attributable to equity holders of the Company was RMB39,986,000, representing an increase of 7.40% and an increase of 701.69% respectively, as compared to that of the Same Period Last Year.The Group had a turnover of RMB1,712,012,000 and profit attributable to owners of the Company of RMB39,861,000 for the six months ended 30 June 2014 under HKGAAP, representing an increase of 7.00% and an increase of 783.84% respectively, as compared with that of the Same Period Last Year.The Board did not recommend the payment of an interim dividend for the six months ended 30 June 2014.BUSINESS REVIEWIn the first half of 2014, the Company actively responded to the impact brought by the fierce competitions in the pharmaceutical market, the increase in environmental protection costs and the increase in management costs resulting from its relocation. The Company used its best endeavors to engage in marketing, conducted technological research and energy-saving work diligently, continued to implement the strategy of internationalization, and strengthened its basic management to achieve a healthy development of the Company. Made full efforts to engage in marketing The Company fully took advantage of its edges as a leader of the pharmaceutical raw material market to expand domestic sales and export and step up its development of the markets of new products and featured products. In the first half of the year, the export and domestic sales of pharmaceutical raw material grew 9% and 10% respectively as compared with the corresponding period of last year. The sales of major efficient varieties such as caffeine and levodopa saw significant growth. The Company also promoted the extensive preparations strategy in a proactive manner. Fully utilizing the advantages of fast coordination of its preparations division, making effort to reduce the production costs of preparation and stressing on the Two New developments (i.e. development of new varieties and new markets), the Company boosted the sales of preparations and recorded a growth of 11.5% in the sales of preparation industrial products (R"uT) in the first half of the year as compared with the corresponding period of last year. Sales of major new preparation products such as glimepiride, Jiening and rabeprazole maintained rapid growth. In addition, the Company leveraged opportunities, tapped into the potential and increased its output to cater the market demand. In particular, the pharmaceutical intermediates of Shouguang Park gradually took up a larger market share with a significant growth in its profitability. Xinhua Medical and Trading Company (elQS) and Xinhua Drug Store (e'Y兗^), both wholly-owned subsidiaries of the Company, had successfully passed the new GSP certification of the PRC, while the online Xinhua Drug Store (} Ne'Y兗^) had been established and made a trial run in July, which made the Company a pioneer in the pharmaceutical e-marketing sector in the PRC. Stepped up efforts in pursuing technology breakthroughs with an aim to lowering production cost The Company streamlined its production management, implemented an assessment mechanism with a an aim to reducing costs, and stimulated the initiative of the staff. New technology and techniques were applied to reduce consumption, while energy-saving and consumption reduction initiatives with the use of technology of recycling of waste were adopted. The result was a remarkable success, with consumption of raw materials reduced by RMB12.11 million and consumption of energy reduced by RMB8.34 million. The costs of major bulk pharmaceuticals such as ibuprofen decreased at varying rates. 3. Increased investment in R&D and expedited R&D of new productsThe investment in R&D increased and R&D work was emphasized. In the first half of the year, the Company obtained 2 certificates and 2 production approvals of new drugs such as calcium polycarbophil and its tablet. The Company completed dynamic inspection for 8 projects and carried out trial production for 9 new drugs. Periodical results were achieved in the technology breakthrough of new products such as glimepiride, rabeprazole sodium, calcium polycarbophil, carbidopa and fish oil. 4. Continued to implement the global strategy and explored the international upscale marketIn the first half of the year, 11 products of the Company including ibuprofen and 3 park areas passed the American site FDA. Following the solid dosage workshop of the Company passed the review of Medicines and Healthcare Products Regulatory Agency of the United Kingdom, the injection workshop of the Company passed the review of IDA (International Dispensary Association) in January this year, and the Company has become a qualified supplier in compliance with the WHO-GMP standards, which laid a foundation for export of injection products to the regulated international markets. In the first half of the year, international commissioned processing of preparations has maintained a high-speed development, with a year-on-year growth rate of 44%.5. Implemented human resources reform and incentivized employees productivityIn the first half of the year, the Company emphasized on effective allocation of staff and improvement of their working performance, actively implemented human resources reform with a focus on post wage, established development, assessment, allotment and incentive mechanism for employees, and further incentivized employees productivity and creativity, so as to secure talent pipeline for a sustainable and healthy development of the enterprise.PLANS FOR THE SECOND HALF OF THE YEAR 2014In the second half of the year 2014, as the situation of domestic overcapacity is not likely to improve in a short term, competition will remain fierce, while the entry requirements of international market will continue to rise with an increment in trade barriers of various forms. Chemical raw materials will see an upward trend in price while the development of preparations which is sensitive to national policies is affected by a lack of a stable market environment.In the meantime, the PRC government's strengthened support to the real economy, the favorable condition of macro policy, the more reasonable policy of the bidding of basic medicines, and the issue of low-priced medicine catalog provide new opportunities to the development of the Company. The implementation of new GMP has strengthened regulations and is favorable to the development of large-scale pharmaceutical enterprises with good brand reputation and standard operation.Continue to strengthen marketingThe controlling capability in the pharmaceutical raw material market will be reinforced while the marketing of leading varieties and efficient varieties will be strengthened. In the meantime, great efforts will be made to develop in the international emerging market, fill the gap in the domestic market and develop new products, so as to nurture new economic growth points.Implementation of the greater preparation strategy will be speeded up with a focus on the marketing of preparation strategy varieties, which will enhance the vitality of the development of the Company. Leveraging the opportunities brought by the improvement in the bidding results of the Company, the inclusion of 60 products in the national low-priced medicine catalog, the upcoming launch of the new product calcium polycarbophil, the inclusion of Jiening (N[) into the local reimbursable drug list, and the implementation of new GMP, the Company will pursue the development of preparations diligently.Deepen efforts in making technology breakthroughs to further reduce costThe Company will adhere to the plan for cost, technology and quality breakthroughs established at the beginning of the year, so as to ensure more than 10 technology breakthroughs to be made during the year, and endeavor to make another achievement in reducing raw material consumption by promoting and applying advanced technologies. The fundamental management and expense control of workshops will be reinforced to ensure further reduction in the production cost of principal products.Enhance management and risk controlThe expense control measures and the rigidity of execution will be further improved by adopting duty-linked policy for person in charge and regular report and appraisal policy, so as to ensure that the three types of expenses for the year will be managed within budget.The risk control and credit management, especially the management on account receivables, will be strengthened, so as to control the fund employed rate at a rational level and minimize the operational risk.Lay emphasis on reform and innovationThe Company will carefully study the Opinions of Provincial Party Committee and Provincial Government on Deepening State-owned Enterprise Reform to develop and promote employee stock ownership, share option incentive and other reforms, so as to improve staffs sense of responsibility, initiate their enthusiasm and enhance vitality for corporate development.The Company will actively promote the existing research and development projects while speeding up the technical breakthroughs in the existing products, so as to ensure that the production transformation of 9 products to be completed, the dynamic audit for 8 projects to be completed and more than 10 reception document numbers to be obtained.Park construction and relocation will be carried out orderly to ensure that obsolete production lines will be closed and new production lines will be put into normal production as scheduled under the construction projects of Wu An series products. In the meantime, Wu An relocation will be fully completed while efforts will be made in the construction of the ancillary facility project in Hutian Park and the second multi-function industrialization center.VI. MANAGEMENT DISCUSSION AND ANALYSISThe Group is mainly engaged in the development, manufacturing and sale of bulk pharmaceuticals, pharmaceutical preparations, chemicals and pharmaceutical commerce. The profit of the Group is mainly attributable to its principal businesses.1. LIQUIDITY AND ANALYSIS OF FINANCIAL RESOURCES AND CAPITAL STRUCTURE UNDER HKGAAPAs at 30 June 2014, the liquidity ratio of the Group was 158.42%, the quick ratio was 118.06%, the turnover ratio of account receivables was 348.65% (turnover ratio of account receivables = turnover / average account receivables and net value of bills x 100%) and the turnover ratio of inventory was 345.64% (inventory turnover ratio = cost of sales / average net value of inventory x 100%).There was no significant seasonal effect on the capital demand of the Group.The main sources of funds for the Group were loans from financial institutions and funds provided by the ultimate holding company of the Company. As at 30 June 2014, the total amount of bank loans was RMB660,284,000, which were floating rate loans based on Hong Kong inter-bank offered rates or rates issued by the Peoples Bank of China, and the total amount of loans from the ultimate holding company was RMB695,350,000. As at 30 June 2014, cash on hand and in bank amounted to RMB253,798,000 (including bank acceptance drafts deposits of RMB2,000,000).As of 30 June 2014, the Groupcharged the land use rights in Hutianzhen,Zhangdian,to a bankforloans. Thebook valueof the land use rightsis RMB65,920,000.There was no charge on the Groups assets except the above charged assets.The Group has stringent internal control systems for cash and fund management in order to strengthen financial management. The Group has sound liquidity and repayment ability.The clarification of the performance results of the Group is referred to in the section headed Results and Financial Analysis under PRC Accounting Standards.As at 30 June 2014, the number of employees of the Group was 6,043. The total salaries for employees in the first half of 2014 amounted to RMB132,688,000.The main investment projects in the second half of 2014 will be Hutian Park project.As at 30 June 2014, the capital debt ratio of the Group was 75.22% (capital debt ratio = total borrowings / equity attributable to owners of the Company x 100%).The cash and bank balances of the Company will mainly be used as working capital for production, operation, projects and research development.The assets and debts of the Group were denominated in RMB. However, the Group achieved USD103,132,000 in its export for the first half of 2014. Therefore, there was a greater impact from foreign exchange. The Group adopted the following measures to minimise the foreign exchange fluctuation risk: (1) raising the export price in order to minimise foreign exchange fluctuation risk; and (2) when the Group enters into larger export contracts, the Group will seek the prior agreement of the purchaser that both parties shall jointly bear the foreign exchange fluctuation risk should the foreign exchange fluctuation exceed the contractual limit as agreed by both parties.2. RESULTS AND FINANCIAL ANALYSIS UNDER PRC ACCOUNTING STANDARDSIn the first half of 2014 the Groups operating income was RMB1,736,817,000, representing an increase of 7.40% as compared to the Same Period Last Year. The increase in operating income was mainly attributable to the increase in marketing, leading to a rise in the sales of certain products. Operating profit amounted to RMB23,570,000, whereas there was a operating loss of RMB13,046,000 in the Same Period Last Year. The main reasons for the increase include the Company diligently carried out energy-saving and technological research work, the consumption of raw material and power fell significantly compared to the same period in the previous year, the Companys subsidiary, Xinhua Pharmaceutical (Shouguang) Company Limited, diligently developed its market resulting in a substantial increase in profitThe net decrease in cash and cash equivalents was RMB31,023,000, while there was a net decrease of RMB221,979,000 in the Same Period Last Year. The main reasons for the change include the Group having recovered bank acceptance deposits during the first half of 2014, payment of bank acceptance deposits in the same period last year; having seized the market opportunities, expanded product sales, and product inventory reduction.The total assets of the Group as at 30 June 2014 amounted to RMB3,931,313,000, representing an increase of RMB81,960,000 or 2.13% as compared to that of RMB3,849,353,000 as at the beginning of this year. The increase was mainly due to the operating profit during the Reporting Period. The Groups loan amount as at 30 June 2014 was RMB1,355,634,000, representing a decrease of RMB8,800,000 from RMB1,364,434,000 at the beginning of this year. The total equity attributable to equity holders of the Company as at 30 June 2014 was RMB1,787,462,000, representing an increase of RMB27,932,000 or 1.59% from RMB1,759,530,000 at the beginning of this year. The increase was mainly attributable to the operating profit during the Reporting Period.An analysis of the Groups turnover from principal operations is as follows (RMB000):By geographical location of customersFirst half of 2014First half of 2013Total turnoverCostsTotal turnoverCostsPRC (incl. Hong Kong)1,043,126819,928949,671783,290Europe222,350182,136249,676199,817Americas314,946273,717291,165262,985Others140,527122,842109,49097,973Total1,720,9491,398,6231,600,0021,344,065By industry and By productIncome from principal operationsCosts of sales of principal operationsGross profit margin(%)Bulk pharmaceutical 821,203  679,855  17.21 Preparations 353,593  219,912  37.81 Commercial circulations 386,011  365,480  5.32 Chemical products and other products 160,142  133,376  16.71 Total 1,720,949  1,398,623  18.73 An analysis of profit as compared to 2013 is as follows:ItemsAmount (RMB000)% of total profitJan.-Jun. 20142013Jan.-Jun. 20142013Operating profit 23,570 (43,862) 44.69 (86.83)Net profit/loss from non-operation activities 29,174  94,378  55.31  186.83 Profit before taxation 52,744  50,516  100.00  100.00 VII. REVIEW OF MAJOR EVENTSSave as disclosed herein:1. There is no material deviation between the actual corporate governance implemented by the Company and the rules and requirements of corporate governance required to be observed by listed companies in the PRC.2. The Board did not recommend the payment of any interim dividend, nor any transfer from reserves to share capital, for the half year ended 30 June 2014.3. The Group was not involved in any material litigation or arbitration, whether pending or threatened during the Reporting Period.4. There was no material purchase of assets or disposal of the Companys assets, nor did any material mergers or acquisitions involving the Company occur during the Reporting Period. Similarly, no transactions of such nature occurred during the last reporting period and were carried over to the Reporting Period.5. During the Reporting Period, there was no material trust, subcontract and lease of assets between the Company and other companies.6. The independent non-executive directors special explanation and independent opinions in respect of the use of funds by related parties and external security provided are as follows:During the Reporting Period, there was no non-operational use of the Companys funds by the controlling shareholder and other related parties.During the Reporting Period, save and except the guarantee of bank accepted bills of exchange of RMB50,000,000 provided by the Company in favour of Xinhua Pharmaceutical (Shouguang) Company Limited, there has been no other material guarantee was provided by the Company, nor has there been any obligations that have not been performed in full by the Company. There were no guarantees provided in favour of any controlling shareholders, non-legal entities or individuals which were prejudicial to the interests of the Company and its shareholders, in particular the minority shareholders of the Company. As at 30 June 2014, the Company had no overdue external guarantee debts and the Company had no liability arising from any guarantee due to the default of a guaranteed party.7. The Company and its shareholders holding more than 5% of total number of issued shares of the Company have provided undertakings for information disclosure as follows: Nil8. Purchase, Sales and Redemption of the Companys listed securitiesDuring the Reporting Period, neither the Company nor its subsidiaries purchased, sold or redeemed any of the Companys listed securities.9. Management of FundsDuring the Reporting Period, the Company did not appoint any person to manage the Companys funds. No such appointment was made in the preceding reporting period and carried over to the Reporting Period.10. Information about holding equity in other listed companies (RMB)Stock CodeAbbreviated NameInitial investment amountProportion of equity interest in investeeBook value of end of the Reporting PeriodProfit/loss in the Reporting PeriodChange of shareholders equity in the Reporting PeriodAccounting coursesShare source601601China Pacific Insurance7,000,000.000.06%88,950,000.00-(3,700,000.00)Available-for-sale financial assetsPurchase601328BANKCOMM14,225,318.000.02%31,890,496.00-328,768.00 Available-for-sale financial assetsPurchaseTotal21,225,318.00-120,840,496.00-(3,371,232.00)--11. Index of important information which has been disclosedThe announcement of the The Notice of the First Extraordinary General Meeting for the 2014 was published on the HKExnews, in the Securities Times B20 in the PRC, on the website: http://www.cninfo.com.cn and on the Companys website on or about 30 January 2013.The announcement of the Announcement of the First Extraordinary General Meeting for the 2014 Resolutions was published on the HKExnews, in the Securities Times B26 in the PRC, on the website: http://www.cninfo.com.cn and on the Companys website on or about 19 March 2014.The announcement of the 2013 Annual Results Announcement was published on the HKExnews, in the Securities Times B31 in the PRC, on the website: http://www.cninfo.com.cn and on the Companys website on or about 31 March 2014.The announcement of the The First Quarter Report of 2014 was published on the HKExnews, in the Securities Times B99 in the PRC, on the website: http://www.cninfo.com.cn and on the Companys website on or about 26 April 2014The announcement of the The Notice of Annual General Meeting for the 2013 was published on the HKExnews, in the Securities Times B14 in the PRC, on the website: http://www.cninfo.com.cn and on the Companys website on or about 14 April 2014.The announcement of the Announcement of 2013 Annual General Meeting Resolutions was published on the HKExnews, in the Securities Times B30 in the PRC, on the website: http:// www.cninfo.com.cn and on the Companys website on or about 31 May 2014.12. Information of reception research, communications and interviews during the Reporting Period: NilVIII. CORPORATE GOVERNANCECOMPLIANCE WITH THE CODE ON CORPORATE GOVERNANCE PRACTICESThe Directors confirmed that the Company was in compliance with the Code on Corporate Governance Practices (the Code) and has not deviated from the Code during the six months ended 30 June 2014. The Code includes the provisions contained in Appendix 14 to the Listing Rules.AUDIT COMMITTEEThe Company set up the audit committee under the Board in accordance with Rule 3.21 of the Listing Rules.The audit committee along with the management of the Company has reviewed the accounting standards, principles and methods adopted by the Group, and considered matters regarding auditing, internal control and financial reporting including the unaudited interim accounts for the six months ended 30 June 2014.The audit committee agreed to the accounting standards, principles and methods adopted by the Group for the unaudited interim accounts for the six months ended 30 June 2014, and it has been disclosed fully.INDEPENDENT NON-EXECUTIVE DIRECTORThe Company has complied with Rules 3.10(1), 3.10(2) and 3.10A of the Listing Rules relating to the appointment of a sufficient number of independent non-executive Directors and at least one independent non-executive Director with appropriate professional qualifications, or accounting or related financial management expertise. The Company has appointed three independent non-executive Directors including two with financial management expertise; details of their biographies were set out in the 2013 Annual Report of the Company and the announcements of the Company in relation to the appointment of director dated 18 March 2014 and 30 May 2014.MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS OF LISTED ISSUERS (MODEL CODE)During the Reporting Period, the Company has adopted a code of conduct regarding transactions by Directors on terms no less exacting than the required standards set out in the Model Code. After having made specific enquiries to the Directors and Supervisors, the Company has confirmed that during the Reporting Period, all Directors and Supervisors have complied with the required standard set out in the Model Code in relation to directors securities transactions and they did not have any non-compliance with the Mode Code. h!. FINANCIAL REPORTS1. Profit and loss account prepared in conformity with PRC accounting standards (Unaudited) Unit: RMBItem First half of 2014First half of 20130ConsolidatedParent companyConsolidatedParent company1.Total operating income1,736,816,836.23997,833,917.341,617,134,270.43 951,197,344.70  Includes: Operating income1,736,816,836.23997,833,917.341,617,134,270.43 951,197,344.70 2.Total operating costs1,717,970,009.37992,901,063.251,631,787,333.60 956,068,458.63  Includes: Operating cost1,420,104,715.71849,440,242.751,363,733,658.96 812,783,451.22  Taxes and surcharges8,936,674.544,070,819.7010,366,384.78 7,096,493.05  Selling expenses141,235,556.6018,400,070.92109,963,731.83 14,769,801.49  Administrative expenses114,951,602.8789,846,187.63101,448,392.30 79,735,424.77  Financial expenses30,025,874.4331,143,742.2546,275,165.73 41,683,288.10  Assets Impairment loss2,715,585.22- -  -  Add: Gain or loss from changes in fair value-- -  -  Investment gain or loss4,722,825.414,722,779.391,606,802.85 1,606,802.85  Includes: Investment gain or loss from related ventures and joint ventures1,779,386.671,779,386.671,432,177.85 1,432,177.85  Exchange gain or loss-- -  - 3. Operating profit23,569,652.279,655,633.48(13,046,260.32)(3,264,311.08) Add: Non-operating income33,915,857.5733,734,212.0624,778,778.41 8,972,598.86  Less: Non-operating cost4,741,146.432,735,237.732,451,846.32 1,709,409.97  Includes: Loss from the disposal of non-current assets699,391.01699,391.01119,826.73 119,826.73 4. Profit before taxation52,744,363.4140,654,607.819,280,671.77 3,998,877.81  Less: Income tax expense10,040,955.625,770,175.193,169,924.91 2,282,582.13 5. Profit after taxation42,703,407.7934,884,432.626,110,746.86 1,716,295.68  Includes: Net Profit attributable to the equity holders of the parent company39,986,470.06-4,987,774.39  -  Minority interest2,716,937.73-1,122,972.47  - 6. Earnings per share00 1) Basic earnings per share0.090.080.01 0.004  2) Diluted earnings per share0.090.080.01 0.004 7.Other comprehensive income(2,964,070.97)(2,865,547.20)(34,421,999.76)(34,000,598.40)8. Total comprehensive income39,739,336.8232,018,885.42(28,311,252.90)(32,284,302.72) Includes: Total comprehensive income attributable to the equity holders of the parent company37,078,015.63-(29,322,887.73) -  Total comprehensive income attributable to the minority interest2,661,321.19-1,011,634.83  - NOTES:xe "s, 1. compared with the latest annual reportA th"1. During the Reporting Period, there was no change in accounting policies and accounting estimates.2. During the Reporting Period, Shandong Xinhua Electrical and Mechanical Engineering Company Limited was added into the scope of consolidated financial statements of the Company.2. FINANCIAL STATEMENTS PREPARED UNDER HKGAAPCondensed consolidated statement of profit or lossNotesSix months ended 30 June20142013RMB000RMB000(unaudited)(unaudited)Revenue31,712,0121,600,002Cost of sales(1,398,623)(1,354,431)Gross profit313,389245,571Investment income4,4581,331Other income37,52641,801Other expenses(7,356)(27,468)Distribution and selling expenses(141,236)(109,964)Administrative expenses(122,140)(106,996)Finance costs(33,823)(36,988)Share of profit of an associate1,7791,432Profit before tax452,5978,719Income tax expense5(10,019)(3,086)Profit for the period42,5785,633Profit for the period attributable to:Owners of the Company39,8614,510Non-controlling interests2,7171,12342,5785,633Earnings per share - basic and diluted 6RMB0.087RMB0.010Condensed consolidated statement of profit of loss and other comprehensive incomeSix months ended 30 June20142013RMB000RMB000(unaudited)(unaudited)Profit for the period42,5785,633Other comprehensive (expense) income:Items that may be subsequently reclassified to profit or loss: Exchange differences arising on translation (99)(421) Fair value loss on available-for-sale investments(3,372)(40,001)Income tax relating to components of other comprehensive income5066,000Other comprehensive expense for the period, net of tax(2,965)(34,422)Total comprehensive income (expense) for the period39,613(28,789)Total comprehensive income (expense) attributable to:Owners of the Company36,952(29,801)Non-controlling interests2,6611,01239,613(28,789)Condensed consolidated statement of financial positionNotes30 June 201431 December 2013RMB000RMB000(unaudited)(audited)Non-current assetsIntangible assets11,53913,248Property, plant and equipment1,748,8491,409,625Construction in progress290,488540,030Prepaid lease payments on land use rights246,027249,532Investment properties61,43663,926Interest in an associate26,68924,910Available-for-sale investments124,040127,412Deferred tax assets20,48518,705Goodwill-2,716 Prepayments for acquisition of land use rights21,06515,4002,550,6182,465,504Current assetsInventories351,610457,676Properties under development74,32674,316Trade and other receivables8686,709460,425Prepaid lease payments on land use rights6,4216,363Amounts due from fellow subsidiaries3,7929,717Tax recoverable3,4643,817Restricted bank balances2,00097,901Bank balances and cash251,798282,8221,380,1201,393,037Current liabilitiesTrade and other payables9568,082540,533Dividend payables5,3115,311Amounts due to fellow subsidiaries3,7314,607Amount due to an associate14025Tax payable6,4141,190Borrowings287,516475,666871,1941,027,332Net current assets508,926365,705Total assets less current liabilities3,059,5442,831,209Capital and reservesShare capital457,313457,313Reserves1,335,8101,298,858Proposed final dividend9,1469,146Equity attributable to owners of the Company1,802,2691,765,317Non-controlling interests39,95137,290Total equity1,842,2201,802,607Non-current liabilitiesDeferred tax liabilities6,1287,034Loan from ultimate holding company695,350694,300Borrowings372,768194,467Deferred income143,078132,8011,217,3241,028,6023,059,5442,831,209NOTES TO THE CONDENSED INTERIM FINANCIAL INFORMATION UNDER HKGAAP1. Basis of preparation Shandong Xinhua Pharmaceutical Company Limited (the Company) is a joint stock limited company established in the Peoples Republic of China (the PRC) with limited liability. The H shares of the Company were listed on The Stock Exchange of Hong Kong Limited (the Stock Exchange) in December 1996 and its A shares were listed on Shenzhen Stock Exchange in July 1997.The directors of the Company regard Hualu Holdings Company Limited, a state-owned limited liability company established in the PRC, as the ultimate holding company and Shandong Xinhua Pharmaceutical Group Company Limited (SXPGC), a wholly state-owned limited liability company established in the PRC, as the immediate holding company.The addresses of the registered office and principal place of business of the Company are disclosed in the Company Information section to the interim report.The unaudited condensed interim financial information are presented in Renminbi (RMB), which is also the functional currency of the Company and its principal subsidiaries. The Company and its subsidiaries (collectively referred to as the Group) are principally engaged in the development, production and sales of bulk pharmaceuticals, preparations, chemical and other products, and commerce circulations.The Groups unaudited condensed interim financial information has been prepared in accordance with the applicable disclosure provisions of Appendix 16 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the Listing Rules) and with Hong Kong Accounting Standard (HKAS) 34, Interim Financial Reporting, issued by the Hong Kong Institute of Certified Public Accountants (HKICPA). The unaudited condensed consolidated interim financial information should be read in conjunction with the annual financial statements for the year ended 31 December 2013.Principal accounting policies The condensed consolidated interim financial information has been prepared on the historical cost basis except for certain financial instruments, which are measured at fair values, as explained in the accounting policies set out below. Historical cost is generally based on the fair value of the consideration given in exchange for assets.Except as described below, the accounting policies and methods of calculation used in the condensed consolidated interim financial information for the six months ended 30 June 2014 are consistent with those followed in the preparation of the Groups annual financial statements for the year ended 31 December 2013.In the current interim period, the Group has applied the following amendments to Hong Kong Financial Reporting Standards (HKFRSs) issued by the HKICPA.Amendments to HKFRS 10, HKFRS 12 and HKAS 27Investment EntitiesAmendments to HKAS 32Offsetting Financial Assets and Financial LiabilitiesAmendments to HKAS 36Recoverable Amount Disclosures for Non-Financial AssetsAmendments to HKAS 39Novation of Derivatives and Continuation of Hedge AccountingHK(IFRIC) Int 21LeviesThe Group has not early applied the following new and revised standards, amendments or interpretations that have been issued but are not yet effective. Amendments to HKFRSsAnnual Improvements to HKFRSs 2010-2012 Cycle1Amendments to HKFRSsAnnual Improvements to HKFRSs 2011-2013 Cycle1HKFRS 9 Financial Instruments2HKFRS 14Regulatory Deferral Accounts3Amendments to HKFRS 9 and HKFRS 7Mandatory Effective Date of HKFRS 9 and Transition Disclosures2Amendments to HKFRS 11Accounting for Acquisition of interests in joint Operations3HKFRS 15Revenue from Contracts with Customers4Amendments to HKAS 19 Defined Benefit Plans - Employee Contributions1Amendments to HKAS 16 and HKAS 38Clarification of Acceptance Methods of Depreciation and Amortisation31 Effective for annual periods beginning on or after 1 July 2014, with earlier application permitted.2 HKFRS 9, as amended in December 2013, amended the mandatory effective date of HKFRS 9. The mandatory effective date is not specified in HKFRS 9 but will be determined when the outstanding phases are finalised. However, application of HKFRS 9 is permitted.3 Effective for annual periods beginning on or after 1 January 2016, with earlier application permitted.4 Effective for annual periods beginning on or after 1 January 2017, with earlier application permitted.Annual Improvements to HKFRSs 2010-2012 CycleThe Annual Improvements to HKFRSs 2010-2012 Cycle include a number of amendments to various HKFRSs, which are summarised below.The amendments to HKFRS 2 (i) change the definitions of vesting condition and market condition; and (ii) add definitions for performance condition and service condition which were previously included within the definition of vesting condition. The amendments to HKFRS 2 are effective for share-based payment transactions for which the grant date is on or after 1 July 2014.The amendments to HKFRS 3 clarify that contingent consideration that is classified as an asset or a liability should be measured at fair value at each reporting date, irrespective of whether the contingent consideration is a financial instrument within the scope of HKFRS 9 or HKAS 39 or a non-financial asset or liability. Changes in fair value (other than measurement period adjustments) should be recognised in profit and loss. The amendments to HKFRS 3 are effective for business combinations for which the acquisition date is on or after 1 July 2014.The amendments to HKFRS 8 (i) require an entity to disclose the judgements made by management in applying the aggregation criteria to operating segments, including a description of the operating segments aggregated and the economic indicators assessed in determining whether the operating segments have similar economic characteristics; and (ii) clarify that a reconciliation of the total of the reportable segments assets to the entitys assets should only be provided if the segment assets are regularly provided to the chief operating decision-maker.The amendments to the basis for conclusions of HKFRS 13 clarify that the issue of HKFRS 13 and consequential amendments to HKAS 39 and HKFRS 9 did not remove the ability to measure short- term receivables and payables with no stated interest rate at their invoice amounts without discounting, if the effect of discounting is immaterial. The amendments to HKAS 16 and HKAS 38 remove perceived inconsistencies in the accounting for accumulated depreciation/amortisation when an item of property, plant and equipment or an intangible asset is revalued. The amended standards clarify that the gross carrying amount is adjusted in a manner consistent with the revaluation of the carrying amount of the asset and that accumulated depreciation/amortisation is the difference between the gross carrying amount and the carrying amount after taking into account accumulated impairment losses.The amendments to HAKS 24 clarify that a management entity providing key management personnel services to a reporting entity is a related party of the reporting entity. Consequently, the reporting entity should disclose as related party transactions the amounts incurred for the service paid or payable to the management entity for the provision of key management personnel services. However, disclosure of the components of such compensation is not required. The directors of the Company do not anticipate that the application of the amendments included in the Annual Improvements to HKFRSs 2010-2012 Cycle will have a material effect on the Groups consolidated financial statements.Annual Improvements to HKFRSs 2011-2013 CycleThe Annual Improvements to HKFRSs 2011-2013 Cycle include a number of amendments to various HKFRSs, which are summarised below.The amendments to HKFRS 3 clarify that the standard does not apply to the accounting for the formation of all types of joint arrangement in the financial statements of the joint arrangement itself.The amendments to HKFRS 13 clarify that the scope of the portfolio exception for measuring the fair value of a group of financial assets and financial liabilities on a net basis includes all contracts that are within the scope of, and accounted for in accordance with, HKAS 39 or HKFRS 9, even if those contracts do not meet the definitions of financial assets or financial liabilities within HKAS 32.The amendments to HKAS 40 clarify that HKAS 40 and HKFRS 3 are not mutually exclusive and application of both standards may be required. Consequently, an entity acquiring investment property must determine whether:(a) the property meets the definition of investment property in terms of HKAS 40; and(b) the transaction meets the definition of a business combination under HKFRS 3.The directors of the Company do not anticipate that the application of the amendments included in the Annual Improvements to HKFRSs 2011-2013 Cycle will have a material effect on the Groups consolidated financial statements.HKFRS 9 Financial InstrumentsHKFRS 9 issued in 2009 introduces new requirements for the classification and measurement of financial assets. HKFRS 9 was subsequently amended in 2010 to include the requirements for the classification and measurement of financial liabilities and for derecognition, and further amended in 2013 to include the new requirements for hedge accounting.Key requirements of HKFRS 9 are described as follows:All recognised financial assets that are within the scope of HKAS 39 Financial Instruments: Recognition and Measurement are subsequently measured at amortised cost or fair value. Specifically, debt investments that are held within a business model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal and interest on the principal outstanding are generally measured at amortised cost at the end of subsequent accounting periods. All other debt investments and equity investments are measured at their fair values at the end of subsequent reporting periods. In addition, under HKFRS 9, entities may make an irrevocable election to present subsequent changes in the fair value of an equity investment (that is not held for trading) in other comprehensive income, with only dividend income generally recognised in profit or loss.With regard to the measurement of financial liabilities designated at fair value through profit or loss, HKFRS 9 requires that the amount of change in the fair value of the financial liability that is attributable to changes in the credit risk of that liability is presented in other comprehensive income, unless the recognition of the effects of changes in the liabilitys credit risk in other comprehensive income would create or enlarge an accounting mismatch in profit or loss. Changes in fair value of financial liabilities attributable to changes in the financial liabilities credit risk are not subsequently reclassified to profit or loss. Under HKAS 39, the entire amount of the change in the fair value of the financial liability designated as fair value through profit or loss was presented in profit or loss. The new general hedge accounting requirements retain the three types of hedge accounting. However, greater flexibility has been introduced to the types of transactions eligible for hedge accounting, specifically broadening the types of instruments that qualify for hedging instruments and the types of risk components of non-financial items that are eligible for hedge accounting. In addition, the effectiveness test has been overhauled and replaced with the principle of an economic relationship. Retrospective assessment of hedge effectiveness is also no longer required. Enhanced disclosure requirements about an entitys risk management activities have also been introduced.The directors of the Company anticipate that the adoption of HKFRS 9 in the future will not have significant impact on amounts currently reported in respect of the Groups financial assets and financial liabilities.Other than disclosed above, the directors of the Company anticipated that the application of other new and revised standards, amendments or interpretation would have no material impact on the results and the financial position of the Group.3. Segment informationDescription of segmentsThe Groups operating segments, based on information reported to the board of directors of the Company, being the chief operating decision maker, for the purposes of resource allocation and assessment of segment performance focuses on the types of goods supplied. The principal types of goods supplied are bulk pharmaceuticals, preparations, chemical and other products and commerce circulations. The Groups reportable segments under HKFRS 8 are as follows:Bulk pharmaceuticalsDevelopment, production and sales of bulk pharmaceuticalsPreparationsDevelopment, production and sales of preparations (e.g. tablets and injections)Chemical and other productsProduction and sales of chemical and other products Commerce circulationsTrading of pharmaceutical products (including retail and wholesale)Information regarding the above segments is reported below. Segment turnover and results The following is an analysis of the Groups turnover and results by reportable segment.For the six months ended 30 June 2014 (Unaudited)Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other products EliminationsTotalRMB000RMB000RMB000RMB000RMB000RMB000REVENUE External sales817,707349,819385,907158,579-1,712,012Inter-segment sales306149,44862,328171,539(383,621)-Total 818,013499,267448,235330,118(383,621)1,712,012Segment profit35,6275,9452,32313,30657,201Unallocated income 34,796Unallocated expenses(7,356)Finance costs(33,823)Share of profits of an associate1,779Profit before tax 52,597For the six months ended 30 June 2013 (Unaudited)Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other products EliminationsTotalRMB000RMB000RMB000RMB000RMB000RMB000REVENUE External sales781,091303,471411,502103,938-1,600,002Inter-segment sales6,006151,6489,642142,785(310,081)-Total 787,097455,119421,144246,723(310,081)1,600,002Segment profit (loss)43,51017,6693,222(9,500)54,901Unallocated income 19,333Unallocated expenses(29,959) Finance costs (36,988)Share of profits of an associate1,432Profit before tax 8,719The accounting policies of the reportable segments are the same as the Groups accounting policies. Segment profit represents the profit earned by each segment without allocation of investment and other income (excluding government grants), other expenses, deprecation for investment properties, finance costs and share of profit of an associate. This is the measure reported to the chief operating decision maker for the purposes of resource allocation and performance assessment.Inter-segment sales are charged at prevailing market rates.Segment assetsThe following is an analysis of the Groups assets by reportable segment.At 30 June 2014 (Unaudited)Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other products TotalRMB000RMB000RMB000RMB000RMB000Segment assets2,073,059394,508242,794730,4003,440,761Unallocated corporate assets489,977Consolidated assets3,930,738At 31 December 2013 (Audited)Bulk pharmaceuticalsPreparationsCommerce circulationsChemical and other products TotalRMB000RMB000RMB000RMB000RMB000Segment assets1,689,688594,002189,506765,8523,239,048Unallocated corporate assets619,493Consolidated assets3,858,541For the purposes of monitoring segment performances and allocating resources among segments: all assets are allocated to reportable segments other than deferred tax assets, interest in an associate, available-for-sale investments, investment properties, tax recoverable, restricted bank balances and bank balances and cash. Assets used jointly by reportable segments are allocated on the basis of revenues earned by individual reportable segments.4. Profit before taxProfit before tax has been arrived at after charging (crediting):Six months ended 30 June20142013RMB000RMB000(unaudited)(unaudited)Depreciation for property, plant and equipment82,27580,870Depreciation for investment properties2,4902,490Amortisation of prepaid lease payments on land use rights3,4473,359Amortisation of intangible assets1,7091,440Total depreciation and amortisation89,92188,159Cost of inventories recognised as an expense1,398,6231,354,431Dividends and interest income(6,237)(2,763)Loss on disposal of property, plant and equipment447120Impairment losses recognised in respect of trade and other receivables27-Impairment losses reversed(5)-Impairment recognised in respect of goodwill2,716-5. Income tax expenseThe major components of income tax expense in the condensed consolidated statement of profit or loss are:Six months ended 30 June20142013RMB000RMB000(unaudited)(unaudited)Current income tax PRC Enterprise Income Tax (EIT)12,7053,628Deferred income tax(2,686)(542)Income tax expense10,0193,086Under the Law of the PRC on Enterprise Income Tax (the EIT Law) and Implementation Regulation of the EIT Law, the tax rate of the PRC companies is 25% for both periods. Pursuant to the relevant laws and regulations in the PRC, the Company was accredited as a high-tech enterprise and is entitled to the preferential tax rate of 15% during the period.6. E-p r s t   x z 2 ª”pbL7L(h9%hCJOJPJQJaJnHtH+h9%hCJOJPJQJaJnHo(tHh9%hCJQJaJo(h9%h5CJQJaJo(&h9%h5CJQJaJnHo(tH*h9%h5CJPJQJaJnHo(tH.jh9%h5CJQJUmHnHo(uh9%h5CJQJo(h9%h5CJOJQJ"h9%h6KHOJPJQJ]h9%h6KHOJQJ]q r s u v  x 2 X 01HI  $v dWD`v a$$da$^ $dT^a$$a$\dd2 X \ ^ ` b p  H O P T U a b s ׽׽׽~~~n_M_D~h9%hua5CJ"h9%hT5CJPJnHo(tHh9%hTCJPJnHtHh9%hTCJPJnHo(tHh9%h5CJ\h9%hCJ$h9%hB*PJnHo(phtH,hULL5B*CJPJ\aJnHo(phtH2h9%h5B*CJPJ\aJnHo(phtH#h9%h5B*CJ\aJph,h9%hB*CJKHOJQJaJo(ph   $(_`ahin0134GHIgV޿yyqgqgh9%h5o(h9%h5h9%h h CJo(h9%h h CJh9%hCJo(h9%h5CJh9%h5CJ\%h9%h5CJPJ\nHo(tH"h9%h5CJPJ\nHtHhyyzCJPJnHo(tHh9%hCJPJnHo(tHh9%hCJh9%h!CJ(VZ  pt567[\]lmo 컮잮앋{rh9%h CJh9%hT,?CJPJnHo(tHh*h5CJh*hCJjh9%hCJUjh9%hCJU h9%hCJOJQJ^JaJh9%hB5CJPJnHo(tHh9%hCJPJnHo(tHh9%hCJh9%hCJo(' rtnoz{9:uv $rdWD^r`a$gdT,?$~dWD^~`a$gdT,? $d7$a$$da$yz{&'()678:KLtvϼƫƎƞƫ~oVƼƼ0h9%h0J.>*B*CJOJQJ^JaJphh9%h0J.B*CJphjh9%hCJUjh9%hCJUjh9%hCJU h9%hCJOJQJ^JaJh9%hCJo(h9%hCJh9%hCJPJnHo(tHh9%hT,?CJPJnHo(tHh9%h CJPJnHo(tH!    (*abhlnpRTʽ뭽ۣۣ룄tjh9%h5o(h9%h5PJnHo(tH+h9%hCJOJPJQJaJnHo(tHh9%h h CJh9%hCJo(jh9%hCJUjh9%hCJU h9%hCJOJQJ^JaJh9%hCJPJnHo(tHh9%hCJh9%h5CJ\'   )*op "$&(*$da$*,.02468:<>@BDFHJLNPR&Ld $$1$Ifa$$da$TVX  FH˿ygU;2h9%h5CJKHOJPJQJaJnHo(tH#h9%h5CJKHOJQJaJ#h9%hCJPJaJnHo(tH&h9%hno5CJPJaJnHo(tH#h9%hno5CJPJaJnHtH#h9%h25CJPJaJnHtHh9%h5CJaJo(h9%h5CJaJ&h9%h5CJPJaJnHo(tHh9%h5h9%h5PJnHo(tHh9%h5HJLd)Ͻ}fUfUfU}ϽϽϽHh9%hGCJKHaJ!h9%h5CJKH\aJo(-h9%h5CJKHPJ\aJnHo(tHh9%hCJKHaJo(!hF|(CJKHPJaJnHo(tH'h9%h&6CJKHPJaJnHo(tHh9%hCJKHaJ#h9%h5CJKHOJQJaJ2h9%h5CJKHOJPJQJaJnHo(tH,hF|(5CJKHOJPJQJaJnHo(tHd);MS{seee$$1$Ifa$gdE#6$1$Ifxkd$$Ifl\ (#  p(#644 lal $$1$Ifa$ ):;LMRST!%&*+;<=W\]bcwy¯¯¯¯¯¯¯¯¯r$hGhGCJKHPJaJnHtHh9%hGCJ'h9%hGCJKHPJaJnHo(tHh9%hGCJKHaJ$h/jhGCJKHOJQJ^JaJ'h/jhGCJKHOJQJ^JaJo('hhG5CJKHOJQJ^JaJ*hhG5CJKHOJQJ^JaJo('ST~ppp$$1$Ifa$gdE#6$1$Ifxkd"$$Ifl\ (#  p(#644 lalxjjj$$1$Ifa$gdE#6w00$IfXDYDxkd$$Ifl\ (#  p(#644 lal!&+<~ppp$$1$Ifa$gdE#6$1$Ifxkdr$$Ifl\ (#  p(#644 lal<=W]cw~ppa$$1$4$Ifa$gdG$$1$Ifa$gdE#6$1$Ifxkd$$Ifl\ (#  p(#644 lalwxy~ssssss $$1$Ifa$$1$Ifxkd$$Ifl\ (#  p(#644 laly Ӽ|kTkTk|-h9%hG5CJKHPJ\aJnHo(tH!h9%hG5CJKH\aJo(h9%hGCJKHaJo(!hGCJKHPJaJnHo(tH'h9%hGCJKHPJaJnHo(tHh9%hGCJKHaJ,hG5CJKHOJPJQJaJnHo(tH2h9%hG5CJKHOJPJQJaJnHo(tH#h9%hG5CJKHOJQJaJ 7I[a~pdp $$Ifa$gds $$1$Ifa$gdE#6$1$Ifxkdd$$Ifl\ (#  p(#644 lal 7HIZ[`as )*12:wjQjwjjwj0hkhW&CJKHOJPJQJ^JaJnHtHh9%hW&CJKHaJ$h/jhW&CJKHOJQJ^JaJ'h/jhW&CJKHOJQJ^JaJo( hW&hW&CJOJQJ^JaJ#hW&hW&CJOJQJ^JaJo('h]hW&5CJKHOJQJ^JaJ*h]hW&5CJKHOJQJ^JaJo('h9%hW&CJKHPJaJnHo(tHabs~pdp $$Ifa$gds $$1$Ifa$gdE#6$1$Ifxkd$$Ifl\ (#  p(#644 lal~pdp $$Ifa$gds $$1$Ifa$gdE#6$1$Ifxkd$$Ifl\ (#  p(#644 lal*2~pdp $$Ifa$gds $$1$Ifa$gdE#6$1$IfxkdV $$Ifl\ (#  p(#644 lal23~pdp $$Ifa$gds $$1$Ifa$gdE#6$1$Ifxkd $$Ifl\ (#  p(#644 lal:g{ $6PTU\b뺦g뺦T뺦T뺦$h/jhW&CJKHOJQJ^JaJ0hkhW&CJKHOJPJQJ^JaJnHtH'h/jhW&CJKHOJQJ^JaJo(#hW&hW&CJOJQJ^JaJo('h]hW&5CJKHOJQJ^JaJ*h]hW&5CJKHOJQJ^JaJo(h9%hW&CJKHaJo(h9%hW&CJKHaJ'h9%hW&CJKHPJaJnHo(tH~pdp $$Ifa$gds $$1$Ifa$gdE#6$1$Ifxkd $$Ifl\ (#  p(#644 lal ~pdp $$Ifa$gds $$1$Ifa$gdE#6$1$IfxkdN $$Ifl\ (#  p(#644 lalPU\c~pdX $$Ifa$gdE#6 $$Ifa$gds $$1$Ifa$gdE#6$1$Ifxkd $$Ifl\ (#  p(#644 lalbcuܲn[nKn[;hw5hW&CJOJQJaJo(hW&CJKHPJaJnHtH$hGhW&CJKHPJaJnHtH!hW&CJKHPJaJnHo(tHhW&hW&CJOJQJaJ#hW&hW&CJOJQJ^JaJo("h]hW&5CJOJQJaJo(*h]hW&5CJKHOJQJ^JaJo('h9%hW&CJKHPJaJnHo(tHh9%hW&CJKHaJ,hkhW&CJOJPJQJ^JaJnHtHcd~rfX$$4$Ifa$gdW& $$Ifa$gds $$Ifa$gdE#6$1$Ifxkd $$Ifl\ (#  p(#644 lal~rfr $$Ifa$gds $$Ifa$gdE#6$1$IfxkdF$$Ifl\ (#  p(#644 lal049?@IJKNTU̸rbPArbhW&hW&CJOJQJaJ"h]hW&5CJOJQJaJo(hw5hW&CJOJQJaJo(hW&CJKHPJaJnHtH!hW&CJKHPJaJnHo(tH$hGhW&CJKHPJaJnHtH#hW&hW&CJOJQJ^JaJo(&h]hW&5CJOJQJ^JaJo(h9%hW&CJKHaJ'h9%hW&CJKHPJaJnHo(tH$h9%hW&CJKHPJaJnHtH49@U~rfr $$Ifa$gds $$Ifa$gdE#6$1$Ifxkd$$Ifl\ (#  p(#644 lalUV~rfr $$Ifa$gds $$Ifa$gdE#6$1$Ifxkd$$Ifl\ (#  p(#644 lalUV[du󸦓rbL:"h]hW&5CJOJQJaJo(*h]hW&5CJKHOJQJ^JaJo(hw5hW&CJOJQJaJo(hW&CJKHPJaJnHtH!hW&CJKHPJaJnHo(tH$hGhW&CJKHPJaJnHtH#hW&hW&CJOJQJ^JaJo(&h]hW&5CJOJQJ^JaJo('h9%hW&CJKHPJaJnHo(tH$h9%hW&CJKHPJaJnHtHh9%hW&CJKHaJ~rfr $$Ifa$gds $$Ifa$gdE#6$1$Ifxkd>$$Ifl\ (#  p(#644 lal45:>?GHIJOUrvw˾˾tcTE3E3#h9%hF5B*CJ\aJphh9%hFB*CJaJphh9%hB*CJaJph h9%h)iB*CJaJo(ph#h9%hCJPJaJnHo(tH#hW&hW&CJOJQJ^JaJo("h]hW&5CJOJQJaJo('h9%hW&CJKHPJaJnHo(tHh9%hW&CJKHaJhw5hW&CJOJQJaJo('h/jhW&CJKHOJQJ^JaJo(hW&hW&CJOJQJaJo(5:?H~rfr $$Ifa$gds $$Ifa$gdE#6$1$Ifxkd$$Ifl\ (#  p(#644 lalHIJKLMNOUrwzzzzzzm\-00$IfXDYDgd{/ -00XDYDgdF -00XDYDxkd$$Ifl\ (#  p(#644 lal wP?w00$IfXDYDgd{/fkd6$$IflF" U t6    44 la-$00$IfXDYD]a$gded-$00$4$IfXDYD]a$gd{/-$00$4$IfXDYDa$gd{/ؾ쯝vb[bG11*h9%h`CJPJhmH nHo(sH tH'h9%h`CJPJhmH nHsH tH h9%h`&h9%h`CJhmH nHo(sH tH$h/jh`CJKHOJQJ^JaJ'h/jh`CJKHOJQJ^JaJo(#h9%h`CJhmH nHsH tHh9%hFKHPJnHtH2h9%hed5B*CJPJ\aJnHo(phtH&h9%hed5B*CJ\aJo(ph&h9%hF5B*CJ\aJo(ph8 vew00$IfXDYDgd{/fkd$$IflF" U t6    44 law$00$IfXDYDa$gd)$$1$Ifa$gdE#6   # 8 9 > @ F G v!!!!!!!!!!!!!! """"H"\"^"b"d"x"""IJIJīIJIJؚIJIJīnnch9%h`CJaJ+h9%h`CJOJPJQJaJnHo(tH*h9%h`CJPJhmH nHo(sH tH h`CJhmH nHo(sH tH h9%h`#h9%h`CJhmH nHsH tH&h9%h`CJhmH nHo(sH tH$h/jh`CJKHOJQJ^JaJ'h/jh`CJKHOJQJ^JaJo(&8 9 v!!!yew$00$IfXDYDa$gd)$$1$Ifa$gdE#6w00$IfXDYDgd{/fkd,$$IflF" U t6    44 la!!!""ym $$Ifa$gd)$$1$Ifa$gdE#6w00$IfXDYDgd{/fkd$$IflF" U t6    44 la""H"^"b"wk $$Ifa$gd)$$1$Ifa$gdE#6w00$IfXDYDgd{/hkd"$$Ifl\F" U t6    44 lab"d""""ym $$Ifa$gd)$$1$Ifa$gdE#6w00$IfXDYDgd{/fkd$$IflF" U t6    44 la""""""""""""" #(#*#4#6#p#r#t#|#̻̕ugugug^ugT@&h9%hF5CJKHOJQJaJo(h9%hFCJo(h9%hFCJh9%hF5CJaJo(h9%hF5CJaJ&h9%h@w5CJPJaJnHo(tH#h9%hFCJPJaJnHo(tH'h/jh`CJKHOJQJ^JaJo( h9%h`CJKHaJnHtHh9%h`CJaJ+h9%h`CJOJPJQJaJnHo(tH$h/jh`CJKHOJQJ^JaJ"""""u $$Ifa$gd)$$1$Ifa$gdE#6 $Ifgd{/fkd$$IflF" U t6    44 la""""4#6#r#t#~##"$|pp $$Ifa$gd{/ $$Ifa$gd{/ $da$gdFgdFfkd$$IflF" U t6    44 la |#~#####$$ $ $$ $"$$$2$4$հjjWC0$h9%h`CJKHPJaJnHtH'h9%h`CJKHPJaJnHo(tH$h9%hFCJKHOJQJ^JaJ(h9%hFCJKHOJPJQJnHtHhGxCJKHOJQJo(h9%hFCJKHOJQJ(h9%hFCJKHOJPJQJnHtH+h9%hF5CJKHOJPJQJnHtHhGx5CJKHOJQJo(.h9%hF5CJKHOJPJQJnHo(tH#h9%hF5CJKHOJQJaJ"$$$4$J$`$$$1$Ifa$gdE#6 $Ifgd{/ekd$$Ifl,F3 > O6    44 la4$H$J$^$`$b$$$$$$$$$$$$$$$%%*%,%8%:%<%%%%%%%%% &¯¯¯¯m[¯[#h9%h`CJKHaJnH o(tH 'h9%h`CJKHPJaJnHo(tHh9%h`CJKHaJh9%h`CJKHaJo($h9%h`CJKHOJQJ^JaJ$h@gh`CJKHOJQJ^JaJ'h@gh`CJKHOJQJ^JaJo('h+ h`5CJKHOJQJ^JaJ*h+ h`5CJKHOJQJ^JaJo(#`$b$$$$$$1$Ifa$gdE#6 $Ifgd{/ekd$$Ifl,F3 > O6    44 la$$$$$$$1$Ifa$gdE#6 $Ifgd{/ekd$$Ifl,F3 > O6    44 la$$%,%:%$$1$Ifa$gdE#6 $Ifgd{/ekd$$Ifl,F3 > O6    44 la:%<%%%%vv$$1$Ifa$gdE#6$IfVDKWDY^`gd (ekd $$Ifl,F3 > O6    44 la%%% &&vv$$1$Ifa$gdE#6$IfVDKWDY^`gd (ekd$$Ifl,F3 > O6    44 la & &&&&&&&@&~&&&&&ık]F2 #h9%hF5CJKHOJQJaJ&h9%hF5CJKHOJQJaJo(,h9%hFB*CJPJaJnHo(phtHh9%hF5CJaJo(&h9%hF5CJPJaJnHo(tHh9%hF5CJaJ&h9%h)i5CJPJaJnHo(tH#h9%hFCJPJaJnHo(tH$h9%h`CJKHOJQJ^JaJ$h@gh`CJKHOJQJ^JaJ'h@gh`CJKHOJQJ^JaJo('h+ h`5CJKHOJQJ^JaJ &&& &"&$&&&&&zzzzzR(<TPL HD@< ^gdF $da$gdFTQ gdFekd$$Ifl,F3 > O6    44 la&&&& ' '&'<'R'}oo$$1$Ifa$gdE#6 $Ifgd{/`kd$$IflF '!@ @  t!    4 la $$Ifa$gd{/ $$Ifa$gd{/&&&&&&&&&&&' ' '$'&':'蛋~i`RE/*h+ h`5CJKHOJQJ^JaJo(h9%h`CJKHaJh9%h`CJKHaJo(h9%hFQJ(h9%hFCJKHOJPJQJnHtHhGxCJKHOJQJo(h9%hFCJKHOJQJo(+h9%hFCJKHOJPJQJnHo(tH+h9%hF5CJKHOJPJQJnHtHhGx5CJKHOJQJo("h9%hF5CJKHOJQJo(.h9%hF5CJKHOJPJQJnHo(tH:'<'P'R'T'x'z'''''''''''''''(((ķq^q^QCq^q^h(I($$1$Ifa$gdM $Ifgd{/`kd$$IflF '!@ @  t!    4 la((#($(2(3(=(>(H(I(J(K(((߾m`NB4h5CJKHOJQJ^JaJ*h*h>5CJKHOJQJ^JaJo($hCJKHOJQJ^JaJ'hCJKHOJQJ^JaJo('h5CJKHOJQJ^JaJ*h5CJKHOJQJ^JaJo( hCJPJaJnHtHh5CJKHOJQJ^JaJ*h*h>5CJKHOJQJ^JaJo($h@gh>CJKHOJQJ^JaJ'h@gh>CJKHOJQJ^JaJo('h+ h>5CJKHOJQJ^JaJ*h+ h>5CJKHOJQJ^JaJo( h9%h>CJPJaJnHtHh9%h>CJOJQJaJ$h/jh>CJKHOJQJ^JaJ'h/jh>CJKHOJQJ^JaJo(C+D+Z+i+w+++{rddVd$$1$Ifa$gd&$$1$Ifa$gdE#6 $Ifgd{/kda$$Ifrn H&d&4 a+++++----..{vnnbbbZZZ$da$ $7$8$H$a$gdF$a$gdFgdFkd$$Ifrn H&d&4 a +++++,%,/,3,d,e,f,|,,,,,,,,,--------- .9.vkZ h`hCJPJaJnHtHhPJnHo(tHhhPJnHo(tHh9%h)i5PJnHo(tHh`hFCJaJnHtHh`h`CJKHaJ h`h ,CJPJaJnHtHh`hFCJaJ h`h\CJPJaJnHtH#h`hFCJPJaJnHo(tH h`hFCJPJaJnHtH9.=.\.].p...............////"/#/ķķ{kcYcYcYh9%h5o(h9%h5h9%h ,5PJnHo(tHh)i5PJnHo(tHh9%h)i5PJnHo(tHhh)iPJnHo(tH!hCJKHPJaJnHo(tHh`hCJKHaJ!hCJKHPJaJnHo(tHhCJPJaJnHo(tH h`hCJPJaJnHtHh`hCJaJ.............#/$/?/@/A/M/X/$$If^a$ $If^7$8$H$$da$#/$/>/?/@/A/J/K/L/M/U/V/W/X/Y/i/////0ȶzezzezXFzFX>h9%h1do(#h9%h5B*CJaJo(phh9%hOJQJaJ)h ,5B*CJPJaJnHo(phtH/h9%h5B*CJPJaJnHo(phtH h9%h5B*CJaJph%h9%hB*CJOJQJaJph#h9%hCJPJaJnHo(tHh9%h5CJaJo(h9%h5CJaJ9h9%h5CJKHOJPJQJ\^JaJnHo(tHX/Y/i/t/////uuuuu$$If^a$$$If^a$okdy$$IfTl4TF "$  t1%6    44 laf4T//00 000i`QQBB$d$Ifa$gdF$d$Ifa$gdEE v$$Ifa$kd $$IfTl4Tr ""$  t1%644 laf4T00000%0-0.0J0K0S0T0000000000000000001!1"1$1&1'1?1@1j11111111ºººӦӦººӦӦ|h9%h5CJaJ#h9%hCJPJaJnHo(tHh9%h1dnHo(tHh9%h1dOJQJ^J h9%h1dh9%h1do( h9%h1dOJQJ^JnHtHh9%h1dCJaJ#hnh1dCJPJaJnHo(tHhnCJPJaJnHo(tH,00%0'0)0+0-0i`QQBB$d$Ifa$gdF$d$Ifa$gdEE v$$Ifa$kd $$IfTl4Tr ""$  t1%644 laf4T-0.0K0M0O0Q0S0i`QQBB$d$Ifa$gdF$d$Ifa$gdEE v$$Ifa$kdl!$$IfTl4Tr ""$  t1%644 laf4TS0T000000i^OO@@$d$Ifa$gdF$d$Ifa$gdEE v$$G$Ifa$kd!"$$IfTl4Tr ""$  t1%644 laf4T0000000i`QQBB$d$Ifa$gdF$d$Ifa$gdEE v$$Ifa$kd"$$IfTl4Tr ""$  t1%644 laf4T0000000i`QQBB$d$Ifa$gdF$d$Ifa$gdEE v$$Ifa$kd#$$IfTl4Tr ""$  t1%644 laf4T001'1-191?1i`QQBB$d$Ifa$gdF$d$Ifa$gdEE v$$Ifa$kd@$$$IfTl4r ""$  t1%644 laf4T?1@1j1v1|111i`QQBB$d$Ifa$gdF$d$Ifa$gdEE v$$Ifa$kd$$$IfTl4Tr ""$  t1%644 laf4T1111111i`QQBB$d$Ifa$gdF$d$Ifa$gdEE v$$Ifa$kd%$$IfTl4Tr ""$  t1%644 laf4T111c2d2e2f2g2h2i2j2ig_g______$da$kd_&$$IfTl4Tr ""$  t1%644 laf4T 111222!2"2,2/2G2H2I2K2M2N2b2c2d2x222222ϢϰώzϢ_K&h9%h)i5CJPJaJnHo(tH5h9%h5CJOJPJQJ\^JaJnHo(tH&h9%h&65CJPJaJnHo(tH&h9%h@w5CJPJaJnHo(tHh9%h5CJaJo( h`5CJPJaJnHo(tHhNh`5CJaJo(h9%h5CJaJ hn5CJPJaJnHo(tH&h9%h5CJPJaJnHo(tHj2k2l2m2n2o2p2q2r2s2t2u2v2w2x2223+3A3W3t333$$If^a$^$da$2233 333333*3+3V3W3333||jYjYjA*,h$Yh5B*CJPJaJnHphtH/h$Yh5B*CJPJaJnHo(phtH h$Yh5B*CJaJph#h$Yh5B*CJaJo(ph/h$Yh5B*CJPJaJnHo(phtH#h$Yh5B*CJaJo(ph4h9%hGB*CJOJPJQJaJnHo(phtH(h9%hB*CJOJQJaJo(ph,h9%hB*CJPJaJnHo(phtH#h9%hCJPJaJnHo(tH334*464<4kYD//$d$1$7$8$H$Ifa$gdE#6$d$1$7$8$H$Ifa$gdd$1$7$8$H$Ifgd_kd'$$IfTֈ ~4 T$ p T$aT3344*45464<4=4>4?4@4A4F4G4j4|4}4~444444444444444 55555555 5!595οοοθοοθοοΒθuοοοθh$YhOk&CJaJ#h$YhOk&CJPJaJnHo(tH#h$YhOk&CJKHOJQJaJo('h$YhOk&CJKHPJaJnHo(tH h9%hOk&h$YhOk&CJKHOJaJh$YhOk&CJKHOJaJo(h$YhOk&5CJKHaJh$YhOk&CJKHaJ h9%h+<4>4@4A4Z4j4VD/$d$1$7$8$H$Ifa$gdd$1$7$8$H$Ifgd_kd'$$IfTֈ ~4 T$ p T$aT$d$1$7$8$H$Ifa$gdE#6j4v4|4~44$d$1$7$8$H$Ifa$gdE#644$kd($$IfTֈ ~4 T$ p  <T$ap<T4444444$d$1$7$8$H$Ifa$gdE#6$d$1$7$8$H$Ifa$gdd$1$7$8$H$Ifgd_44$kd)$$IfTֈ ~4 T$ p  <T$ap<T445555 5$d$1$7$8$H$Ifa$gdE#6$d$1$7$8$H$Ifa$gdXd$1$7$8$H$Ifgd_ 5!5$kd$+$$IfTֈ ~4 T$ p  <T$ap<T95:5@5A5E5F5L5M5R5S5W5X5\5]5d5e5j5k5l5m5n5o55555555555555555555555ȶȦȶȦȅxh$YhOk&CJKHaJh$YhOk&CJaJ h9%hOk&h$YhOk&CJKHOJaJh$YhOk&CJKHOJaJo(#h$YhOk&CJPJaJnHo(tH'h$YhOk&CJKHPJaJnHo(tH$h$YhOk&CJKHPJaJnHtH h$YhOk&CJOJQJ^JaJ+!5X5]5e5j5l5n5$d$1$7$8$H$Ifa$gdE#6$d$1$7$8$H$Ifa$gdXd$1$7$8$H$Ifgd_n5o5$kdp,$$IfTֈ ~4 T$ p  <T$ap<To5555555$d$1$7$8$H$Ifa$gdE#6$d$1$7$8$H$Ifa$gdd$1$7$8$H$Ifgd_55$kd-$$IfTֈ ~4 T$ p  <T$ap<T5555555$d$1$7$8$H$Ifa$gdE#6$d$1$7$8$H$Ifa$gdd$1$7$8$H$Ifgd_555$ Z$4$IfgdE?*kd/$$IfTֈ ~4 T$ p  <T$ap<T55$6*6168696>6?6@6A6B6C6L6[6\6c6d6i6j6k6l6m6n666666666666666ĴēnaāĴh$YhOk&CJKHaJ$h$YhOk&CJKHPJaJnHtH#h$YhOk&CJPJaJnHo(tHh$YhOk&CJaJ h9%hOk&h$YhOk&CJKHOJaJh$YhOk&CJKHOJaJo('h$YhOk&CJKHPJaJnHo(tH$h*hE?*CJKHPJaJnHtH'h*hE?*CJKHPJaJnHo(tH%56+61696>6@6B6$d$1$7$8$H$Ifa$gdE#6$d$1$7$8$H$Ifa$gd Z$4$IfgdE?*B6C6$kdT0$$IfTֈ ~4 T$ p  <T$ap<TC6L6\6d6i6k6m6$d$1$7$8$H$Ifa$gdE#6$d$1$7$8$H$Ifa$gdd$1$7$8$H$Ifgdmm6n6$kd1$$IfTֈ ~4 T$ p  <T$ap<Tn6666666$d$1$7$8$H$Ifa$gdE#6$d$1$7$8$H$Ifa$gdd$1$7$8$H$Ifgd_666$"kd2$$IfTֈ ~4 T$ p  <T$ap<T6666677677787K77777777777ͼ흋zm]NC4m]ChB,=ho\B*OJQJphh$Yho\CJaJh$Yho\CJKHOJaJh$Yho\CJKHOJaJo(h$Yho\CJKHaJ hB,=h5B*OJQJph#h$Yh5B*CJaJo(ph h$Yh5B*CJaJphh9%h5CJaJo( hB,=5CJPJaJnHo(tH&h9%h5CJPJaJnHo(tHh9%h5CJaJ#h9%hCJPJaJnHo(tH67787L7z777777{fW$d,$Ifa$gdV$d$1$7$8$H$Ifa$gdE#6d$1$7$8$H$Ifgd_]kd84$$IflFP" "    4 la $If^$da$ 77777zk$d,$Ifa$gdV$d$1$7$8$H$Ifa$gdE#6d$1$7$8$H$Ifgd_]kd4$$IflFP" "    4 la77 888zk$d,$Ifa$gdV$d$1$7$8$H$Ifa$gdE#6d$1$7$8$H$Ifgd_]kd.5$$IflFP" "    4 la77 8888 8,8-86878@8A8Y8Z8`8a8e8f8l8m8r8s8w8x8888888888888888(9/96979ĹĹoooooĹĹĹo$h$Yho\CJKHPJaJnHtH h$Yho\CJOJQJ^JaJ'h$Yho\CJKHPJaJnHo(tH#h$Yho\CJPJaJnHo(tHh$Yho\CJaJh$Yho\CJKHOJaJh$Yho\CJKHOJaJo(h$Yho\CJKHaJhB,=ho\B*OJQJph+8 8-878@8zk$d,$Ifa$gdV$d$1$7$8$H$Ifa$gdE#6Xd$1$7$8$H$IfgdE#6]kd5$$IflFP" "    4 la@8A8x888zk$d,$Ifa$gdV$d$1$7$8$H$Ifa$gdE#6Xd$1$7$8$H$IfgdE#6]kd06$$IflFP" "    4 la88888zk$d,$Ifa$gdV$d$1$7$8$H$Ifa$gdE#6d$1$7$8$H$IfgdE#6]kd6$$IflFP" "    4 la88888zk$d,$Ifa$gdV$d$1$7$8$H$Ifa$gdE#6d$1$7$8$H$IfgdE#6]kd27$$IflFP" "    4 la88/979@9r$d,$Ifa$gdV$d$1$7$8$H$Ifa$gdE#6 Z$4$IfgdE#6]kd7$$IflFP" "    4 la7989@9A9J9Q9R9[9\999999999999999::U:ӿӿuh_ULBLBLh9%hfsCJo(h9%hfsCJh9%hCJo(h9%hCJho\CJPJnHo(tHh9%ho\OJQJh$Yho\CJKHaJ$h$Yho\CJKHPJaJnHtHh$Yho\CJKHOJaJh$Yho\CJKHOJaJo('h$Yho\CJKHPJaJnHo(tHhB,=ho\B*OJQJphh$Yho\CJaJ#h$Yho\CJPJaJnHo(tH@9A9J9R9[9zk$d,$Ifa$gdV$d$1$7$8$H$Ifa$gdE#6d$1$7$8$H$IfgdE#6]kd48$$IflFP" "    4 la[9\9999xg$d,$4$Ifa$gdV$d$1$7$8$H$Ifa$gdE#6d$1$7$8$H$IfgdE#6_kd8$$IflFP" "    4 la99999;;<<Z=[===@@@@ $da$gdfs$da$]kd:9$$IflFP" "    4 laU:V:::::::::::;;U;V;s;z;;;;;;;;<<;<<<e<f<<<<<<<<<,=-=Y=^==== >>>[>f>ͻh9%h5CJ\hB,=CJPJnHo(tHh9%hCJPJnHo(tHh9%hCJh9%hCJo("h9%hfs5CJPJnHo(tHh9%hfsCJPJnHtHh9%hfsCJPJnHo(tHh9%hfsCJh9%hfsCJo(2f>>>>>>>???@@@@@@@@@&A'A(A)ATAUAdAeAkAlAAAAx[Rh9%h-CJ9h9%h5CJKHOJPJQJ\^JaJnHo(tHh9%h5o(h9%h5h9%h)i5PJnHo(tH#h9%hCJPJaJnHo(tHh9%hCJo(h9%h5CJ\%h9%h5CJPJ\nHo(tH"h9%h5CJPJ\nHtHh9%hCJPJnHo(tHh9%hCJ@@@@@@@@@@@@@@@@@@@@@@@@@'A(AA7$8$H$$da$AAAAAABBBZM$$If^a$kd9$$Iflr4{"7m t64 la$If^gd7 $If^^AAAAAAAAAAAAAAABBBBBBBBBB*B.B/B0BȰٰٰȰٰٰs^K%h9%hB*CJOJQJaJph(h9%hB*CJOJQJaJo(ph#h9%h5B*CJaJo(phh9%hOJQJh9%hmOJQJ)h)5B*CJPJaJnHo(phtH/h9%hm5B*CJPJaJnHo(phtH h9%hm5B*CJaJph#h9%hm5B*CJaJo(ph(h9%hB*CJOJQJaJo(phBBBBBB*B+B,B-B.B`kdk:$$Iflr4{"7m t64 la $If^$$If^a$ .B/BABJBNBRBVBwjj]]]$If^gd$$If^a$kd;$$Iflr4{"7m t64 la0B1B3B@BABIBJBMBNBRBUBVBWBeBfBkB|BBBBBBBҢwaVҢ;ҢaV4h9%hyhB*CJOJPJQJaJnHo(phtHh9%hOJQJ+h9%h5B*CJOJQJaJo(ph+h9%hl&5B*CJOJQJaJo(ph(h9%hl&B*CJOJQJaJo(ph(h9%hB*CJOJQJaJo(ph4h9%hB*CJOJPJQJaJnHo(phtH%h9%hB*CJOJQJaJph4h9%hl&B*CJOJPJQJaJnHo(phtHVBWBfB}BBBBwjj]]]$If^gd$$If^a$kd;$$Iflr4{"7m t64 laBBBBBBBBwjZZMMM$If^gd$$If^a$gdl&$$If^a$kdo<$$Iflr4{"7m t64 laBBBBBBBBBBBBBBBBBCCCC#C&C'C+C,C0C$$Iflr4{"7m t64 lakClC|CCCCCwjj]]]$If^gdE#6$$If^a$kd/?$$Iflr4{"7m t64 lalC{C|C}CCCCCCCCCCCCDNDODSDVDWD[D\D`DlDmDtDDDDD躥te躥te躥h9%hu&OJQJnHtH+h9%hu&5B*CJOJQJaJo(ph4h9%hu&B*CJOJPJQJaJnHo(phtH(h9%hu&B*CJOJQJaJo(ph%h9%hu&B*CJOJQJaJph4ho\hu&B*CJOJPJQJaJnHo(phtH.hu&B*CJOJPJQJaJnHo(phtHCCCODSDWD[Dwjj]]]$If^gdE#6$$If^a$kd?$$Iflr4{"7m t64 la[D\DmDDDDDDDwjZZZMMM$If^gdE#6$$If^a$gdo\$$If^a$kd@$$Iflr4{"7m t64 laDDDDDDDDDE'EQEVEYEZE^E_EyEEEEEEEEEеП}e}eеПe}eJеП4hlhu&B*CJOJPJQJaJnHo(phtH.hu&B*CJOJPJQJaJnHo(phtH%h9%hu&B*CJOJQJaJphh9%hu&OJQJnHtH+h9%hu&5B*CJOJQJaJo(ph4h9%hu&B*CJOJPJQJaJnHo(phtH(h9%hu&B*CJOJQJaJo(ph4hu&hu&B*CJOJPJQJaJnHo(phtHDDDREVEZE^EwjZMMM$If^gd$$If^a$gdu&$$If^a$kd?A$$Iflr4{"7m t64 la^E_EyEEEEEwjj]]]$If^gd$$If^a$kdA$$Iflr4{"7m t64 laEEEEEEEwjj]]]$If^gd$$If^a$kdB$$Iflr4{"7m t64 laEEEEEEEEEEEFF#F(F+F,F0F1FBFCFYF^FaFbFfFgFvFwFFFFFFFFFFFFFFFFFFFF4h9%hu&B*CJOJPJQJaJnHo(phtH%h9%hu&B*CJOJQJaJph(h9%hu&5B*CJOJQJaJph+h9%hu&5B*CJOJQJaJo(ph(h9%hu&B*CJOJQJaJo(phh9%hu&OJQJ/EEEEEEEwjj]]]$If^gd$$If^a$kdOC$$Iflr4{"7m t64 laEEF$F(F,F0Fwjj]]]$If^gd$$If^a$kdC$$Iflr4{"7m t64 la0F1FCFZF^FbFfFwjj]]]$If^gd$$If^a$kdD$$Iflr4{"7m t64 lafFgFwFFFFFwjj]]]$If^gd$$If^a$kd_E$$Iflr4{"7m t64 laFFFFFFFwggZZZ$If^gd$$If^a$gdL]kdF$$Iflr4{"7m t64 laFFFFFFFwjj]]]$If^gd$$If^a$kdF$$Iflr4{"7m t64 laFFFFFFFwjj]]]$If^gd$$If^a$kdoG$$Iflr4{"7m t64 laFFFFFFFFFGBGGGJGKGOGPGTGȲ|a|LaL6+h9%h)OJQJ+h9%h)5B*CJOJQJaJo(ph(h9%h)B*CJOJQJaJo(ph4h9%h)B*CJOJPJQJaJnHo(phtH.h)B*CJOJPJQJaJnHo(phtH%h9%h)B*CJOJQJaJphh9%hu&OJQJ+h9%hu&5B*CJOJQJaJo(ph(h9%hu&B*CJOJQJaJo(ph#h9%hu&5B*CJaJo(ph h9%hu&5B*CJaJphFFFCGGGKGOGwggZZZ$If^gdE#6$$If^a$gdE#6kdH$$Iflr4{"7m t64 laOGPG_GvGzG~GGwjj]]]$If^gd$$If^a$kdH$$Iflr4{"7m t64 laTG_GuGzG}G~GGGGGGGGGGGGGGGGGGGG H?H@HDHGHHHLHMH]H^HoHpHsHҽ彧ҽ彧ҽ彧uuҽ彧ҽҽu.h)B*CJOJPJQJaJnHo(phtHh9%h)OJQJnHtHh9%h)OJQJ+h9%h)5B*CJOJQJaJo(ph(h9%h)B*CJOJQJaJo(ph%h9%h)B*CJOJQJaJph4h9%h)B*CJOJPJQJaJnHo(phtH%GGGGGGGwjj]]]$If^gd$$If^a$kdI$$Iflr4{"7m t64 laGGGGGGGwjj]]]$If^gd$$If^a$kd/J$$Iflr4{"7m t64 laGGG@HDHHHLHwjj]]]$If^gdE#6$$If^a$kdJ$$Iflr4{"7m t64 laLHMH^HpHtHyH}Hwjj]]P$If^gdE#6$If^gd$$If^a$kdK$$Iflr4{"7m t64 lasHtHxHyH}H~HHHHHHHHHHHHHHHHHH͸e͸eI7h9%h)5B*CJOJPJQJaJnHo(phtH4h9%h)B*CJOJPJQJaJnHo(phtH%h9%h)B*CJOJQJaJphh9%h)OJQJnHtH+h9%h)5B*CJOJQJaJo(ph(h9%h)B*CJOJQJaJo(ph.h)B*CJOJPJQJaJnHo(phtH4h)h)B*CJOJPJQJaJnHo(phtH}H~HHHHHHwjj]]]$If^gd$$If^a$kd?L$$Iflr4{"7m t64 laHHHHHHHwjj]]]$If^gd$$If^a$kdL$$Iflr4{"7m t64 laHHHIIOMPMMMNN3Nwummmummbum $da$gdE?*$da$kdM$$Iflr4{"7m t64 la HHHHHHHHIII!I'I6IsIIIIIIIIIIIIIIJJJJJJJJJ#J$JAJBJJ佰wjhB,=CJPJnHo(tHh9%hCCJPJnHo(tHh9%hBCJPJnHtHh9%hBCJPJnHo(tHhlIhlICJo(hlICJPJnHo(tHhSyCJPJnHo(tHh9%hCJo(h9%hCJPJnHo(tHh9%hCJ#h9%hCJPJaJnHo(tH)JJJJK K`KaKKKLLwLxLLL,M-MGMHMNMOMPMMMMMMMNNNN2N3Nʾܠog]h9%h5o(h9%h5#hE?*hCJPJaJnHo(tHh9%hE?*CJPJnHo(tHh*hE?*CJPJnHtHh*hE?*CJPJnHo(tHh9%h5CJaJo(h9%h5CJaJ#h9%hCJPJaJnHo(tHh9%hCJPJnHo(tHh9%hCJh9%hCJo("3N4NNNOOQQwQxQQQSSSSUU4Z5ZS[T[m^n^^ & F&gdE?*`gdE?*gdE?* $da$gd$ $da$gd[)j3N4NoNpNNNNNNNNNNNN O OOOO!O$O(O?OMOUOVO`OaO̴ֿynZIyy hh[)jCJPJaJnHtH'hh[)jCJPJQJaJnHo(tHhh`FCJaJhh[)jCJaJo(#hh`FCJPJaJnHo(tH#hh[)jCJPJaJnHo(tHhh[)jCJaJh9%h[)jCJaJh[)jCJPJnHo(tHh9%h[)jCJo(h9%h[)jCJPJnHo(tHh9%h[)jCJhp@pHpJpRpVpdpfpppppp q$q&qVqķġďďďďķķya.h[)jhE?*CJOJPJQJ\aJnH o(tH +h,hE?*CJOJPJQJ\aJnHtH#h,hE?*CJOJPJQJ\aJ+h,hE?*CJOJPJQJ\aJnH tH hE?*CJOJQJ\aJh,hE?*CJOJQJ\aJ.h,hE?*CJOJPJQJ\aJnH o(tH %hE?*CJOJPJQJ\aJnH tH &%n$q&qqqssssttuuuuXwYwxxzzzz{ $da$gdwj ^`$da$h^hgdE?* & F"gdE?*gdE?*VqqqqZr`rarrrrrr)s*ssssss tttttttttuuuuuv|hV#h)ShE?*CJOJPJQJ\aJ'h[)jhE?*CJOJQJ\aJnHtHh)ShE?*CJOJQJ\aJhE?*CJOJQJ\aJ#h[)jhE?*CJOJPJQJ\aJ.h[)jhE?*CJOJPJQJ\aJnH o(tH +h[)jhE?*CJOJPJQJ\aJnHtH+h)ShE?*CJOJPJQJ\aJnHtHh[)jhE?*CJOJQJ\aJ!vvXwYwwwxx)x3x5x8x9xBxPxYxZx[xkxtxyxxxxxxxxyyyy@yGyyyyz zzzzz⺧⧺{khE?*hX5PJnHo(tH+h[)jhE?*CJOJPJQJ\aJnH tH +h[)jhE?*CJOJPJQJ\aJnHtH%hE?*CJOJPJQJ\aJnH tH .h[)jhE?*CJOJPJQJ\aJnH o(tH h)ShE?*CJOJQJ\aJh[)jhE?*CJOJQJ\aJhE?*CJOJQJ\aJ*zzzz{ {%{&{.{/{1{4{B{K{n{o{{{{{{{{{{{ҿ|pbpbpbE9h9%h5CJKHOJPJQJ\^JaJnHo(tHh9%h5CJaJo(h9%h5CJaJ3h9%hCJKHOJ PJQJ ^J aJnHo(tHh*hwjCJo(h*h;CJPJnHo(tHh*h;CJPJnHtHh*hwjCJh9%hwjCJo(h9%hwjCJ#h9%hCJPJaJnHo(tHh9%h5o(h9%h5{{{{w}x}}}23΂ς$%ǃȃWX $da$gd2 $da$gdZ6 $da$gdwj$da$7$8$H${{{{||(|.|1|5|D|E|K|Q|R|k|l|||}||||||||}}}}!}m}n}v}x}}}qaqqaqh9CJPJQJ]aJnHo(tH*h9CJPJnHo(tHh9CJPJnHo(tHh*hwjCJ߀&'13CDElpqru‚ĂłȂ̂͂΂ςܲܲ¥ҥ¥܅ueh9%h2CJPJnHo(tHh9%h-LCJPJnHo(tHh9%hd9CJPJnHo(tHh9%h`(CJPJnHo(tHh[ZCJPJnHo(tHh9%hC7CJPJnHo(tHh9%hCJPJnHo(tHh9%hCJo(h9%hCJh9%hc!CJPJnHo(tHh9%hZ6CJo($"#$567:acdfiŃȃ()2<IWXз~neUh9%hCJPJnHo(tHhE?*hCJhE?*hDwlCJPJnHo(tHhE?*hp"CJPJnHo(tHhE?*h[ZCJPJnHo(tHh9%hCJh9%hCJPJnHo(tHh9%hCJo(h9%h2CJPJnHtHh[ZCJPJnHo(tHh9%h2CJPJnHo(tHh9%h2CJo(h9%h2CJ XDEWXYZÅą &*:<=AJck7еݑh9%h5CJaJ4h9%hwjB*CJOJPJQJaJnHo(phtHh9%hCJh9%hwjCJPJnHtHh[ZCJPJnHtHh[ZCJPJnHo(tHh9%hwjCJo(h9%hwjCJPJnHo(tHh9%hwjCJ489abPQw $$1$Ifa$ $da$gdE?*7$8$H$$da$^789PR]^_opstLJȇ͇̇R6CGQYZ`bfjrĊŊȊˊ̊ϊۊ܊ſŵh*hE?*CJh*hE?*CJo( hE?*CJhZhE?*CJo(hZhE?*CJ3h5CJKHOJPJQJ\^JaJnHo(tHh9%h5CJaJo(D24Mk?AQRSVW^nrŌΌیߌ.278:>EHIVX`efi~̍ h*hE?*CJPJnHo(tHh*hE?*CJo(h*hE?*CJW"'*+.12FLOSUVYabceoqtux|}ÎĎŎDIJNOPưuuuh9%h5CJaJo(h9%h5CJaJ hE?*5CJPJaJnHo(tHhE?*hCJPJnHo(tHh9%hE?*CJPJnHo(tH hE?*CJh9%hE?*CJo(hp*hE?*CJhp*hE?*CJo(h9%hE?*CJh*hE?*CJh*hE?*CJo(-PQvwഝq]L9.h9%hCJKH$h9%hCJKHPJaJnHtH!hICJKHPJaJnHo(tH'h9%h@uCJKHPJaJnHo(tH'h9%hCJKHPJaJnHo(tH/h9%h5CJKHOJPJQJaJnHtH,hI5CJKHOJPJQJaJnHo(tH2h9%h5CJKHOJPJQJaJnHo(tH#h9%h5CJKHOJQJaJ&h9%h5CJKHOJQJaJo(h9%hQJ]o(Ïɏ $$1$Ifa$$1$IfhkdON$$Ifl4?F  6    44 la]f4Ïȏɏʏ *+4DTU\l{|ƐǐͺyeSeSeS#h9%h5CJKHOJQJaJ&h9%h5CJKHOJQJaJo(h9%hQJ]o(h9%hICJKHh9%hICJKHnHtHhIhICJKHaJhIhI5CJKHaJ$h9%hICJKHPJaJnHtHh9%hCJKH$h9%hCJKHPJaJnHtH'h9%hCJKHPJaJnHo(tH ɏʏphZZZZ$$1$Ifa$gdE#6$1$IfkdN$$Ifl4?r)A644 la]f4 "*sk]]]]$$1$Ifa$gdE#6$1$IfkdUO$$Ifl?r)A644 la]*+4<DLTsk]]]]$$1$Ifa$gdE#6$1$IfkdO$$Ifl?r)A644 la]TU\dlt{sk]]]]$$1$Ifa$gdE#6$1$IfkdUP$$Ifl?r)A644 la]{|sk]]]]$$1$Ifa$gdE#6$1$IfkdP$$Ifl?r)A644 la]ǐ&se]RRR $$1$Ifa$$1$IfVDWD^`kdUQ$$Ifl?r)A644 la]%&':;z{Ǒȑɑӑߑ DEʒ˒̒ϻnbVh*h5CJaJh9%h5CJaJ&h9%hC5CJPJaJnHo(tHh9%hICJKHaJo(h9%hICJKHhIhICJKHaJ$h9%hICJKHPJaJnHtH'h9%hICJKHPJaJnHo(tHh9%hCJKH#h9%h5CJKHOJQJaJ&h9%h5CJKHOJQJaJo(&';Pez~ppp$$1$Ifa$gdE#6$1$IfxkdQ$$Ifl?\644 la]z{Ǒ~ppp$$1$Ifa$gdE#6$1$IfxkdMR$$Ifl?\644 la]Ǒȑ ~ppp$$1$Ifa$gdE#6$1$IfxkdR$$Ifl?\644 la] EZo~ppp$$1$Ifa$gdE#6$1$Ifxkd=S$$Ifl?\644 la]ʒ~ppp$$1$Ifa$gdE#6$1$IfxkdS$$Ifl?\644 la]ʒ˒̒ /~~~sss $$1$Ifa$$da$xkd-T$$Ifl?\644 la] ./01=>?wdJ3,hI5CJKHOJPJQJaJnHo(tH2h9%h5CJKHOJPJQJaJnHo(tH$h9%hCJKHOJQJ^JaJh9%hCJKH#h9%h5CJKHOJQJaJ&h9%h5CJKHOJQJaJo(h9%hCJo(h9%h5CJaJo(h9%h5CJaJh*h5CJaJ&h*hE?*5CJPJaJnHo(tH&h*h@u5CJPJaJnHo(tH/01@ETY $$1$Ifa$$1$IfhkdT$$Ifl4?Fq && &  6    44 la]f4?@BCDEQRSTVWXYZͳoU>ͳ3h9%hCJKH,hI5CJKHOJPJQJaJnHo(tH2h9%h5CJKHOJPJQJaJnHo(tH&h9%h5CJKHOJQJaJo(0h9%hCJKHOJPJQJ^JaJnHtH-hICJKHOJPJQJ^JaJnHo(tH3h9%h@uCJKHOJPJQJ^JaJnHo(tH3h9%hCJKHOJPJQJ^JaJnHo(tH/h9%h5CJKHOJPJQJaJnHtHYZkzphZZZZ$$1$Ifa$gdE#6$1$Ifkd&U$$Ifl4?rq &&&'& 644 la]f4Zjkzȓɓؓ,;JYZ[\wxyʽʽʽʽʽʽmaSmh9%h5CJaJo(h9%h5CJaJ)h9%h5CJPJ\aJnHo(tHh9%h5o(h9%h5h9%hC5PJnHo(tHh9%hPJnHo(tHh9%hICJKHhIhICJKHaJhIhI5CJKHaJ$h9%hICJKHPJaJnHtH'h9%hICJKHPJaJnHo(tHɓؓsk]]]]$$1$Ifa$gdE#6$1$IfkdU$$Ifl?rq '''''' 644 la],;JYsk]]]]$$1$Ifa$gdE#6$1$IfkdV$$Ifl?rq '''''' 644 la]YZ[\xyhiskkkakakkkk ^`$da$kdAW$$Ifl?rq '''''' 644 la] giޕwxٖږ+09:NO×ƗJMĘƘۘ伯|h9%h~CJh9%h~CJo(h9%hCJPJnHo(tHh9%h~CJPJnHo(tHhCJPJnHo(tHh9%h` CJPJnHo(tHh9%h` CJnH o(tH h9%h` CJo(h9%h` CJh9%hCJo(h9%hCJ0ėŗKLPQ!"9:LM7$8$H$ $da$gdi $7$8$H$a$gdi $7$8$H$a$$da$$*.1Ampvܚ ,Z]:QY}KOQROֆ}}}h9%hiCJh9%h)5CJPJnHo(tHh9%hiCJo(h9%hiCJPJnHtHhCJPJnHo(tHh9%hiCJPJnHo(tHh9%hCJo(h9%hCJh9%h}CJPJnHo(tHh9%hCJPJnHo(tH1  !"#8:AFOP~ܞ $%.KLMɹɹɹɹҩɠ|nZ'h9%h5CJKHPJaJnHtHh9%h5CJKHaJ3h9%hCJKHOJ PJQJ ^J aJnHo(tHh9%h4$.CJo(h9%h4$.CJh9%hCJPJnHo(tHh9%hCJPJnHo(tHh9%hCJh9%hCJo(h9%hAoCJPJnHo(tHh9%hiCJh9%hiCJo(#MXiן2ER $$1$Ifa$ ERSr~ѠҠ?@FSTUVefŸpeŸpeŸh9%h>CJKH h9%h>CJPJaJnHtH h*h>CJPJaJnHtHh*h>CJPJaJh*h>CJPJaJo(h9%h>CJaJh9%h>CJPJaJh9%h>CJKHaJh9%hCJKH'h9%h5CJKHPJaJnHtHh9%h5CJKHaJ$RSZr)!!$1$IfkdW$$Ifl %;IFC!%F1C*ppp$$$$44 larȠѠ $$Ifa$ $$Ifa$gd& $$Ifa$gd_ѠҠ٠)!!$1$Ifkd Y$$IflY %;IFC!%F1C*ppp$$$$44 la6? $$Ifa$ $$Ifa$gd& $$Ifa$gd_?@F) $$1$Ifa$kd5Z$$IflY %;IFC!%F1C*ppp$$$$44 laFTVegvxz $$Ifa$ $$Ifa$gd8 $$Ifa$gd& $$Ifa$gd_fgvwxz{|HMNOPQкЯ|ococ|c|o|ZJ@J@hh*CJo(hh*CJPJnHo(tHhh*CJh*CJPJnHtHh*CJPJnHo(tHh+h*CJhCJPJnHo(tHh9%hCJo($h9%hCJKHPJaJnHtHh9%h>CJKH+h9%h>CJOJPJQJaJnHo(tH h9%h>CJPJaJnHtHh*h>CJPJaJo( h*h>CJPJaJnHtHz{|<6..$da$7$8$H$kd^[$$IflYִ%;IFC!%wC*ppp    44 laQ cdefgţǣȣͣѣңԣգGK*."}hh*CJQJaJo(hh*CJo(hh*CJPJnHtHhh*CJPJnHo(tHhh*CJLԣգIJ_`pq۩ܩ7$8$H$$da$gd* $da$gd*Χϧ HIJ_asŵym_B9/9h9%hCJo(h9%hCJ9h9%h5CJKHOJPJQJ\^JaJnHo(tHh9%h5CJaJo(h9%h5CJaJ3h9%hCJKHOJ PJQJ ^J aJnHo(tHh9%h5o(h9%h5h9%hKHPJnHo(tHh9%hCJPJnHo(tHhh{_CJPJnHo(tHhhiCJPJnHo(tHhhCJo(hhCJPJnHo(tHsv¨ %0_`opq}کܩ efr9h9%h5CJKHOJPJQJ\^JaJnHo(tHh9%h5CJaJo(h9%h5CJaJ3h9%hCJKHOJ PJQJ ^J aJnHo(tHhB,=CJPJnHo(tHh9%hCJPJnHo(tHh9%h5CJ\h9%hCJh9%hCJo(, 12:Dfj߬in~ukukukukuku[u[ukuku[uh9%hCJPJnHo(tHh9%hCJo(h9%hCJ9h9%h5CJKHOJPJQJ\^JaJnHo(tHh9%h5CJaJo(h9%h5CJaJ3h9%hCJKHOJ PJQJ ^J aJnHo(tHhB,=CJPJnHo(tHh9%hCJPJnHo(tHh9%hCJh9%hCJo(# iٲڲ $$1$Ifa$$7$8$H$]a$ ^` $da$gdo}_ $da$gd7$8$H$$da$ĭŭ./=ծ֮ƷַrrUJh9%hCJaJ9h9%h5CJKHOJPJQJ\^JaJnHo(tHh9%h5CJaJo(h9%h5CJaJ h5CJPJaJnHo(tH3hhCJKHOJ PJQJ ^J aJnHo(tHh*hCJPJnHtHh*hCJPJnHo(tHh*hCJhCJPJnHo(tHh9%hCJh9%hCJo(jkǯ<>p GH\]hiʺ{oaoaoM&h9%h5CJPJaJnHo(tHh9%h5CJaJo(h9%h5CJaJ&h9%hC5CJPJaJnHo(tHh9%hC5CJaJ,h9%h5;CJPJ\aJnHo(tHh9%h5h9%hj5PJnHo(tHh9%ho}_CJaJo(h9%hCJaJo(h9%hCJaJ#h9%hCJPJaJnHo(tHiϲزٲڲ߲۴t]E1'h9%hCJKHPJaJnHo(tH/h9%h5CJKHOJPJQJaJnHtH,hB,=5CJKHOJPJQJaJnHo(tH2h9%h5CJKHOJPJQJaJnHo(tH#h9%h5CJKHOJQJaJ&h9%h5CJKHOJQJaJo(h9%hPJnHo(tHh9%hCJh9%hCJPJnHo(tHh9%hCJo(4h9%h5;@KHOJPJQJ\nHo(tH:<TVrtvȴʴ;̈́;l^R^BhIhI5CJKH\aJhIhI5CJaJhIhI5CJaJo(/h9%hICJKHOJPJQJaJnHo(tH'h9%hCJKHPJaJnHo(tH#h9%h5CJKHOJQJaJ&h9%h5CJKHOJQJaJo(h9%hCJKHOJQJ$h9%hCJKHPJaJnHtH!hB,=CJKHPJaJnHo(tHh9%hCJKHaJo(<Vt $$1$Ifa$$1$Ifekdc\$$IflF"&J &&J%6    44 la5tvʴ ,sk_QCC$$1$Ifa$gds $$1$Ifa$gdE#6 $$Ifa$gdE#6$1$Ifkd\$$Iflr>"&J &&&&%644 la5,.h ./AQRlm}~ʼn]L>nhhICJKH\aJ!hhI5CJKH\aJo(!hh5CJKH\aJo($h9%hICJKHPJaJnHtH'h9%hICJKHPJaJnHo(tHhIhICJKHaJhIhI5CJKHaJhIhI5CJaJhIhI5CJaJo(/h9%hICJKHOJPJQJaJnHo(tHh9%hICJKHOJQJhIhICJKH\aJ,.h̵saUG99$$1$Ifa$gds $$1$Ifa$gdE#6 $$Ifa$gdE#6L$1$IfWD^L`kd{]$$Iflr>"&J ''''%644 la5 /AQsk_QCC$$1$Ifa$gds $$1$Ifa$gdE#6 $$Ifa$gdE#6$1$Ifkd^$$Iflr>"&J ''''%644 la5QRm~sk_QCC$$1$Ifa$gds $$1$Ifa$gdE#6 $$Ifa$gdE#6$1$Ifkd^$$Iflr>"&J ''''%644 la5ʶ˶׶ض*+89XYyzѷҷ߷ ()568bcݸ޸ннннЕнннhIhI5CJKHaJo(h9%hICJKHaJo(hIhI5CJaJhIhI5CJaJo($h9%hICJKHPJaJnHtH'h9%hICJKHPJaJnHo(tHh9%hICJKHOJQJhIhICJKHaJ4˶ضsk__QQ$$1$Ifa$gds $$Ifa$gdE#6$1$IfkdI_$$Iflr>"&J ''''%644 la5+9IXsk__QQ$$1$Ifa$gds $$Ifa$gdE#6$1$Ifkd_$$Iflr>"&J ''''%644 la5XYqzsk]QQCC$$1$Ifa$gds $$Ifa$gdE#6 $1$IfWD` $1$Ifkd}`$$Iflr>"&J ''''%644 la5ҷ saUUGG$$1$Ifa$gds $$Ifa$gdE#6 $1$IfWDp^ `kda$$Iflr>"&J ''''%644 la5 )68Mbsk_QCC$$1$Ifa$gds $$1$Ifa$gdE#6 $$Ifa$gdE#6$1$Ifkda$$Iflr>"&J ''''%644 la5bcsaSSEE$$1$Ifa$gds $$1$Ifa$gdE#6 $1$IfWDp^ `kdKb$$Iflr>"&J ''''%644 la5޸sk__QQ$$1$Ifa$gds $$Ifa$gdE#6$1$Ifkdb$$Iflr>"&J ''''%644 la5 !cdpq}~45PQ^_lmʶʶʶwdʶ$h9%hICJKHOJQJnHtHhIhICJKH\aJhIhI5CJKHaJo($h9%hICJKHPJaJnHtHh9%hICJKHaJo('h9%hICJKHPJaJnHo(tHh9%hICJKHOJQJhIhICJKHaJhIhI5CJaJhIhI5CJaJo('dq~saUUGG$$1$Ifa$gds $$Ifa$gdE#6 $1$IfWDp^ `kdc$$Iflr>"&J ''''%644 la5йsm__QQ$$1$Ifa$gds $$1$Ifa$gdE#6$Ifkdd$$Iflr>"J ''''%644 la5%4sk__QQ$$1$Ifa$gds $$Ifa$gdE#6$1$Ifkdd$$Iflr>"&J ''''%644 la545Q_m|saUUGG$$1$Ifa$gds $$Ifa$gdE#6D$1$IfWD^`DkdMe$$Iflr>"&J ''''%644 la5κܺsaUUGG$$1$Ifa$gds $$Ifa$gdE#6 $1$IfWDp^ `kde$$Iflr>"&J ''''%644 la5ܺݺ !+,DE^_lmz{»λϻ !=>GHɵɵsɵs$h9%hICJKHOJQJnHtHhIhICJKH\aJ$h9%hICJKHPJaJnHtHh9%hICJKHaJo('h9%hICJKHPJaJnHo(tHh9%hICJKHOJQJhIhICJKHaJhIhI5CJaJo(hIhI5CJaJ-ܺݺ!,8DsaUUGG$$1$Ifa$gds $$Ifa$gdE#6 $1$IfWD^` kdf$$Iflr>"&J ''''%644 la5DE_m{sk__QQ$$1$Ifa$gds $$Ifa$gdE#6$1$Ifkdg$$Iflr>"&J ''''%644 la5»ϻݻsk__QQ$$1$Ifa$gds $$Ifa$gdE#6$1$Ifkdg$$Iflr>"&J ''''%644 la5!/=sk__QQ$$1$Ifa$gds $$Ifa$gdE#6$1$IfkdOh$$Iflr>"&J ''''%644 la5=>saUG99$$1$Ifa$gds $$1$Ifa$gdE#6 $$Ifa$gdE#6$1$IfWD ^`kdh$$Iflr>"&J ''''%644 la5¼ۼܼ$% DFNPVƲƲwhhUGhhI5CJaJo($h9%hICJKHOJQJnHtHhIhICJKHQJaJhIhI5CJKHaJhIhI5CJaJhIhI5CJaJo($h9%hICJKHPJaJnHtH'h9%hICJKHPJaJnHo(tHh9%hICJKHOJQJhIhICJKHaJhIhICJKH\aJhIhI5CJKHaJo(¼ܼsk_QCC$$1$Ifa$gds $$1$Ifa$gdE#6 $$Ifa$gdE#6$1$Ifkdi$$Iflr>"&J ''''%644 la5%&'sk]]OO$$1$Ifa$gds $$1$Ifa$gdE#6$1$Ifkdj$$Iflr>"&J ''''%644 la5 FPZftsaUUGG$$1$Ifa$gds $$Ifa$gdE#6 $1$IfWD^` kdj$$Iflr>"&J ''''%644 la5VXZtvƾȾʾ <>Z\ڿ )*ͺykͺyy]yy]yhIhICJKH\aJhhI5CJaJo(hIhI5CJaJhIhI5CJaJo($h9%hICJKHPJaJnHtH'h9%hICJKHPJaJnHo(tH$h9%hICJKHOJQJnHtHhIhICJKHaJ#hhI5CJPJaJnHtH&hhu5CJPJaJnHo(tHtvʾ־saUUGG$$1$Ifa$gds $$Ifa$gdE#6 $1$IfWD^` kdQk$$Iflr>"&J ''''%644 la5 >\|saUUGG$$1$Ifa$gds $$Ifa$gdE#6 $1$IfWD^` kdk$$Iflr>"&J ''''%644 la5ڿ )saUUGG$$1$Ifa$gds $$Ifa$gdE#6 $1$IfWD^` kdl$$Iflr>"&J ''''%644 la5)*saUG99$$1$Ifa$gds $$1$Ifa$gdE#6 $$Ifa$gdE#6 $1$IfWD^` kdm$$Iflr>"&J ''''%644 la589:;BCDz{~мДteN;N2h9%hCJ$h9%hCJfHq &-jh9%hCJUfHq &h9%hCJaJnHtHh9%h5CJaJ'h9%h56PJ\]nHo(tHh9%hPJnHo(tHhIhI5CJaJhIhI5CJaJo('h9%hICJKHPJaJnHo(tH$h9%hICJKHOJQJnHtHhIhICJKHaJhIhI5CJKHaJo(#8saUG99$$1$Ifa$gds $$1$Ifa$gdE#6 $$Ifa$gdE#6 $1$IfWD^` kdm$$Iflr>"&J ''''%644 la589:;BCsqg_q__T_ $da$gd)$da$ T^kdSn$$Iflr>"&J ''''%644 la5 ~6WZcɹ}i]I]>h9%hCJaJ&h9%h5CJPJaJnHo(tHh9%h5CJaJ&hB,=hx5CJPJaJnHo(tH0hxhCCJPJfHnHo(q &tHhxhCJPJnHo(tHhxhxCJhxhxCJo(hxhxCJPJnHo(tH$h$hCJfHo(q &h9%hCJPJnHo(tHh9%hCJh9%hCJo(%$!d$4$Ifa$gds %$!d$Ifa$gds d$If^`gds dgd-0$da$ !"$%&'()*:Ĵsi[sO?h'h-0>*CJPJnHtHh-0CJPJnHtHh o%h-0>*CJnH tH h-0CJnH tH hQh-0CJPJnHtHhQh-0CJ h-0CJh-0h-0>*CJOJQJnHtHh-0CJOJPJQJnHtHh-0CJOJPJQJnHtHh-0>*CJOJQJ$hQh-0CJOJPJQJnHtHh-0CJaJh9%h5CJaJo(h-05CJ"'yaa$d$&dIfPa$gds $d$Ifa$gds Zd$If^Z`gds bkdn$$IfFrp#n0 .$    44 ayts '()*2:ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukdio$$If\rp#n.$44 ayts :;<=IUufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukdo$$If\rp#n.$44 ayts :;UVZ[eoxyz$%7Fߗ~h98h-0CJaJh-0CJPJaJnHtHh-h-0hQCJnH tH hQh-0CJPJnHtHh-0CJPJnHtHht[h-0CJ h[h-0h-h-0CJnH tH h-0CJnH tH h Fxh-0CJnH tH h-0CJh-0+UVWXYZufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukdqp$$If\rp#n.$44 ayts Z[ceoyufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukdp$$If\rp#n.$44 ayts yzufNN$d$&dIfPa$gds $d$Ifa$gds Zd$If^Z`gds ukdyq$$If\rp#n.$44 ayts ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukdq$$If\rp#n.$44 ayts ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukdr$$If\rp#n.$44 ayts ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukds$$If\rp#n.$44 ayts ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukds$$If\rp#n.$44 ayts $ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukdt$$If\rp#n.$44 ayts $%GHR\ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukdt$$If\rp#n.$44 ayts FGHR[\]tuvԶ륜ԏޅvgԏh9h-0CJPJnHtHh_SSh-0CJPJnHtH *ht[h-0CJhDkh-0CJnH tH h-0h,*NCJ hBh-0CJPJaJnHtHh0)h-0CJnH tH h-0h-h-0CJnH tH h-0CJnH tH h Fxh-0CJnH tH h-0CJh,*Nh-0CJPJnHtH%\]uvufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukdu$$If\rp#n.$44 ayts ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukdu$$If\rp#n.$44 ayts ufNN$d$&dIfPa$gds $d$Ifa$gds Zd$If^Z`gds ukdv$$If\rp#n.$44 ayts ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukdv$$If\rp#n.$44 ayts ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukd%w$$If\rp#n.$44 ayts  (ufNN$d$&dIfPa$gds $d$Ifa$gds Zd$If^Z`gds ukdw$$If\rp#n.$44 ayts  '()+-.CDEKLQRSUWXgmo묝{pcZh[h-0CJh:=h-0CJnH tH h98h-0CJaJh-0CJPJnHtHht[h-0CJh^h-0CJnH tH hOh-0CJPJnHtHhh-0CJnH tH  *ht[h-0CJh-0hDkh-0CJnH tH h-0CJnH tH h Fxh-0CJnH tH h-0CJh"h-0CJPJnHtH"()*+,-ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukd-x$$If\rp#n.$44 ayts -.DELRsdLL$d$&dIfPa$gds $d$Ifa$gds Xd$IfWD^X`gds ukdx$$If\rp#n.$44 ayts RSTUVWufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukd5y$$If\rp#n.$44 ayts WXsdUU$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds wkdy$$IfG\rp#n.$44 ayts whYY$d$Ifa$gds $d$Ifa$gds d$IfVDG^gd-0ukdAz$$If\rp#n.$44 ayts whPP$d$&dIfPa$gds $d$Ifa$gds d$IfVDG^gd-0ukdz$$If\rp#n.$44 ayts ķΪηķꎳn`K)hh-0B*CJOJQJnH phtH h-0CJPJaJnHtH hxbh-0CJPJaJnHtHh-05CJPJaJnHtHh[h-0B*CJphh,*Nh-0CJPJnHtHht[h-0CJh-0hDkh-0CJnH tH h-0CJnH tH h:=h-0CJnH tH h[h-0CJPJnHtH h-0CJh-0CJOJ PJQJ nHtHwhYY$d$Ifa$gds $d$Ifa$gds d$IfVDG^gd-0ukdI{$$If\rp#n.$44 ayts ufNN$d$&dIfPa$gds $d$Ifa$gds Zd$If^Z`gds ukd{$$If\rp#n.$44 ayts ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukdQ|$$If\rp#n.$44 ayts &ufII'$ d$&dIfPa$gds $d$Ifa$gds Zd$If^Z`gds ukd|$$If\rp#n.$44 ayts %&'(yz{|}ٿp`pQMG=0Gh o%h >CJnH tH h >CJnH tH h >CJh >h >>*CJOJQJnHtHh >CJOJPJQJnHtHh >CJOJPJQJnHtHh >>*CJOJQJh >CJaJh >5CJ3h9%h5B*CJOJPJQJnHo(phtHh-05CJOJQJ3h9%hC5B*CJOJPJQJnHo(phtHh-0)ht[h-0B*CJOJQJnHphtHh-0CJOJQJnH tH &'(z{|bbZFd$If^`gds dgd >&9TPL HD@<+{d<^ukdY}$$If\rp#n.$44 ayts |}t`Q9$d$&dIfPa$gds $d$Ifa$gds Zd$If^Z`gds bkd}$$IfFrp#F0 .$    44 ayts %$!d$Ifa$gds %$!d$Ifa$gds %&(*+ijkmnp۷Ѫۡᖊۡ{ۡ{l]h[h >CJPJnHtHhOh >CJaJnH tH hSh >CJaJnH tH h >CJaJnH tH hSh >CJaJht[h >CJh:h >CJnH tH h:=h >CJnH tH hl|h >CJnH tH h >CJnH tH h >CJh >h'h >CJPJnHtHh >CJPJnHtH$q]N??$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukdY~$$If\rp#F.$44 ayts $d$&dIfPa$gds ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukd~$$If\rp#F.$44 ayts ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukda$$If\rp#F.$44 ayts sdLL$d$&dIfPa$gds $d$Ifa$gds Xd$IfWD^X`gds ukd$$If\rp#F.$44 ayts ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukdi$$If\rp#F.$44 ayts '()*ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukd$$If\rp#F.$44 ayts *+jklmsdUU$d$Ifa$gds $d$Ifa$gds Jd$IfWDj^J`gds ukdq$$If\rp#F.$44 ayts mnsgXX$d$Ifa$gds d$Ifgds $d$IfWD^`$gds ukd$$If\rp#F.$44 ayts <=AFGHJLMahqwǸ֩|mf]|||ThOh >CJht[h >CJ hOh >hQOh >CJaJnH tH hOh >CJaJhQxh >CJnH tH h Oh >CJh >CJaJnH tH hOh >CJaJnH tH hCJaJnH tH hSh >CJaJnH tH h >hQOh >CJnH tH h >CJnH tH hQOh >CJ h >CJ sdUU$d$Ifa$gds $d$Ifa$gds Wd$IfWD?^`Wgds ukdy$$If\rp#F.$44 ayts <=AqX@$d$&dIfPa$gds $d$IfWD^`a$gds d$IfVD2WDq^`gd >ukd$$If\rp#F.$44 ayts AGHIJKLgSD55$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukd$$If\rp#F.$44 ayts !$d$&dIfPWD^`a$gds LMsdLL$d$&dIfPa$gds $d$Ifa$gds d$IfWD^`gds ukd$$If\rp#F.$44 ayts  "#18:AIгЌnj}ph<h >CJnH tH hSh >CJaJh > h >CJhl|h >CJnH tH h >CJaJh >CJaJnH tH hOh >CJaJht[h >CJhOh >CJ hOh >hQOh >CJnH tH h >CJnH tH hQOh >CJh Oh >CJ)ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukd$$If\rp#F.$44 ayts sdU==$d$&dIfPa$gds $d$Ifa$gds $d$Ifa$gds $d$IfWD^`$gds ukd$$If\rp#F.$44 ayts q]N??$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukd$$If\rp#F.$44 ayts $d$&dIfPa$gds  !"sdUU$d$Ifa$gds $d$Ifa$gds $d$IfWD^`$gds ukd$$If\rp#F.$44 ayts "#9:AJwhYY$d$Ifa$gds $d$Ifa$gds d$IfVDG^gd >ukd$$If\rp#F.$44 ayts IJKZ[flqrstuvwxyzùÝùЉqgWhfh5PJnHo(tHhfh5o(/hhC5B*CJPJaJnHo(phtH *h >CJhQOh >CJnH tH ht[h >CJnH tH h{h >CJPJnHtHh >CJnH tH h<h >CJnH tH h >CJh >CJOJ PJQJ nHtHh[h >CJh >h~%h >CJnH tH JKeflrwhPP$d$&dIfPa$gds $d$Ifa$gds d$IfVDG^gd >ukd$$If\rp#F.$44 ayts rstuvwwhYY$d$Ifa$gds $d$Ifa$gds d$IfVDG^gd >ukd$$If\rp#F.$44 ayts wxyzsdLL$d$&dIfPa$gds $d$Ifa$gds Zd$If^Z`gds wkd%$$If \rp#F.$44 ayts ufWW$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds ukd$$If\rp#F.$44 ayts _TTK? $$Ifa$gds $Ifgds $da$gdf)9TPL HD@<+{d<^gdukd1$$If\rp#F.$44 ayts Ѽqqj[E[EjјE+hm4h>*CJOJPJQJaJnHtHh98hCJOJQJaJ h98h(hLhCJOJPJQJaJnH tH "hCJOJPJQJaJnH tH "hCJOJPJQJaJnHtH"hCJOJPJQJaJnHtH(h^hCJOJPJQJaJnHtHh|FhCJaJh|FhCJh98hCJaJhfhf5PJnHo(tHI@4 $$Ifa$gds $Ifgds xkd$$If\rY#F$44 aytf"%$!xd0$&dIfPUD2]xa$gd%$!d8$&dIfPa$gds mdX $$Ifa$gds $Ifgds xkdD$$If\rY#F$44 aytf%$!xd0$IfUD2]xa$gd 23467HIJQWXYwx̺⬡□zodYzoQJYzo h*rhhCJaJh*rhCJaJhzwhCJaJhT4hCJaJhr-hCJaJ h|FhCJPJaJnHtHh4EhCJaJh{hCJaJh98h5CJ\aJ"hCJOJPJQJaJnHtHh|FhCJaJh98hCJaJ h98h+hm4h>*CJOJPJQJaJnHtH~rXX%$!xd0$IfUD2]xa$gd $$Ifa$gds $Ifgds xkd͊$$If\rY#F$44 aytf 3456~rXX%$!xd0$IfUD2]xa$gd $$Ifa$gds $Ifgds xkdV$$If\rY#F$44 aytf67IJQXxl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkdߋ$$If\rY#F$44 aytfXYwxxl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkdh$$If\rY#F$44 aytfxl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkd$$If\rY#F$44 aytf &)34;ABCabckrstǼdž~džodždžahCJPJaJnHtHh*rhCJaJnH tH hCJaJhT4hCJaJh|FhCJaJh*hCJaJnH tH h*rhCJPJaJnHtHh_hCJaJhr-hCJaJ h|FhCJPJaJnHtHh*rhCJaJ h*rhhzwhCJaJ%xl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkdz$$If\rY#F$44 aytf xl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkd$$If\rY#F$44 aytf34;Bxl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkd$$If\rY#F$44 aytfBCbcksxl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkd$$If\rY#F$44 aytfstxl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkd$$If\rY#F$44 aytfxl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkd'$$If\rY#F$44 aytf üünc[hCJaJh_hCJaJ h7hCJPJaJnHtHh*rhCJaJh*hCJaJh*rhCJaJnH tH hCJaJnH tH h1qCJaJnH tH h*rhhzwhCJaJhT4hCJaJhr-hCJaJh|FhCJaJ h'hCJPJaJnHtH~rZZ$d$$&dIfPa$gds $$Ifa$gds $Ifgds xkd$$If\rY#F$44 aytf~rcc$d$$Ifa$gds $$Ifa$gds $Ifgds xkd9$$If\rY#F$44 aytf~rZZ$d$$&dIfPa$gds $$Ifa$gds $Ifgds xkd‘$$If\rY#F$44 aytf ~rXX%$!xd0$IfUD2]xa$gd $$Ifa$gds $Ifgds xkdK$$If\rY#F$44 aytf  ,-5<=>Z[\cijk·άncXάF#h*hr^CJPJaJnHo(tHhT4hCJaJh]hCJaJ h|FhCJPJaJnHtHhU%PhCJ\aJhzwhCJaJh_hCJaJhr-hCJaJh*rhCJaJh|FhCJaJh|Fh5CJaJ h*rh+hm4h>*CJOJPJQJaJnHtH(h#hCJOJPJQJaJnHtH ~rXX%$!xd0$IfUD2]xa$gd $$Ifa$gds $Ifgds xkdڒ$$If\rY#F$44 aytf ,-5=xl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkdc$$If\rY#F$44 aytf=>[\cjxl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkd$$If\rY#F$44 aytfjkxl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkdu$$If\rY#F$44 aytf!"#;<=CIJKbxpepxepZxeh{hCJaJhT4hCJaJhCJaJh*hCJaJh*rhCJaJnH tH hCJaJnH tH h*hCJPJaJnHtHh*rhCJaJ h*rhhzwhCJaJhC hCJaJhr-hCJaJhhCJaJ#h*hCJPJaJnHo(tH#xl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkd$$If\rY#F$44 aytfxl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkd$$If\rY#F$44 aytf"xl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkd$$If\rY#F$44 aytf"#<=CJxl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkd$$If\rY#F$44 aytfJKbcksxlTT$d$$&dIfPa$gds $$Ifa$gds $IfWDd`gds xkd"$$If\rY#F$44 aytfbckrstuvwxyz{ͬꡙnbVh*h5CJaJh|Fh5CJaJ+hm4h>*CJOJPJQJaJnHtH(h#hCJOJPJQJaJnHtHhCJaJhC hCJaJh{hCJaJhV\hCJaJh*rhCJaJ h*rhhzwhCJaJhT4hCJaJhr-hCJaJh*hCJaJstuvwx~rcc$d$$Ifa$gds $$Ifa$gds $Ifgds xkd$$If\rY#F$44 aytfxyz{~rZZ$d$$&dIfPa$gds $$Ifa$gds $Ifgds xkd4$$If\rY#F$44 aytf~rXX%$!xd0$IfUD2]xa$gd $$Ifa$gds $Ifgds xkd$$If\rY#F$44 aytf~rXX%$!xd0$IfUD2]xa$gd $$Ifa$gds $Ifgds xkdF$$If\rY#F$44 aytf#()*EFJLMIJraVrKVKVh|FhCJaJhzwhCJaJ h|FhCJPJaJnHtHh*rhCJaJnH tH hCJaJnH tH h*rhhCJaJhT4hCJaJhr-hCJaJ#h*hCJPJaJnHo(tH#h*hr^CJPJaJnHo(tHh*rhCJaJ h|Fh.h|Fh5>*CJOJPJQJaJnHtHxl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkdϙ$$If\rY#F$44 aytfxl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkdX$$If\rY#F$44 aytf#)xl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkd$$If\rY#F$44 aytf)*EFJMxl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkdj$$If\rY#F$44 aytfMNZ[agxl]]$d$$Ifa$gds $$Ifa$gds $IfWDd`gds xkd$$If\rY#F$44 aytfMNZ[afghrst|ؤͯnbh|Fh5CJaJ+hm4h>*CJOJPJQJaJnHtH(h#hCJOJPJQJaJnHtHhGhCJaJhV\hCJaJhCJaJh{hCJaJhzwhCJaJhT4hCJaJhr-hCJaJh|FhCJaJh*rhCJaJ h*rh"ghst|xlTT$d$$&dIfPa$gds $$Ifa$gds $IfWDd`gds xkd|$$If\rY#F$44 aytfrfWW$d$$Ifa$gds $$Ifa$gds a$IfVDnWDc^a`gdxkd$$If\rY#F$44 aytf~rZZ$d$$&dIfPa$gds $$Ifa$gds $Ifgds xkd$$If\rY#F$44 aytf~rXX%$!xd0$IfUD2]xa$gd $$Ifa$gds $Ifgds xkd$$If\rY#F$44 aytf~rZZ$d$$&dIfPa$gds $$Ifa$gds $Ifgds xkd$$If\rY#F$44 aytf $'(67?GHRۮţۍ~p~_TI~hoDhfCJaJhfhfCJaJ h*rhfCJPJaJnHtHh*rhf5CJ\aJ h*rhfhfCJaJh*rhfCJaJh\hCJaJhUEhCJaJh|Fh5CJaJhV\hCJaJh|FhCJaJh*rhCJaJ h*rhhCJaJhC hCJaJh|ZhCJaJ~rcc$d$$Ifa$gds $$Ifa$gds $Ifgds xkd)$$If\rY#F$44 aytf ~rZZ$d$$&dIfPa$gds $$Ifa$gds $Ifgds xkd$$If\rY#F$44 aytf sddd$d$Ifa$gds Zd$If^Z`gds xkd;$$If\rY#F$44 aytf$%&'sdUU$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds xkdĠ$$Ifl\rY#F$44 laytf'(67?GufWW$d$Ifa$gds $d$Ifa$gds d$IfWDd`gdJxkdD$$Ifl\rY#F$44 laytfGHQR\fufWW$d$Ifa$gds $d$Ifa$gds d$IfWDd`gdJxkdġ$$Ifl\rY#F$44 laytfR\^`bfgźОГۅzoaГh*rhf5CJ\aJhV\hfCJaJhT4hfCJaJhfCJPJaJnHtHh}hfCJaJ h*rhfCJPJaJnHtHh5hfCJaJhoDhfCJaJh&hfCJaJh*rhfCJaJ h*rhfhfCJaJhC hfCJaJhfhfCJaJ&fgufNN$d$&dIfPa$gds $d$Ifa$gds d$IfWDd`gdJxkdD$$Ifl\rY#F$44 laytfsdUU$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds xkdĢ$$Ifl\rY#F$44 laytfsdUU$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds xkdD$$Ifl\rY#F$44 laytfsdLL$d$&dIfPa$gds $d$Ifa$gds Zd$If^Z`gds xkdʣ$$Ifl\rY#F$44 laytfsdUU$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds xkdJ$$Ifl\rY#F$44 laytf&sdLL$d$&dIfPa$gds $d$Ifa$gds Zd$If^Z`gds xkdʤ$$Ifl\rY#F$44 laytf%&')*+,@CDEFGHabhmnoشؘ|p_N h*rhEy~CJPJaJnHtH hhEy~CJPJaJnHtHhEy~CJaJnH tH hoDhfCJaJ h*rhfCJPJaJnHtH hhfCJPJaJnHtHhf5CJ\aJh*rhf5CJ\aJh#hfCJaJh*rhfCJaJ h*rhfhkhfCJaJhC hfCJaJhfhfCJaJ&'()*+sdUU$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds xkdJ$$Ifl\rY#F$44 laytf+,DEFGsdUU$d$Ifa$gds $d$Ifa$gds Zd$If^Z`gds xkdʥ$$Ifl\rY#F$44 laytfGHabhno`QQ$d$Ifa$gds $d$Ifa$gds nd$IfVDGWD2^`ngdfxkdJ$$Ifl\rY#F$44 laytfnoo`QQ$d$Ifa$gds $d$Ifa$gds nd$IfVDGWD2^`ngdfxkdʦ$$Ifl\rY#F$44 laytfǶ٣ǘ|qf_|T_Eh*rhfCJOJQJaJhV\hfCJaJ h*rhfhoDhfCJaJhT4hfCJaJhfhfCJaJ h*rhfCJPJaJnHtHh*rhfCJaJhEy~CJaJh*rhEy~CJaJ h*rhEy~CJPJaJnHtH h*rhEy~hoDhEy~CJaJhT4hEy~CJaJhh9%hY5B*CJKHOJPJQJ\aJnHo(phtHHL ns_z|tu$״we#hfhCJPJaJnHo(tHhCJPJaJnHo(tHhfCJPJaJnHo(tHhOCJPJaJnHo(tHhfB*CJaJnH phtH )h hfB*CJPJaJnHphtHhfCJPJaJnHtHhfCJaJhhfCJaJh5hfCJaJh$hfCJaJ$?@|}HI $d^a$gdfd & Fd1$ $da$gd3l$d^a$gd= d^gdf$d^a$gdf\H =LM`ڲ|mcVIVh8?.hfCJPJ aJh49/hfCJPJ aJhfCJPJ aJh8?.hfB*CJaJph h2hfCJPJaJnHtHh2hfCJaJnH tH h2hfCJaJhOJhfCJaJ h3'hfCJPJaJnHtHhfCJaJnH tH hhfCJaJhfCJaJh9%h5CJ\aJh9%h5CJ\aJo( MabxTkdΪ$$Ifl0W% t#644 layts $7$8$H$Ifgds F$7$8$H$IfVDWD^F`gdf`abwx(GHTUVhiopqr Ͼܾܲܜܒvk`hVhfCJaJhIhfCJaJh8?.hfB*CJaJphhohfCJPJ aJhfCJPJ aJ+h8?.hfB*CJH*]aJnH ph# tH hfCJaJnH tH h49/hfCJPJ aJnH tH h8?.hfCJPJ aJh49/hfCJPJ aJ h8?.hfh8?.hfhCJPJ aJ!y%Tkd$$Ifl0W% t#644 layts U$7$8$H$IfWDe^U`gds F$7$8$H$IfVDWD^F`gdfTkd3$$Ifl0W% t#644 layts UVipyk$7$8$H$Ifgds Tkd$$Ifl0W% t#644 layts U$7$8$H$IfWDe^U`gds F$7$8$H$IfVDWD^F`gdfpqr !Pv^U$7$8$H$IfWDe^U`gds F$7$8$H$IfVDWD^F`gdf $^a$gdf$d^a$gdfTkdb$$Ifl0W% t#644 layts  NOPQBCDE{|}~OPQRϵhVhfCJaJnH tH hVhfCJaJhfCJH*aJnH tH hVhfCJaJhTjhfCJaJnH tH h>hfhTjhfCJH*PJ aJhTjhfCJPJ aJh>hfCJaJnH tH 5PQfy%Tkd,$$Ifl0T$ t"644 layts U$7$8$H$IfWDe^U`gds F$7$8$H$IfVDWD^F`gdfTkdǬ$$Ifl0T$ t"644 layts yTkd$$Ifl0T$ t"644 layts U$7$8$H$IfWDe^U`gds F$7$8$H$IfVDWD^F`gdfDEy%Tkd[$$Ifl0T$ t"644 layts U$7$8$H$IfWDe^U`gds F$7$8$H$IfVDWD^F`gdfTkd$$Ifl0T$ t"644 layts E\yTkd$$Ifl0T$ t"644 layts U$7$8$H$IfWDe^U`gds F$7$8$H$IfVDWD^F`gdfy%Tkd$$Ifl0T$ t"644 layts U$7$8$H$IfWDe^U`gds F$7$8$H$IfVDWD^F`gdfTkd%$$Ifl0T$ t"644 layts 7}~yj[C$7$8$H$VDWDO^`a$gdf7$8$H$VD^gdf$d^a$gdfTkd$$Ifl0T$ t"644 layts U$7$8$H$IfWDe^U`gds F$7$8$H$IfVDWD^F`gdfPijEFl$B7$8$H$VD^Ba$gdfB7$8$H$VD^Bgdf^$7$8$H$VD^a$gdf$7$8$H$VD^`a$gdfklmXPQynfWnfH8hfB*CJaJnH phtH h49/hfB*CJaJphhf5B*CJ\aJphhfCJaJh49/hfCJaJhfB*CJaJph'hS RhfB*CJ\]nH ph# tH ,hfhfB*CJPJaJnHo(phtH!hfB*CJ\]nH ph# tH 'h_DhfB*CJ\]nH ph# tH -h_Dhf56B*CJ\]nH ph# tH &hB*CJPJaJnHo(phtHlmvwNOWX$B7$8$H$VD^Ba$gdfB7$8$H$VD^Bgdf^QR $d^a$ d^`^$B7$8$H$VD^Ba$gdfB7$8$H$VD^Bgdf$ & FWd7$8$H$VD^`Wa$gdf$Sd7$8$H$VDb^S`a$gdf12op"=j+MNOjŹwiwiwiwiw^Vw^VwNh'CJaJh$sCJaJh5h$sCJaJh$sCJPJaJnHtH h5h$sCJPJaJnHtH#h5h$s5CJPJaJnHtH#h9%hCJPJaJnHo(tHh9%h5CJ\o(h9%h5CJ\,hfhfB*CJPJaJnHo(phtHhfB*CJaJnH phtH %hLhfB*CJaJnH phtH MQkdT$$If06" 44 ayts $d$IfVD6WD^`a$gd$sVd$IfVD^Vgd$s$d^a$gd$s$9d^9a$gd$sdgd$s & F 7$8$H$gd$s$%&uvwxyz*+ijklʼʰѠʰ܌сo#hh59CJPJaJnHo(tHh9%h =nHtH&h'h$sCJPJ]aJnHo(tHh5h$sCJ]aJnH tH h5h$sCJ]aJh'CJPJaJnHtH h5h$sh5h$sCJaJ h5h$sCJPJaJnHtH#h'h$sCJPJaJnHo(tH&%uhd$IfVD6WD^`gd$s$Vd$IfVD^Va$gd$sQkd$$If06" 44 ayts nd$IfVDWD^n`gd$suvwxy1Qkd$$If06" 44 ayts nd$IfVDWD^n`gd$sVd$IfVD^Vgd$sQkd&$$Ifn06" 44 ayts hnd$IfVDWD^n`gd$sQkd $$If06" 44 ayts $d$IfVD6WD^`a$gd$sVd$IfVD^Vgd$s*+.Qkd$$If06" 44 ayts $d$IfVD6WD^`a$gd$sVd$IfVD^Vgd$sQkdy$$If06" 44 ayts +,jl~i$\d$VDQ^\`a$gd$s$\#d$VDQ^\`#a$gd$sA7$8$H$VD^`Agd$s7$8$H$VD^gd$s & F 7$8$H$gd$s$RxdVDbWD2^R`xa$gd$RndVDbWD2^R`na$gd$s$d^a$gd$s l  ȳvhhWF;-h$sCJPJaJnHtHh[(h$sCJaJ h[(h$s>*B*CJaJph h h$s>*B*CJaJphh$s>*B*CJaJph&h$s>*B*CJPJaJnHphtH,h5h$s>*B*CJPJaJnHphtH"h$s>*B*CJaJnH phtH )h5h$sB*CJPJaJnHphtHh5h$sB*CJaJph#h5h$s5CJPJaJnHtH,h5h$s5B*CJPJaJnHphtH./0=>Tqrs$d$$&dIfPa$gds &d$$If^`&gds ˿ݏ˃tttbSbh@ h$sCJaJnH tH "h"h$shewCJaJnH tH h"h$sCJaJnH tH h$sCJaJnH tH h$sCJPJ]aJnHtH"h[(h$sh CJaJnH tH h4h$sCJaJnH tH h[(h$sCJ]aJ#h[(h$sCJPJ]aJnHtH h[(h$sh[(h$sCJaJ h[(h$sCJPJaJnHtH'&d$$If^`&gds kd]$$If֞ ^:!%nnnn0p#44 a8yts $d$$Ifa$gds '&d$$If^`&gds kd=$$If֞ ^:!%nnnn0p#44 a8yts $d$$Ifa$gds '&d$$If^`&gds kd$$If֞ ^:!%nnnn0p#44 a8yts $d$$Ifa$gds '&d$$If^`&gds kd$$If֞ ^:!%nnnn0p#44 a8yts $d$$Ifa$gds 'kd$$If֞ ^:!%nnnn0p#44 a8yts $(07?IK$d$$&dIfPa$gds qd$$IfVD&WD^`qgd$s$'(/0>?HIJKLMNSTV[{ҹufҹVhGh$sCJ]aJnH tH h@ h$sCJaJnH tH h$sB*CJaJph#h[(h$sCJPJ]aJnHtHh[(h$sCJaJh[(h$sCJaJnH tH h[(h$sCJ]aJ h[(h$s"h"h$shewCJaJnH tH h"h$sCJaJnH tH h$sCJaJnH tH #hkh$sCJPJ]aJnHtHKLM'&d$$If^`&gds kdϷ$$If֞ ^:!%nnnn0p#44 a8yts MNOPQRS$d$$Ifa$gds ST'kd$$If֞ ^:!%nnnn0p#44 a8yts T[cks{$d$$&dIfPa$gds $$&dIfPa$gds qd$$IfVDWD^`qgd$s'&d$$If^`&gds kd$$If֞ ^:!%nnnn0p#44 a8yts $d$$Ifa$gds 'kd$$If֞ ^:!%nnnn0p#44 a8yts $d$$Ifa$gds $$&dIfPa$gds qd$$IfVDWD^`qgd$s $()12ȼoȼ`oȼoȼhCJPJaJnHo(tH h[(h$sCJPJaJnHtHh$sCJPJ]aJnHtHh[(h$sCJaJh[(h$sCJ]aJ h[(h$shoh$sCJaJnH tH h$sCJaJnH tH &h[(h$shewCJPJaJnHtH%hEh$sB*CJaJnH phtH h$sB*CJaJnH phtH %'&d$$If^`&gds kdg$$If֞ ^:!%nnnn0p#44 a8yts $d$$Ifa$gds '&d$$If^`&gds kdM$$If֞ ^:!%nnnn0p#44 a8yts $d$$Ifa$gds '&d$$If^`&gds kd3$$If֞ ^:!%nnnn0p#44 a8yts     $d$$Ifa$gds $'&d$$If^`&gds kd$$If֞ ^:!%nnnn0p#44 a8yts $%&'()2$d$$Ifa$gds 23T'&d$$If^`&gds kd$$If֞ ^:!%nnnn0p#44 a8yts 23<CFJSTXY^_`aegho{vdR"h$s>*B*CJaJnH phtH #h[(h$sCJPJ]aJnHtHh[(h$sCJaJhoh$sCJaJnH tH h$sCJaJnH tH &h[(h$shewCJPJaJnHtH h[(h$sCJPJaJnHtHh\eh$sCJ]aJnH tH h$sCJ]aJnH tH h$sCJPJ]aJnHtHh[(h$sCJ]aJ h[(h$sTUVWXY_$d$$&dIfPa$gds $d$$Ifa$gds _`a'&d$$If^`&gds kd$$If֞ ^:!%nnnn0p#44 a8yts abcdefg$d$$Ifa$gds gh{'&d$$If^`&gds kd$$If֞ ^:!%nnnn0p#44 a8yts {|}~$d$$&dIfPa$gds $d$$Ifa$gds 'kd$$If֞ ^:!%nnnn0p#44 a8yts    % & ' $d$$&dIfPa$gds &d$$If^`&gds $\d$VDQ^\`a$gd$sA7$8$H$VD^`Agd$s$\#d$VDQ^\`#a$gd$s% - . _ ` g h o p t õ鵤zibbbPD5h4h$sCJaJnH tH h[(h$sCJ]aJ#h[(h$sCJPJ]aJnHtH h[(h$s h[(h$sCJPJaJnHtHh$sCJPJaJnHtHh[(h$sCJaJ h[(h$s>*B*CJaJph h h$s>*B*CJaJphh$s>*B*CJaJph"h$s>*B*CJaJnH phtH &h$s>*B*CJPJaJnHphtH,h5h$s>*B*CJPJaJnHphtH' - $d$$&dIfPa$gds - . / '&d$$If^`&gds kd$$If֞ ^:!%nnnn0p#44 a8yts / 7 ? G O W _ $d$$Ifa$gds _ ` a '&d$$If^`&gds kd$$If֞ ^:!%nnnn0p#44 a8yts a b c d e f g $d$$Ifa$gds g h p '&d$$If^`&gds kde$$If֞ ^:!%nnnn0p#44 a8yts p q r s t u v $d$$Ifa$gds t u v w y                             ɷطxxxxl]Rh[(h$sCJaJh[(h$sCJaJnH tH h[(h$sCJ]aJh"h$sCJaJnH tH #hkh$sCJPJ]aJnHtH"h"h$shewCJaJnH tH h$sCJaJnH tH #h[(h$sCJPJ]aJnHtHh$sCJPJ]aJnHtH h[(h$sh4h$sCJaJnH tH "h[(h$sh CJaJnH tH v w  '&d$$If^`&gds kdK$$If֞ ^:!%nnnn0p#44 a8yts        $d$$Ifa$gds   'kd1$$If֞ ^:!%nnnn0p#44 a8yts         $d$$&dIfPa$gds qd$$IfVD&WD^`qgd$s   '&d$$If^`&gds kd$$If֞ ^:!%nnnn0p#44 a8yts        $d$$Ifa$gds   'kd$$If֞ ^:!%nnnn0p#44 a8yts          ! * + 4 5 6 7 = > F L S T Z [ a b o p q w x y z      Ϯ۔υυυqbbhoh$sCJaJnH tH &h[(h$shewCJPJaJnHtHhTrh$sCJaJnH tH h$sCJPJ]aJnHtHh[(h$sCJaJ"h"h$shewCJaJnH tH h"h$sCJaJnH tH h$sCJaJnH tH #h[(h$sCJPJ]aJnHtHh[(h$sCJ]aJ h[(h$s%     ! + 5 $d$$&dIfPa$gds qd$$IfVDWD^`qgd$s5 6 7 '&d$$If^`&gds kd$$If֞ ^:!%nnnn0p#44 a8yts 7 8 9 : ; < = $d$$Ifa$gds = > 'kd$$If֞ ^:!%nnnn0p#44 a8yts > T [ b h p q x $d$$Ifa$gds $d$$&dIfPa$gds qd$$IfVDWD^`qgd$sx y z '&d$$If^`&gds kd$$If֞ ^:!%nnnn0p#44 a8yts z { | } ~   $d$$Ifa$gds    '&d$$If^`&gds kd$$If֞ ^:!%nnnn0p#44 a8yts        $d$$Ifa$gds                                     ! Ϗۏrg﹞h[(h$sCJaJh\eh$sCJ]aJnH tH h$sCJ]aJnH tH h$shOJCJaJnH tH h[(h$sCJ]aJh$sCJPJ]aJnHtH h[(h$shoh$sCJaJnH tH h$sCJaJnH tH &h[(h$shewCJPJaJnHtH h[(h$sCJPJaJnHtH$   '&d$$If^`&gds kd{$$If֞ ^:!%nnnn0p#44 a8yts        $d$$Ifa$gds    '&d$$If^`&gds kda$$If֞ ^:!%nnnn0p#44 a8yts        $d$$Ifa$gds    '&d$$If^`&gds kdG$$If֞ ^:!%nnnn0p#44 a8yts        $d$$&dIfPa$gds $d$$Ifa$gds    '&d$$If^`&gds kd-$$If֞ ^:!%nnnn0p#44 a8yts        $d$$Ifa$gds   - '&d$$If^`&gds kd$$If֞ ^:!%nnnn0p#44 a8yts ! - 1 2 7 8 9 :    ) * + 9 `   YȼrbrSrSG8hh$sB*nH phtH h$sB*nH phtH h\eh$sB*nH phtH hHB*PJnHo(phtHh$sB*PJnHphtH!h\eh$sB*PJnHphtH(hMh$s>*B*CJaJnH phtH h[(h$shoh$sCJaJnH tH h$sCJaJnH tH &h[(h$shewCJPJaJnHtH h[(h$sCJPJaJnHtH#h[(h$sCJPJ]aJnHtH- . / 0 1 2 8 $d$$&dIfPa$gds $d$$Ifa$gds 8 9 'kd$$If֞ ^:!%nnnn0p#44 a8yts 9 : YZijsd$d$`a$gd$\d$VDQ^\`a$gd$d$WD`a$gd $d$a$gd & F 7$8$H$gd$d$^a$gd59$7$8$H$WD`a$gd$s$7$8$H$UD,VD]^a$gd$s$\#d$VDQ^\`#a$gd$s YZiqcqOc>1%h&;hCJ]aJh&;hPJnHtH h h>*B*CJaJph&h>*B*CJPJaJnHphtHh>*B*CJaJph"h>*B*CJaJnH phtH ,h)h>*B*CJPJaJnHphtH,h#h>*B*CJPJaJnHphtHhB*CJaJnH phtH )h&;hB*CJPJaJnHphtH,h)h5B*CJPJaJnHphtH#h$shPCJPJaJnHo(tH )*0$d$$&dIfPa$gds &d$$If^`&gds gd (012Z[\abpqųňyyݳųynňݳyh>NhCJaJh{>hCJaJnH tH h{>hCJaJhCJaJhZhCJPJaJhZhCJaJ#h{>hCJPJ]aJnHtHh{>hCJ]aJh&;hCJ]aJ h&;hh&;hCJaJ h[(hCJPJaJnHtH'012:BJRZaM>>>>>$d$$Ifa$gds &d$$If^`&gds kd$$Ifֈq mG$ nt"44 a8yts Z[\]^_`aaM>>>>>$d$$Ifa$gds &d$$If^`&gds kd$$Ifֈq mG$ nt"44 a8yts abq{aM>>>>>$d$Ifa$gds &d$$If^`&gds kd_$$Ifֈq mG$ nt"44 a8yts aM>>>>>$d$$Ifa$gds &d$$If^`&gds kd$$Ifֈq mG$ nt"44 a8yts aM>>>>$d$$Ifa$gds &d$$If^`&gds kd$$Ifֈq mG$ nt"44 a8yts I5&$d$$Ifa$gds &d$$If^`&gds kd$$Ifֈq mG$ nt"44 a8yts $d$&dIfPa$gds R>&d$$If^`&gds kdC$$Ifֈq mG$ nt"44 a8yts $d$$Ifa$gds 2kd$$Ifhֈq mG$ nt"44 a8yts $&d$$&dIfP^`&a$gds $d$$Ifa$gds 0xdxSF:) h*rhCJPJaJnHtHh*rhCJ]aJh#hPJnHtH h h>*B*CJaJph&h>*B*CJPJaJnHphtHh>*B*CJaJph"h>*B*CJaJnH phtH h#h>*B*CJaJph,h&;h>*B*CJPJaJnHphtH)h>*B*CJPJaJnHo(phtH%hMhB*CJaJnH phtH h&;hh>NhCJ]aJnH tH 12?Ursy$d$$&dIfPa$gds &d$$If^`&gds gd$d$`a$gd$\d$VDQ^\`a$gd01>?qyz{ +7ѿݿѿxݿf#h)hCJPJ]aJnHtHh>{hCJaJnH tH hhCJaJnH tH hhCJPJaJnHtHhhCJPJaJhhCJaJ#h*rhCJPJ]aJnHtHh*rhCJ]aJ h*rh h*rhCJPJaJnHtHh*rhCJaJ$yz{aM>>>>>$d$$Ifa$gds &d$$If^`&gds kd$$Ifֈq mG$ nt"44 a8yts aM>>>>>$d$$Ifa$gds &d$$If^`&gds kdn$$Ifֈq mG$ nt"44 a8yts aM>>>>>$d$Ifa$gds &d$$If^`&gds kd'$$Ifֈq mG$ nt"44 a8yts aM>>>>>$d$$Ifa$gds &d$$If^`&gds kd$$Ifֈq mG$ nt"44 a8yts   aM>>>>$d$$Ifa$gds &d$$If^`&gds kd$$Ifֈq mG$ nt"44 a8yts I5&$d$$Ifa$gds &d$$If^`&gds kdX$$Ifֈq mG$ nt"44 a8yts $d$$&dIfPa$gds 3R>&d$$If^`&gds kd$$Ifֈq mG$ nt"44 a8yts $d$$Ifa$gds 34567A$&d$$&dIfP^`&a$gds $&d$$If^`&a$gds 7@ABC  Rj-5PįzndWnMF9FhCJPJ\nHtHhCJ\h9%hCJ\h9%h5CJ\o(hS>5CJ\o(h9%h5CJ\%hh5>*CJPJnHo(tHhB*CJaJnH phtH #hB*CJPJaJnHphtH)h)hB*CJPJaJnHphtH&h>*B*CJPJaJnHphtH h)hh>{hCJ]aJnH tH hhCJ]aJnH tH ABCaR=8d$d$UDs]^a$gd$d$`a$gdkd$$Ifֈq mG$ nt"44 a8yts ]^_xyzeO#qd$IfWD^`qgds Vkd$$If440#eT"44 a8f4yts $d$Ifa$gds d$Ifgds $d`a$gd $d^a$ d^`P[\]^xyz}~ŹɹɜŹŹŹŀuuŀjɹh1hCJaJhyhCJaJh98hCJaJ hOJhCJPJaJnHtHhCJPJaJnHtHhhCJaJnH tH hCJaJnH tH hhCJaJh hCJPJ\nHtHhCJPJ\nHtHhCJ\h hCJ\#z}gXX$d$Ifa$gds #qd$IfWD^`qgds ikd$$If44FY#T"    44 a8f4yts $d$&dIfPa$gds pp$d$Ifa$gds #qd$IfWD^`qgds ikd$$If44FY#T"    44 a8f4yts pp$d$Ifa$gds #qd$IfWD^`qgds ikd$$If44FY#T"    44 a8f4yts pp$d$Ifa$gds #qd$IfWD^`qgds ikd$$If44FY#T"    44 a8f4yts  &pp$d$Ifa$gds #qd$IfWD^`qgds ikd&$$If44FY#T"    44 a8f4yts &'`afglmn~8?@GHIN{ڴ햇 hhCJaJnH tH hüïxk_]JA7h9%hCJo(h9%hCJ%h9%h5CJPJ\nHo(tHUh9%h5CJ\h9%h5CJ\o(,hsHhB*CJPJaJnHo(phtHh^$whsHB*CJph%h|hsHB*CJaJnH phtH h|hsHB*CJphhv_\CJ\hahv_\CJ\hv_\5CJ\hv_\)hhhv_\B*CJPJaJnHphtHhv_\B*CJaJnH phtH =>{{f`SG $d^a$ d^`^$VdUD]V^a$gdsH$VdUD]V^a$gdv_\dgdv_\gkdC$$If44FBY#T"    44 a8f4yts arnings per shareThe calculation of the basic earnings per share is based on the Groups profit for the period attributable to the owners of the Company of RMB39,861,000 (2013: RMB4,510,000) and based on the weighted average of 457,312,830 shares (2013: 457,312,830 shares) in issue during the period.Basic earnings per share and diluted earnings per share for the six months ended 30 June 2014 and 2013 are the same as there were no dilutive events existed during both periods.7. Dividends(a) The board of the directors of the Company did not recommend the payment of an interim dividend for the six months ended 30 June 2014 (2013: nil).(b) Dividends attributable to the previous financial year, approved during the interim period.Six months ended 30 June20142013RMB000RMB000(unaudited)(unaudited)Final dividend in respect of the financial year ended 31 December 2013, approved during the following interim period, of RMB 0.02 per share (year ended 31 December 2012: RMB0.01 per share)9,1464,5738. Trade and other receivables30 June 201431 December 2013RMB000RMB000(unaudited)(audited) Trade and bills receivables657,115448,272Less : Allowance for doubtful debts of trade receivables(61,654)(61,649)595,461386,623Other receivables, deposits and prepayments90,01069,587VAT recoverable7,36910,329Consideration receivable on disposal of land8,0008,000Less : Allowance for doubtful debts of other receivables(14,131)(14,114)91,24873,802Total trade and other receivables686,709460,425The Groups revenue from export sales is on letter of credit. The credit period is agreed upon and stipulated in the sales contract. Except for some particular customers where payment in advance is normally required, the Group allows an average credit period of 30 days to its local trade customers and 90 days for local hospital customers. The following is an aged analysis of the trade and bills receivables net of allowance for doubtful debts presented based on the invoice date, which approximated to the revenue recognition dates, at the end of the reporting period.30 June 201431 December 2013RMB000RMB000(unaudited)(audited) Within one year592,945384,847More than one year but within two years1,982952More than two years but within three years534824595,461386,623 9. Trade and other payablesThe following is an aged analysis of accounts payable presented based on the invoice date at the end of the reporting period.30 June 201431 December 2013RMB000RMB000(unaudited)(audited)Within one year354,475344,789 More than one year but less than two years7,9263,396 More than two years but less than three years1,3182,098 Over three years2,2462,745 365,965353,028Other payables and accrued charges202,117187,505568,082540,533i!. DOCUMENTS FOR INSPECTION AND PLACE FOR INSPECTION(1) DOCUMENTS FOR INSPECTION1. The original copy of the Company s 2014 Interim Report signed by the Chairman of the Board.2. Financial statements for the six months ended 30 June 2014 signed by the Chairman of the Board, the financial controller and the chief of the accounting department of the Company.(2) PLACE FOR INSPECTIONOffice of the Secretary to the Board of the Company.By Order of the BoardShandong Xinhua Pharmaceutical Company LimitedZhang DaimingChairman31 July 2014, Zibo, PRCAs at the date of this announcement, the Board comprises: Executive Directors:Mr. Zhang Daiming (Chairman)Mr. Du DepingIndependent Non-executive Directors:Mr. Zhu BaoquanMr. Liu HongweiMr. C1m~qeR%h9%h5CJPJ\nHo(tHh9%h5CJ\h9%h5CJ\o(%h9%h0^5CJPJ\nHo(tH h98hv_\CJPJaJnHtHhv_\CJaJh98hv_\CJaJhv_\CJPJaJnHtHhhv_\CJhv_\CJnH tH h''hv_\CJh''hv_\CJPJnHtHhv_\CJPJnHtH hv_\CJ 01$d$Ifa$gds d$Ifgds $HdVDWD8^`Ha$gdv_\d^ d^`dgdv_\$d^a$gdv_\ {|   #$%ܷܠܠxxi[Jxx hOJhv_\CJPJaJnHtHhv_\CJPJaJnHtHhhv_\CJaJnH tH hv_\CJaJnH tH hv_\hv_\CJaJhshv_\CJPJ\nHtHhv_\CJPJ\nHtHhOJhv_\CJ\h[Pehv_\CJPJ\nHtHhv_\CJ\nH tH h$J8hv_\CJ\hv_\CJ\h9%h5>*CJh9%hCJPJnHo(tH }}$d$&dIfPa$gds #qd$IfWD^`qgds Tkd$$If440B# T"44 a8f4yts #ss$d$Ifa$gds #qd$IfWD^`qgds gkd5$$If44FBY#T"    44 a8f4yts #$%1=ss$d$Ifa$gds #qd$IfWD^`qgds gkd$$If44FBY#T"    44 a8f4yts %=>?ABCEF $/012>?@P|qah^hv_\>*CJaJnH tH h98hv_\CJaJ hv_\CJh9%hCJh9%h5CJ\o(h9%h5CJ\%h9%h5CJPJ\nHo(tH,h9%hB*CJPJaJnHo(phtHh[Pehv_\CJaJnH tH h[Pehv_\CJaJhv_\CJaJnH tH hv_\hv_\CJaJ&=>?@Ass$d$Ifa$gds #qd$IfWD^`qgds gkdC$$If44FBY#T"    44 a8f4yts ABCDEss$d$Ifa$gds #qd$IfWD^`qgds gkd$$If44FBY#T"    44 a8f4yts EF hh$d$&dIfPa$gds #d$IfVDWD^`gdv_\gkdQ$$If44FBY#T"    44 a8f4yts 012;@RymUUU$d$&dIfPa$gds d$Ifgds d^gdv_\ d^`^gkd$$If44FBY#T"    44 a8f4yts PQRST[\cdefqr|}~ʿʿҿʸқʸҐvʸvh98hv_\CJOJQJaJh%|hv_\CJaJhJohv_\CJaJhv_\CJPJaJnHtHh $hv_\CJaJnH tH hhv_\hhv_\CJaJhv_\CJaJh98hv_\CJaJ h98hv_\h^hv_\>*CJaJnH tH hv_\CJaJnH tH +RST\d$d$Ifa$gds d$Ifgds bkd_$$IflF#&T"    44 layts defr}#$d$Ifa$gds d$Ifgds bkd$$IflF#&T"    44 layts }~#$d$Ifa$gds d$Ifgds bkd'$$IflF#&T"    44 layts r#$d$Ifa$gds #$d$Ifa$gds d$Ifgds bkd$$IflF#&T"    44 layts pX#$d$&dIfPa$gds #$d$&dIfPa$gds d$If^`gds bkd$$IflF#&T"    44 layts r#$d$Ifa$gds #$d$Ifa$gds d$Ifgds bkdY$$IflF#&T"    44 layts s[$d$&dIfPa$gds $d$&dIfPa$gds %!d$Ifgds bkd$$IflF#&T"    44 layts s$d$Ifa$gds $$Ifa$gds %!$Ifgds bkd-$$IflF#&T"    44 layts AHOs$d$Ifa$gds $$Ifa$gds %!$Ifgds bkd$$IflF#&T"    44 layts AGHNOP_`eflmnȻȂpȒȂe]Nh98hv_\CJOJQJaJhv_\CJaJh98hv_\CJaJ"hv_\CJOJPJQJaJnHtHh~hv_\h-CJPJaJhv_\hNCJaJnH tH $hNhv_\CJOJQJaJnHtH hhv_\h~hv_\CJPJaJhv_\CJPJaJhNnhv_\CJaJnH tH hv_\CJaJnH tH $h98hv_\CJOJQJaJnHtHOP`fms$d$Ifa$gds $$Ifa$gds %!$Ifgds bkd$$IflF#&T"    44 layts mnx$d$Ifa$gds $$Ifa$gds %$Ifgds bkdk$$IflF#&T"    44 layts pX#$d$&dIfPa$gds #$d$&dIfPa$gds d$If^`gds bkd$$IflF#&T"    44 layts s$d$Ifa$gds $$Ifa$gds %!$Ifgds bkd?$$IflF#&T"    44 layts     -.56>?@LS|}GJȹȹxiTiTiTiTiTiT)hyhS>B*CJPJaJnHphtHhyhS>B*CJaJphhv_\CJ\(hL"hv_\CJOJPJQJaJnHtH"hv_\CJOJPJQJaJnHtHhIhv_\CJaJhv_\CJaJh $hv_\CJaJnH tH hv_\CJaJnH tH h98hv_\CJOJQJaJ hhv_\h%|hv_\CJaJhhv_\CJaJ ya$d$&dIfPa$gds $$&dIfPa$gds %!$Ifgds bkd$$IflF#&T"    44 layts    s$d$Ifa$gds $$Ifa$gds %!$Ifgds bkd$$IflF#&T"    44 layts   .6>ya$d$&dIfPa$gds $$&dIfPa$gds %!$Ifgds bkd}$$IflF#&T"    44 layts >?@rfN$d$&dIfPa$gds d$Ifgds $d^a$gdv_\$d^a$gdS> d^gdv_\bkd$$IflF#&T"    44 layts JV\kpr{۶xixiexexexexZZhD=hv_\CJaJhv_\hMhv_\CJaJnH tH hv_\CJaJnH tH hv_\CJaJhv_\CJ\hPhv_\CJ\hS>hv_\CJ\hyhS>B*CJ\ph"hyhS>h (B*CJ\ph%hyhS>B*CJaJnH phtH )hyhS>B*CJPJaJnHphtHhyhS>B*CJaJph#n__$d$Ifa$gds #qd$IfWD^`qgds bkdQ$$IfF#&U"    44 a8yts $d$&dIfPa$gds ww$d$Ifa$gds #qd$IfWD^`qgds bkd$$IfF#&U"    44 a8yts ww$d$Ifa$gds #qd$IfWD^`qgds bkdG$$IfF#&U"    44 a8yts ww#$d$Ifa$gds #qd$IfWD^`qgds bkd$$IfF#&U"    44 a8yts  #$%OPTWXYZ[\]efnopqrt~ƥ鞌ym`y`Vh9%hCJ\h9%h5CJ\o(h9%h5CJ\%h9%h5CJPJ\nHo(tH"h9%hCJPJ\nHo(tH h9%hhzhv_\CJaJhL_hv_\CJaJhhv_\CJaJ *h*cAhv_\CJaJhdYhv_\CJaJhv_\CJaJnH tH hv_\hv_\CJaJhD=hv_\CJaJ  $wh#$d$Ifa$gds $d$Ifa$gds #qd$IfWD^`qgds bkd=$$IfF#&U"    44 a8yts $%PTXnV#$d$&dIfPa$gds $d$&dIfPa$gds #qd$IfWD^`qgds bkd$$IfF#&U"    44 a8yts XYZ[\wh#$d$Ifa$gds $d$Ifa$gds #qd$IfWD^`qgds bkd?$$IfF#&U"    44 a8yts \]^fnnV$d$&dIfPa$gds $d$&dIfPa$gds #qd$IfWD^`qgds bkd$$IfF#&U"    44 a8yts noq teeY d$Ifgds $d^a$gdv_\ $d^a$ d^`$d^a$gdgbkdA$$IfF#&U"    44 a8yts   )-./0@ABXYZ\]lmpqsu|}~ ǿtth4Rhv_\CJaJhv|hv_\CJaJh49/hv_\CJaJh !hv_\CJaJhv_\hhv_\CJaJnH tH hv_\CJaJnH tH hv_\CJaJh (hv_\CJPJ\nHtHhv_\CJPJ\nHtH h, hv_\CJPJaJnHtHh, hv_\CJaJ-./08@n__$d$Ifa$gds #qd$IfWD^`qgds bkd$$IfFBY#T"    44 a8yts $d$&dIfPa$gds @ABNXww$d$Ifa$gds #qd$IfWD^`qgds bkd=$$IfFBY#T"    44 a8yts XYZ[\ww$d$Ifa$gds #qd$IfWD^`qgds bkd$$IfFBY#T"    44 a8yts \]mu~ww#$d$Ifa$gds #qd$IfWD^`qgds bkd3$$IfFBY#T"    44 a8yts ~ww#$d$Ifa$gds #qd$IfWD^`qgds bkd$$IfFBY#T"    44 a8yts ww#$d$Ifa$gds #qd$IfWD^`qgds bkd5$$IfFBY#T"    44 a8yts  nn#$d$&dIfPa$gds #qd$IfWD^`qgds bkd$$IfFBY#T"    44 a8yts   '()KST\]^_`aijrsTVøҩޓҩ҂scYQYh9%h5h9%h5o(h9%h0^5PJnHo(tHh !hv_\CJaJnH tH h\hv_\CJPJaJnHtHh98hv_\CJaJhv|hv_\CJaJhvhv_\CJaJnH tH h5hv_\CJaJh\hv_\CJaJnH tH hv_\CJaJnH tH hv_\h4Rhv_\CJaJhv_\CJaJh49/hv_\CJaJwh#$d$Ifa$gds $d$Ifa$gds #qd$IfWD^`qgds bkdC$$IfFBY#T"    44 a8yts  (wh$d$Ifa$gds $d$Ifa$gds #qd$IfWD^`qgds bkd$$IfFBY#T"    44 a8yts ()LT\nn$d$&dIfPa$gds #qd$IfWD^`qgds bkdK$$IfFBY#T"    44 a8yts \]^_`ww$d$Ifa$gds #qd$IfWD^`qgds bkd$$IfFBY#T"    44 a8yts `abjrnn$d$&dIfPa$gds #qd$IfWD^`qgds bkdG$$IfFBY#T"    44 a8yts rstlnhjlml$7$8$H$WD^`a$gd{u $7$8$H$a$gd{u7$8$H$$da$bkd$$IfFBY#T"    44 a8yts VjlnJLfj  BFbcklmu^,h9%hB*CJKHOJQJ\aJphh9%h{uCJ\o("h9%h5TCJPJ\nHo(tHhv_\CJPJ\nHo(tH"h9%h{uCJPJ\nHo(tHh9%h{uCJ\"h9%hCJPJ\nHo(tH9h9%h5CJKHOJPJQJ\^JaJnHo(tHh9%h5o(h9%h5 34op$$G$Ifa$gdv_\ $$G$Ifa$$G$a$$^a$ $ ^ a$gd7"$0TPL HD@< ^ a$$ ^ a$ ^ gd}^йtXB$:h9%h6B*CJOJPJQJ]aJnHo(phtH+h9%h6B*CJOJQJ]aJph7h9%h5B*CJOJPJQJ\aJnHphtH7h9%hG5B*CJOJPJQJ\aJnHphtH+h9%h5B*CJOJQJ\aJph%h9%hB*CJOJQJaJph,h9%h0^B*CJPJaJnHo(phtH,h9%hB*CJPJaJnHo(phtH/h9%hB*CJKHOJQJ\aJo(ph "&'234Ĭ~eNA4&Ah9%hGPJnHo(tHh9%hGPJnHtHh9%hPJnHtH,h9%hB*CJPJaJnHo(phtH1h9%hB*CJOJPJQJaJnHphtH4h9%h3AB*CJOJPJQJaJnHo(phtH%h9%hB*CJOJQJaJph.hv_\B*CJOJPJQJaJnHo(phtH4h9%h)mB*CJOJPJQJaJnHo(phtH@h9%h0^56B*CJOJPJQJ\]aJnHo(phtHddd0d1d?d@dDdJdKdXdYd[d\d]d_d`dbdcdedfdhdidodpdqdsdtdzd{d|d}d~d˼䚒~~z~o~h0J$mHnHuh| h|0J$jh|0J$Uh'*jh'*Uh9%hnHo(tHh9%ho(h9%h]={PJnHo(tHh9%h]={PJnHtHUh9%hPJnHo(tHhv_\PJnHo(tHh9%hPJnHtHh9%hGPJnHo(tH)ddd1d@dLdYdZdGkd=$$If0!64 a $$G$Ifa$ han Chung Kik, LewisNon-executive Directors: Mr. Ren FulongMr. Xu Lie Mr. Zhao BinPAGE PAGE 5Zd[d\d^d_dadbdddedgdhdqdrdsd~ddddd#$a$##&`#$gd7Gkd$$If0!64 a~dddddh9%hnHo(tHh'*h| h|CJ /0P/ =!"H#$n% nu*l?xK-PNG  IHDRryJzgAMA pHYsLLXtcPLTE#$ 84*&'"51;7.*?;2-2./+40)%(#,(=9950,+'=83.627383B>B?A=C?@=QNUQNJFBJFXU\Y^[DAZWIF]ZOKHDWSQMMJKHSOD@YUVSLISPFCYV[W^ZROLHOLWTb_`\a^b^`]iftrfc}pn|ymjxupmvtywc`li~{}{wt}{rogdvsda~{xuebnkkgkholtqheqnpnspzw{x~}ƵG'IDATx}|yNg˲$Dz6d[r^ 8&!iP*`Ԙ˒lbh^ZQ@!M#'MI4mt/kvӦMO$nwvgyfgwgt7<3(Z8˱!}t%O_dKU}*meDW܇lL7{]+>IcMC|l4IzO̚*Irìi.! gKz8T*%,佫X ˏ<&K$]vUtɑ,VEzIyH.#Ϛ!tifPIѳf$]Nfx$]F䜳fX$]>.fpHl]Κatg&o#K>k.8ietgƾUFI9|֌4&(D2I$ʴ[K\Co~$]YgȎ*FC$A#eY/c#"OFj+ <#۠1kZǮWM?f5$=Y!R+K.>k*qبPެM`$oY _&I1k̊/ 6/~"G̚J]Y͠E-%B$cJME.s`SϒrĬ9ö"^}2JOfdGʶ*Fwt%YSYw-V21 1y oU2l"lJK=G5ڠ}>i&{1kF%03%)Iy?|Tjzώ|vK{Áw돳L&)sI:i<";ZKܔ{< 5$1FT=twLW|^2? 6{) _%R;I1fI~3Dv F)+I3kFf4b[jNv)I3k* 5lc557{"bcfMsWz_&[lJ@E"̚ K,iM%]r̬IUlr̙p +颐cfM ߽٨Ɇ7t1QQai˿.9fdUll)] @5mB*ëN* tQ~͗26w_pS Iw5km{ޕCL3u B]!G͚,6gt9fִ: qsѪ”%(Y(iD TW#fMA$)/pY AA8z=CfMQ`J/{]MYS:Naq&(D08J;0tCfMQ@ "4\ҝfȶsidz?t;"G͚DtGaJJrܬs"paL IE5yBRlLB ͚.BSl鱊1;K;O9kz~"bsz s[QG#gMe~6iDjcLI!GΚ~ؤS\m%]Κ~$N#)}BܬQ`]j]|sa\Q#y0Y >/ <ʔ>&FzQœt/8EXlFt<ʔ_k=+= 071ox ɕpAqQj] *>~.6Q,tzM (Q_6\#frRLQB]uIRvpzM eۣ|mwJ63;VVX RԣLQ']iѧ3O޵ˍznq(ybE>)ΉFIX88S:U ,U3sdθT`"NBBonaEBORVV+x2j ' s%NR08E=ƓGVhbf#i+zbiӪ8SR"DKnb5rSWMu;6rH[!V#3S0Ow.Bd.A#[̕`XPg #ȂE#/93fZeɌ\S{<03Ol#4 2)J{d<=`[Sԗ ˀ\S%-x,-|@u=݅}55FJ77(\dcs'`}IIFKgnFmNڳw8B?Hz,s-ډ-}ֽ-V,a \954O|\*Kѹ\nW"ZO_^6MSa&y <07t|-s<7{<2*C6m,^YZ=@9Q(iE0b+ANlzQ~O9Q_\jVv^X !*y{F0DiR#ϲӓO5||@c|ȋA^Ɍ=t*"GIgPݙ-M> 9RP86uimڰJsp>/;|(|=i :\2noi@ Wߍ}kj qg@>a19i?K]~되>>7xlgߗ@g sh.~K|~ xs>"¹7U­Ůһ4vvg^i4so8xgkSdpG+'rmS}̈́ð)wh39jkku?ʒa@VfN6:%BwSTjc9u h5#p%k _=ANWvm)eͯlW+RuKw)]zYv})K-_%)kxb[nZ TVdxN~Uwjb;? bPVWȵ!|,<}qP ~9kZgL/g}lIV6z tNyPw\ܵ!1[gtwA[h%#N0y@d z|+C ŕ5G.Yn1<'`MMM7}dy(B#,yKg\7S;w²n r<0w :ҹ0)oux9֖~e⯖gs4[_Sۿ[ rf;G^8}EO{뢂G\Y/XId(Wp=Lh+ve7(so+}Gi'Mp_kk'KD74mфG-1 >cUƱe9 +5?r/:i@~D Gu݅fIZ`UEN 'D%=u\ 3A~ YoaEٷs7Dޠ_E8@-J1|s )rOAO.мE%!185<Ӧi_r`/qc/*!wR?̱+[=aǎ0{̱~}ee];Mf-nz1_W<o5O_cc>YF3>xפ@r.GΏcM]G}EuT)My+78ϻﵱ7Wa=U=_sYjr uK7xCuQ_?Yf n% ؜G-Y`n9 R9؆۳˔F„܀?mG^ {:Fߘ2C7CTk=\@pFk}j&'jv r5qC[:+@ުv߈MarCij BNԓ~P-w9j| 4E"G9 eljUc9!~sS̊PSFF:"YeSC\yHf GL2;6h3c&TiWyf|;tk$o59Yh{w{QȉJN,tΐH#\2*ّ$ʥ ~G0M}"'߇ǽ#FCx#;]vkr"']yVjMN\wn^ZǡWZ#Oo3w,J1G%EBOM_!X#ׯͦۡ"'rLQ5r})mx }M(%r3>QH}/yfN^܌ur"ȹOf5Z.\F|ߩch !~ kn*e#7vReUS8%!G~e`[pCheeAUsn+dz.~#GF3ܟ 9fu<' tW:H<:Kg I;N]:֜op?vԼ,Bkm܍VE8'w c$a_SPTVn58pi.7Ȋ|֜N)meX>wK*)07f^xz)G4w0oVjtP\RQ^so= PկMAwoIң_:û]ul#t0tHq}g:v.;'ѻ\^Vz9WʽRm5ݪ~yv N}Y!Pr&lj&(9f4@k|9!KE\oEqo*<#Z8kcu#QMe"w,:p/ė%"'W+S3'rN"Cr{\]^-P:~pOqL /r[+:@0#ֳ!9bb0,~[;|oB-l$rS't| !G4>ޱ ANg\RSVtDåZ-rTuif=˿1ȭ$K!O8f;`ŽsݦFvzozpWލ+++^=aG>@W2۱ή^=":۷{Eeu}sǂX>h#'Jg 3'U y>K ;rMyUQ v77- ?r*3arCޛ}u7^=n^n7]Vjz~T,PT|' %zo^ IL]" *^e6rg2OCy|l oPVmR rK?1f>B7pvk^77eT$r*gFE/AFj69iF= )N75u cy~iFƧ s|n14#kꑎ,EwA"^(m<x$|Drn=2P Wʻ Sp J<񉲋Jܔ3U=F/5>JtM"@4j|:@ !,rE/*քU5lώU}Mmy=wMu%{nA܇+ߒnzkݼhMBt#`+iyWw T?%EeM}'jӖb76f5`D<$Z $}7uQdk"%Z CrŃ⏤79#㦪5ǥDxOQEWaTnePu}?L(*hc^*R^QbEP/{ |%.#;f?d ?iKz $"l+is=x(J|kc.85`(hJ(l_sY^c%NQHiЕĶXĻCY#+=raDF+CBb~X?ĉx >< ptAwEԜӇjZRI7f. qmZ8CbeA!x%%p/ =K5Q$ݴkG\#^UC6I7rfU;o6n^6 _)ꊝeml 1vi,w.x4̉J.8IoIýlw'kmb JSQ>c釐<7 HһGGZSKG{WD{s{i\^6 <$=ߍq3htcS<W} 4|lMbϛvU*=8N1g,3{6]"Iqԋ[$|V'[g 4rgrH:X^6rWoqH8*n+t0E}hW f%&PQ U籤CE<L%.Iq`JmDCBO> NotesdB*CJaJphHOH Subhead 1Td^T ;CJaJ~O~ Subhead 2B$'PL HD@<Q^`a$5B*\phO Body textc$>TPL HD@<Td1$7$8$H$^Ta$-B*CJOJQJ_HaJmH nHphsH tHDZ@D ~e,g$a$CJOJPJQJaJnHtH<O< write $a$CJPJnHtHpOpChar Char Char Char!d1$CJKHPJaJmHnHtHu.". yblFhe,g"CJaJ6 @26 u#9r G$CJaJ)@A uxP@RP u w%!d1$CJKHOJPJQJaJtH 0b0 le,g&G$CJaJPOrP Anrede' 1$KHOJPJQJaJtH VOV W[CQ W[CQ(d1$CJKHPJaJmHnHtHuPQ@P ckee,g 3)$a$!B*CJOJPJaJnHphtHBL@B eg*$a$CJOJPJQJaJnHtHvOv Report Text-+$d1$5$7$8$9DH$^a$KHPJaJmH sH tH VT@V e,gWW!,$:d1$]:^a$CJKHPJaJtH `O` Default-1$7$8$H$)B*CJPJ_HaJmH nHphsH tH*U@* c >*B*phXOX xl137/dd1$[$\$ CJKHOJPJQJaJnHtHpOp Body Single0$ (1$a$$B*CJPJ_HhmH phsH tH 2V@2 ]vc >*B* ph0`@"0 HTML 0W@W26]Be@2B  HTML @BP h4$<@&a$5CJ OJPJQJ\^JaJ K@ y|T5([@b( 5uP[N~{T6\J@r\ oRh7$d8<@&a$"5CJ KHOJPJQJ\^JaJ - [e,g48 ` @ 1$3$5$7$8$G$0CJKHOJPJQJ^J_HaJmH nHsH tH6%@6 [ON0W@W9G$ OJQJ^J.?@. ~_g:dVD4^d4/@4 Rh;8WD8^`8<2@< Rh 2<d8VDWD8^d`8<3@< Rh 3=d8VDWD8^d`8<4@< Rh 4>d8VDXWD8^d`8<5@< Rh 5?d8VD WD8^d`8,1@, RhS @ & F 0:@0 RhS 2 A & F 0;@"0 RhS 3 B & F 0<@20 RhS 4 C & F0=@B0 RhS 5 D & F4D@R4 Rhc~ExVD^8E@b8 Rhc~ 2FHxVD^H8F@r8 Rhc~ 3GxVDX^8G@8 Rhc~ 4HxVD ^8H@8 Rhc~ 5I4xVD^400@0 Rhyv&{S J & F46@4 Rhyv&{S 2 K & F47@4 Rhyv&{S 3 L & F48@4 Rhyv&{S 4 M & F49@4 Rhyv&{S 5 N & F$$vU_ 1O00vU_ 2PVD^00vU_ 3QHVD^H00vU_ 4RVDX^00vU_ 5SVD ^00vU_ 6T4VD^400vU_ 7U VD^ 00vU_ 8V| VDx^| 00vU_ 9W VD@^ $@$ ybleW[X*j* ybl;NY5\(^@( nf(Qz)Z,@@, ~{T[dVD4^dX$@X 6eON0W@W(\d&+D/G$VDx^d OJQJ^J$ $"}_ 1]0 0"}_ 2^VD^0 0"}_ 3_VD^00"}_ 4`XVDX^X00"}_ 5a VD ^ 00"}_ 6bVD^00"}_ 7cVD^00"}_ 8dxVDx^x00"}_ 9e@VD@^@6!6 "}_hf5OJQJ\^J8"8 lgCJOJPJ QJ^JaJ4#4 VhvU_h8VDWD8`8(+( >\le,giG$8Y8 ech~gVj-D M I@ Oo`hok8$d%d&d'd-DM NOPQVDWD ^8` OJQJ^J0,0 _evU_lVD^<.< _evU_hmxOJPJQJ^J(B@( ckee,gnx4M@4 ckeL)ۏoWDd`8C@8 ckee,g)ۏpxVD^8N@8 ckeL)ۏ 2qWD`0@"0 cke)ۏrWD`2P@22 ckee,g 2 sdxBR@BB ckee,g)ۏ 2tdxVD^DS@RD ckee,g)ۏ 3uxVD^CJaJ*O@* lʑhv$a$TOrT 7h_1wdd1$XDdCJKHPJaJhmH sH tH 6O6 short_text1CJaJZOZ Table Texty$a$$B*CJPJ_HhmH phsH tH ZOZ Table Text Char$B*CJPJ_HhmH phsH tH JOJ body text{xx1$CJKHaJtH VOV RQk=|d1$WD`CJKHOJPJQJaJtH <O< tw4winMark<B* H*phVOV gnUk=~d1$WD`CJKHOJPJQJaJtH 8O8 c!apple-style-spanO c!hpsBOB c!apple-converted-space:O!:  highlight1q PO1P #- Char Char$CJKHPJ_HaJmH nHsH tH&OA& 1hps atn$OQ$ >st1d>Oa> = Char Char1OJPJQJtH Or <ordinary-output target-outputdd1$[$\$KHOJPJQJ^JnHtH4O4 <high-light-bg4JOJ  Footer CharOJPJQJ^JmHsHtH VOV [)j Char Char3(CJKHOJPJQJ_HmH nHsH tH:O: Pa0dB*OJPJph<O< ,}eW[ W[CQCJKHOJQJnHtHVOV E?* Char Char2(CJKHOJPJQJ_HmH nHsH tHKj z{56MN2W})6}#)**+SLK00)0 K00@)@0K00PX=@0 K00X=@ OJQJo(K00X=@&K00X=@0K00 0Y=B2Qfg '56HS^m|}"#9HVhz{|    , 7 8 H S b  !!! ! !!*!,!.!0!2!3!c!e!g!k!m!n!u!w!y!{!}!~!!!!!!!!" """"I"U"["g"m"n""""""""B#C#D#E#F#G#H#I#J#K#L#M#N#O#P#Q#R#S#T#U#V#W#### $ $6$S$~$$$$ %%%%% %9%I%U%[%]%_%`%%%%%%%%%%%%%%&7&<&D&I&K&M&N&h&m&u&z&|&~&&&&&&&&&&& '''''!'"'+';'C'H'J'L'M'''''''''((+(Y(i(j(p(|((((((((((( ))) )W)_)h)i)))))))))*** *)*1*:*;*n*v******n,o,--9.:...111111111111111111111111111122s2t2y222222222222 3 3 3 333 3)3-3135363E3\3`3d3h3i3w33333333333333344 4 44>4B4F4J4K4[4444444.52565:5;5L5h5w5555555165696=6>6X666666666666666666677 777"797=7A7E7F7V7m7q7u7y7z77777777777777777777"8&8*8.8/8>8U8Y8]8a8b8p88888888888889#9'9+9,9=9O9S9X9\9]9i9{999999999999q:r:.>/>e>f>>>??v?w?@@AAVBWBgBhBzD{DDDFF I!I?J@JKKLLcNdNNNPPPPSS*T+TUUVVWWYYYYg[h[]]^^__``+a,aaa"b#bccddffffgg!h"hiiii%l&lmmmmenfnooWoXooopp)s*skslsvvCxDx){*{+{,{{{{{{{{{{{{{||%|-|5|6|=|E|M|U|]|^|g|o|w||||||||||||||||||}B}Y}Z}n}}}}}}}}}}~(~=~R~S~x~~~~~~~~~~~89?Pbcdsx )89P_n}ƀǀ78~9:ɅʅӈԈɉʉTUlm9: .exƌȌ׌ #)79EirsyΑϑÒĒ$%@A|}DE89šÚ)*?@ɝ &9:<IXetuОў 01IZi{ǟٟ.<=VesàѠ (7FGcpr̡ΡС%2@NOƢԢբ  4BO_noģţP[fr~äѤҤ %&?M[iwxȥ֥إ#%3HI_`acefƦ̦ӦԦ/0N\jz !gtvAB&'Z[\b{|}~ĪƪЪڪ۪&'9:@FGTU\cdst|֫׫./5;<=>?@ASU\bcvx #$*012345678?EFGHIJKsu~ۭܭݭޭ&2345678NOV\]^_`abˮ̮ͮήϮ JKS\]123:;DEFGHIJưǰͰӰ԰հְװذٰڰ۰)*+1>OPQRZbcdeq{|}~رٱCDLTUklsz{òIJ̲Բղ =>ELMNOPQRST^hijklmn}~ij˳̳%&,23XY_efvw}ôĴ̴Դմִ״شٴڴ۴ܴ ')19:LMSYZ}~µȵɵԵյݵ!)*+,-./UV`jklmnopǶȶ !+56PQX_`abcders}·÷ɷϷз!"23;CDEFGHIJKU_`abcdefgq{|}ٸڸNOABݽ޽12345SU&`awlm!?@d-.EuvFHIJKLxy}~DEXY;<Z[{|\]56'(?@XY%&;uvwxy,-./0FGDEwxyz  !"#$,-./0123DLT\dfpq"#*+,-./0123GHIJKLSTijklmnvw456CDZwxy *08>FPRSTUVWXYZ[bjrz'(6789:;EFghijklrstuvwxyz{}~234IJWm#$%&'/01234567KLMNOYZ[\]{|} %-5=GHIJKLMNOlmnopxyz{|}~ef{|ELST{&-456789fpz{,/12MQST '().345=EFGS_`abcdUVlm=>KLDEF_`afklmu}~]cijk BKTUVWXYZbjklmno;DMNOPQRSZabcdef&'()*+;CKLtz~f g h q v                       @ F M N _ e l m n o p q r z                  " #   : ; T U         =>Sp~ "#$%'(*+-.01:;<GHIL000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 00 000 0 0 0 0 0 0 0 0 0 0 0 0 w0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0-0-0-0-0-0-0-0 -0 -0-0 0 w0 0 w0 0 w0 0 w0 0 w0 0 w0 0 w0 0 0 0 w0 0 0 0 w0 0 0 0 0 0 0 0 0000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000000 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000 00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000000000000000000000000 0 0 0 0 00 0 0 0 0 v0 0 0 0 0 0 v0 0 0 0 0 0 v0 0 0 0 0 0 v0 0 0 0 0 0 v0 0 0 0 0 0 v0 0 0 0 0 0 v0 0 0 0 0 0 v0 0 0 0 0 0 v0 0 0 0 0 0 000000000000000000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X0 0 0 0 0 0 0 X0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Z0Z0Z0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X0 0 0 0 X0 0 0 0 0 0 0 0 0 0 0 0 Z0 0 0 0 0 0 0 0 0 0 0 0 00000000000000000000000000000000000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000000000000000000000& 0000000000& 0000000000000000000000" 000000" 0000" 000000" 0000000000000000000000000000000000000000000000000 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000 0 0 0  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000000000000000000000000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000000000000000000000000000000000000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000000000000 %0 %0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 '0 '0 0 0000 %0 %0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 %0 %0 0 0 0 %0 %0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 %0 %0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 %0 0 0 0 0 %0 0 0 0 0 0 0 0 0 0 00000000000000000000 000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0 0 0 0 0 0 0 000000000000000000000000000000000000000000000 00 0000000000 00000 0 0 0 0 0 0 0 0 0 0 0 00 0 0 0 0 0 00 0 0 000 0000000 00 000 00 0 000 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000 00 000 00 0 000 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000 0000000 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000000 0 00 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 00000000 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 000000 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 000000000000000000 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 0000 00 0 0 0 0 0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 0 #0 #0 0 %0 0 0 0 %0 0 0 0 %0 0 0 0 %0 0 0 0 %0 0 0 0 0 #0 #0 0 %0 0 0 0 %0 0 0 0 %0 0 0 0 %0 0 0 0 000000 00 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 #0 #0 0 #0 0 #0 0 #0 0 #0 0 #0 0 #0 0 #0 0 0 0 000000 00 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 #0 #0 0 #0 #0 #0 0 #0 #0 #0 0 #0 #0 #0 0 #0 0 #0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 #0 0 0 0 000000000000000000000000000 00000 0 0000 0 0 0@0ȑ00=@0ȑ00=@0ȑ00=@0ȑ00=@#0@#0@0@#0@#0@0ȑ00d=qrsuv"DE+;<deMNYZno  T U  N O q r ( ) l m r  2 3 j 6<BVWXv:@ARryz h/;BClqv45q}'()4QVcjz{U$56<KMNOPyz"12EVWm|} %CZder}()*(>Qfg '56H^|}"#9Vhz{|    , 7 8 H S b  !!! ! !!*!,!.!0!2!3!c!e!g!k!m!n!u!w!y!{!}!~!!!!!!!!" """"I"U"["g"m"n""""""""B#C#### $ $6$S$~$$$$ %%%%% %9%I%U%]%_%`%%%%%%%%%%%%%%&7&<&D&I&K&M&N&h&m&u&z&|&~&&&&&&&&& '''''!'"'+';'C'H'J'L'M'''''''''((+(Y(i(j(p(|((((((((((( ))) )W)_)h)i)))))))))*** *)*1*:*;*n*v*****-9.:...1122s2t2y222222222222 3 3 3 333 3)3-3135363E3\3`3d3h3i3w33333333333333344 4 44>4B4F4J4K444442565:5;5h5w555555165696=6>6X666666666666666666677 777"797=7A7E7F7V7m7q7u7y7z77777777777777777777"8&8*8.8/8>8U8Y8]8a8b8p888888888888#9'9+9,9=9O9S9X9\9]9i9{999999999999q:.>/>e>f>>??v?w?@@AAVBfffg!h"hiiii&lmmmmenfnooWoXooopp*sks+{{{{{{{{{{{{{|5|6|=|]|^|g|||||||||||}B}Y}Z}n}}}}}}~R~S~x~~~~~~89?Pbcdsx89P_n}ƀǀ78~9:ɅʅԈɉʉUlm9 .ex #)irsy$%@A|}DE89š)*?@ɝ &9:<IXetuОў 01Ii{ǟٟ.<=V 7FGcr̡ΡС@NOƢԢբ  4_noģţPr~äѤҤ%&?iwxȥإ%3HI_`acef̦ӦԦ/0Nz !gvAB&'Z{|ڪ۪&'FGcd;<@Abc 0156EFJKsu~ۭ2378\]abήϮ\]DEIJӰ԰ذٰOPbc{|TUz{Բղ LMQRhimn˳̳23efԴմٴڴ9:YZȵɵ!)*./UV`jkopǶȶ56_`deϷз!"CDHI_`defgq{|ٸڸ5SU`a?@-.uv\]56'(?@uvxy,-/0#$23pq*+23STvwRSZ['(EFrsz{/067YZ GHNOxyf{|ST4589z{,/12MQST'(34EF_`cdVlmKL_`kl}~]cijk TUXYjknoMNQRabef&'*+KL~            M N l m p q           #$L0000000000000000000000000000000000000000000000000000000000000000000000000000@0 K00@0@0 K00@0 @w0 K00@0K00@0@0 K00n@0@0K00oK00nK00m@0 @0 @0@0 @0@0 @0 @0@0 @0K00@0@0 @0K00@0@0 @0K00@0@0 @0K00 @0@0 @0K0 0 @0@0 @0K00w@0@0 @0K00v@0@0@000@0 @0 00@000@0@0 @0 K040x@0 @0 00@000@0@0 @0 K050x@0 @0 00@0K00d@0@0 00@0K00d@00-0-0-0 -0 -0-0 0 @w0 @w0 @0 @w0 @w0 @0 @w0 @w0 @0 @w0 @0 @0 @w0@0@0 @w0@0@0 @0@0@0@0 0000000000 @0K051%00G@0 @0%00G@0 @0%00G@0 @0%00G@0 @0 %0 0G@0 @0 %0 0 @0 00000000 @0K0N1K0N1@0 @0K0Q1R@0 @000_@0 @000_@0 000000000  000000 @0K00{K00 K0g1K0g1@0 @0@0 @0K0o1pK00{K0o1}K0o1z@0 @0K0 0{K0r1xs@0 00@0@0K0 0{00K0u1vv@0 @0K00{00K0{1t@0 00000000000 0 0 00 00 0 0 0 0v0 0 0 0 0 0v0 0 0 0 0 0v0 0 0 0 0 0v0 0 0 0 0 0v0 0 0 0 0 0v0 0 0 0 0 0v0 0 0 0 0 0v0 0 0 0 0 0v00 0 0 0 0000@0@000 0 0 0 0 0 0@0 @0 K00@0 @0 @0 @0@0 @0 K0k2@0 @0 @0@0 @0 K00@0 @0 @0 @0@X0 @0 K00@0 @0 @0 @0@X0 @0 K00@0 @0 @0 @0@0 @0 K00 @0 @0 @0 @0@0 @0 K0 0 @0 @0 @0 @0@0 @0 K0 0@0 @0 @0 @0@0@0K00@0 @0@0@0@0 @0 K00@0 @0 @0 @00000 0 0 0@0 K00@0 @0@0 K0k2@0 @0@0 K00@0 @0@X0 K00@0 @0@X0 K00@0 @0@0 K00 @0 @0@0 K0 0 @0@0@0 K0 0@0 @0@0K00@0 @0@0 K00@0 @000000000000000 0 0 0 0 00 0 0 0 0 00 0 0 0 0 00 0 0 0 0 00 0 0 0 0 00 00 0 0 0 0 0 0 0 0 0 00 0 0 0 0 00 0 0 0 0 0@0 @0 @0 @0 @0 @0 @0 @0 @0@0@0 @0 @0 @0 @0 @0 @0 @0 @0 @0@0 @0 @0 @0 @0 @0@0 @0 @0 @0 @0 @0@0 @0 @0 @0 @0 @0@0 @0 @0 @0 @0 @0@0 @0 @0 @0 @0 @0@0 @0 @0 @0 @0 @0@0 @0 @0 @0 @0 @0 @0 @0 @0 @0 @0 @0@0 @0 @0 @0 @0 @0@0 @0 @0 @0 @0 @0 @0 @0 @0 @0 @0 @0@0 @0 @0 @0 @0 @0@0 @0 @0 @0 @0 @0@0 @0 @0 @0 @0 @0 @0 @0 @0 @0@0 @0 @0 @0 @0 @0@0 @0 @0 @0 @0 @000000000@0@0@0@0@0@0@0@00000000000000000000000000000000 0 0 0 0 0 0 0 0 0@0 K03n@0@0 K03n@0@0 K03n@0@0 K03n@0@0 K03n@000 0 0 0 0@0 K03n@0@0 K03n@0@0 K03n@0@0 K03n@0@0 K03n@0000 0 0 0 0 0 0 0 0 0@0 K03n@0@0 K03n@0@0 K03rK03qK03pK03n@00000000000000000000000000000000 0 0 0 0 0 0 0 0 0@0 @0 @0 @0 @0 @0 @0@0 @0 @0 @0 @0@0 @0@0 @0 @0 @0@0 @0000000000000000000000000000000000 0 0 00 0 0 0 0 0@0 @0@0@0@0@0 @0@0@0@0@0 @0@0@0@0@0 @0@0@0@0@0 @0@0@0@0 @0@0@0@0@0 @0@0@0@0 @0@0@0@0 @0@0@0@0@0 @0@0@0@0@0@0 @0@0@0@0 @0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0@0 @0@0@0@0@0@0 @0@0@0@0 @0@0@0@0 @0@0@0@0 @0@0@0@0 @0@0@0@0@0@0@0@0@0@0 0000000000ʑ04T*0ʑ04T,*0ʑ04Td*0ʑ04T*0ʑ04TԼ*0ʑ04T *0ʑ04TD*0ʑ04T|*0ʑ04T*0ʑ04T*0ʑ04T$*0ʑ04T\*0ʑ04T*0ʑ04T̾*0ʑ04T*0ʑ04T<*0ʑ04Tt*0ʑ04T*0ʑ04T*0ʑ04T*0ʑ04TT*0ʑ04T*0ʑ04T*0ʑ04T*0ʑ04T4*0ʑ04Tl*0ʑ05T*0ʑ05T*0ʑ05X*ʑ05W ʑ05V ʑ05T 00ʑ0 5 *@0 ʑ05*@0 ʑ05H*@0 ʑ05*@0 ʑ05*@0 ʑ05*@0 ʑ05(*@0 ʑ05`*@0 ʑ05*@0 ʑ05*@0 ʑ05 *@0 ʑ0!5"@*@0 ʑ0#5$x*@0 ʑ0%5&*@0 ʑ0'5(*@0 ʑ0)5* *@0 ʑ0+5,X*@0 ʑ0-5.*@0 ʑ0/50*@0 ʑ0152*@0 ʑ03548*@0 ʑ0556p*@0 ʑ0758*@0 ʑ0:5;*@0Dx(0<5=4*@0Dx(0>5?l*@0Dx(0@5A*@0Dx(0B5C*@0Dx(0D5E*@0Dx(0F5GL*@0Dx(0H5I*@0Dx(0J5K*@0Dx(0L5M*@0Dx(0N5O,*@0Dx(0P5Qd*@0Dx(0R5S*@0Dx(0T5U*@0Dx(0V5W *@0Dx(0X5YD*@0Dx(0Z5[|*@0Dx(0\5]*@0Dx(0^5_*@0Dx(0`5a$*@0Dx(0b5c\*@0Dx(0d5e*@0Dx(0f5g*@0Dx(0h5i*@0Dx(0j5k<*@0Dx(0l5mt*@0Dx(0n5o*@0Dx(0p5q*@0Dx(0r5s*@0Dx(0t5uT*@0Dx(0v5w*@0Dx(0x5y*@0Dx(0z5{*@0Dx(0|5}4*@0Dx(0~5l*@0Dx(05*@0Dx(05*@0Dx(05*@0Dx(05L*@0Dx(00@0Dx(0000@0Dx(00@0Dx( 05H*@0 05*05 05 05 @0 05*@0 05*@0 05$*@0 05\*@0 05*@0 05*@0 05*@0 05<*@0 05t*@0 05*@0 05*@0 05*@0 05T*@0 B3H05*@0 B3H05*@0 05*@0 054*@0 05l*@0 05*@0 05*05 05 05 @0 00000 00ʑ05#*0 ʑ05#*0 ʑ05#*0 ʑ05#,*0 ʑ05#d*0 ʑ05#*0 ʑ05#*0 ʑ05# *0 ʑ05#D*0 ʑ05#|*0 ʑ05#*0 ʑ05#*0 ʑ05#$*0 ʑ05#\*0 000000@00000005t*@ 005*@ 005*@ 005*@ 005T*@ 005*@ 005*@ 0,0ʑ05* 0 ʑ05P* 0 ʑ05* 0 ʑ06* 0 ʑ06* 0 ʑ060* 0 ʑ06h* 0 ʑ0 6 * 0 ʑ0 6 * 0 ʑ06* 0 ʑ06H* 0 ʑ06* 0 ʑ06* 0 ʑ06* 0 ʑ06(* 0 ʑ06`* 0 ʑ06* 0 ʑ06* 0 ʑ06 * 0 ʑ0!6"@* 0 ʑ0#6$x* 0 ʑ0%6&* 0 ʑ0'6(* 0 ʑ0)6* * 0 ʑ0+6,X* 0 ʑ0-6.* 0 ʑ0/60* 0 ʑ0162* 0 ʑ03648* 0 ʑ0566p* 0 ʑ0768* 0 ʑ096:* 0 ʑ0;6<* 0 ʑ0=6>P* 0 0ʑ0@6OA*0 ʑ0B6OC*0 ʑ0D6OE*0 ʑ0F6OGL*0 ʑ0H6OI*0 ʑ0J6OK*0 ʑ0L6OM*0 ʑ0N6OO,*0 ʑ0P6OQd*0 ʑ0R6OS*0 ʑ0T6OU*0 ʑ0V6OW *0 ʑ0X6OYD*0 ʑ0Z6O[|*0 ʑ0\6O]*0 ʑ0^6O_*0 000ʑ0c6dx*0 ʑ0e6f*0 ʑ0g6h*0 ʑ0i6j *0 ʑ0k6lX*0 ʑ0m6n*0 ʑ0o6p*0 ʑ0q6r*0 ʑ0s6t8*0 ʑ0u6vp*0 ʑ0w6x*0 ʑ0y6z*0 ʑ0{6|*0 ʑ0}6~P*0 ʑ06*0 00000000000000@0 ʑ05xĺ@0 00ʑ06*0 ʑ06*0 ʑ06*0 ʑ06,*0 ʑ06d*0 ʑ06*0 ʑ06*0 ʑ06 *0 ʑ06D*0 00000ʑ06*0ʑ06@*0ʑ06x*0ʑ06*0ʑ06*0ʑ06 *0ʑ06 ʑ06 ʑ06 000ʑ06A*0 ʑ06A8*0 ʑ06Ap*0 ʑ06A*0 ʑ06A*0 ʑ06A*0 ʑ06AP*0 ʑ06A*0 ʑ06A*0 ʑ06A*0 ʑ06A0*0 ʑ06Ah*0 ʑ06A*0 ʑ06A*0 ʑ06A*0 ʑ06AH*0 ʑ06A*0 ʑ06A*0 ʑ06A*0 ʑ06A(*0 ʑ06A`*0 ʑ06A*0 ʑ06A*0 ʑ06A*0 ʑ06A@*0 ʑ06D ʑ06C ʑ06A 0 000ʑ06<*K03(wʑ06t*K03(wʑ06*K03(wʑ06*K03(wʑ06*K03(wʑ06T*K03(wʑ06*K03(wʑ06*K03(wʑ06*K03(wʑ064*K03(wʑ06l*K03(wʑ07*K03(wʑ07  ʑ07  ʑ07 K03K03(w}0 K03`w}0 0 $$$'2 VTH)y :bU"|#4$ &&:'((_))*A++9.#/01239556779U:f>A0BBlCDEFTGsHHJ3NaOPQSV^adgNilnVqvz{}߀X7P?ZfQsiV~:FI bMRD` l2t   ! Y07P%PJ V~dd "'*.69>BCEFGHIJKMNOPQRTUVXYZ[\]_`abdkrtvz|}#)07<AEFHJNVY[acnw $+-./4  *dS<wa2cUHw8 !"b""""$`$$$:%%&&R''(I(2))) ***C++.X//0-0S0000?111j23<4j44444 5!5n5o55555B6C6m6n666778@8888@9[99@AB.BVBBBB+CkCC[DD^EEEE0FfFFFFFOGGGGLH}HHH3N^%n{ɏ*T{&zǑʒ/YYMRrѠ?Fzt,QX b4ܺD=t)8':UZy$\(-RW&|*mAL"Jrw6XBs =j"Jsx)Mg 'Gf&+Gn? pPElu+KMST$2T_ag{' - / _ a g p v        5 7 = > x z            - 8 9 0Zay3Az&mH(Gjn#=AERd}Om >$X\n@X\~(\`rZdd    !#$%&()+,-/01234578:;<=?@ADLSW^cefghijlmnopqsuwxy{~     !"$%&'(*+,-./12345689:;=>?@BCDGIKLMOPQRSTUWXZ\]^_`bdefghijklmopqrstuvxyz{|}~    !"#%&'()*,03d;K  KXXXX  '!!l,b$l?xK-}*1j@(  f  c 6A!SHANDONB S  ?sK`8t _Hlt267921118_Hlt267921119 OLE_LINK10 OLE_LINK11_Hlk267059321_Hlk361991755 OLE_LINK8 OLE_LINK9 OLE_LINK6 OLE_LINK7\\N N L@@ aaM^ ^ L'w9T w9D w9TWw94 "w9t "w9 "w9w9w9Dw9w9w9w9Dw9w9w9 w9D w9 w9 w9!w9D!w9!w9!w9"w9D"w9"w9"w9#w9D#w9#w9#w9$w9D$w9$w9$w9$Sx9L%x9%x9%  ~33>/ a a && ) )IIIofofvfBoBoIo|6|^|^|rbb  L     !"#$%&<FF8 i i &&%)%)IIIufzfzfHoMoMo|<|f|f|wgg  L   !"#$%& ; *urn:schemas-microsoft-com:office:smarttagsaddress:*urn:schemas-microsoft-com:office:smarttagsStreet=*urn:schemas-microsoft-com:office:smarttags PlaceType=*urn:schemas-microsoft-com:office:smarttags PlaceNameB"*urn:schemas-microsoft-com:office:smarttagscountry-region8$*urn:schemas-microsoft-com:office:smarttagsCity9&*urn:schemas-microsoft-com:office:smarttagsState9'*urn:schemas-microsoft-com:office:smarttagsplace<*urn:schemas-microsoft-com:office:smarttagschmetcnv>%*urn:schemas-microsoft-com:office:smarttags PersonName D<013.1a Cao ChangqiuFalseHasSpaceNegative NumberType ProductID SourceValueTCSCUnitName'&% $&"' '$&''&'"'"''''''"'"   '"'$V`\c   !!h%n%%%&& &$&N&U&&&"'&'''*'M'T'(() )9)?)@)D)i)p))) *$*%*(*;*B*33:3=3>3D3p3v33344S4Z444D5K55555B6G6667!7N7U7~77777778=8i8o888888849<9a9d9nFvFSHWHHHHHHIIIdJjJJJK#K^OkO>PIPKPVPgPtPvPP ]]*]1]3]5]ofufclmlolxlBoHoqqqq*v3vTZu~V\^ft|X`<D08+3usxagw{28ekp|hnY_kuWd]g%MW_i    ]dw}%%''((*+-.01ILv!  %BZc""Z#\#''99::@JKoLsLvPP2\]eekknnppssttvvO}V} x{   U  %%''((*+-.01IL3333333333333333333333333v<eZo r 3 j vARzh/Cl5qij{UcPz!"} %CZe*g| 8 S b  3!c!~!!!!"I""#6$ %`%%&7&&&M'''(+(Y((( )W))*;*n****t222c3i333333333334 44K4[444.5h555165666677"7=7@7q7t7z7777&8)8/8>8Y8\8b8p8888888889&9'9+9,9=9O9]999YY_`qXq{||}B}S~x~~9cdUm׌Eirs%+7*- <uEV ̡SqPդ&?zȥIahԦ0N&g\/Ksޭ K]3J+ORرٱDkl >&3YZ~/Vkp!з|5U&awm@.E(Y;y0GzFl[]f|E9f,TdF]k Bo;fLth    @       !   %%''((*+-.01IL%%''((*+-.01IL&|qD}NDC~(B* A@eNrޚMr0Liv@KS}@07JZ"%$ A5TV`0 R " H2<,|E;(wh},cgcr >evV %V[S& S, q-4#f\e;7v`R70^62>)X:l@JuEY`Q\F`9 Gt5.RnеiUԽ^ c"V$FB`[z.l2qܸ|#1nrvr{cr+uA>w=<  VD WD8^`. TTVDXWD8^T`. VDWD8^`.   VDWD8^ `. VD WD8^`OJQJo(l TTVDXWD8^T`OJQJo(l VDWD8^`OJQJo(l   VDWD8^ `OJQJo(lhhWD8^h`. hhWD8^h`OJQJo(l ^` CJOJQJaJo(l  ^` OJQJo(n  ^` OJQJo(u b  ^b ` OJQJo(l B  ^B ` OJQJo(n " ^"` OJQJo(u  ^` OJQJo(l  ^` OJQJo(n  ^` OJQJo(uh^h`o(. ^` 0 ^` . ^` .`  ^` ` 0@  ^@ ` .  ^ ` . ^` 0 ^` .--^-`o(()  ^` hH0 e e^e` hH. E  E ^E ` hH. %  % ^% ` hH0  ^` hH.  ^` hH.  ^` hH0  ^` hH.^`OJPJQJ^Jo(- t  ^t ` OJQJo(n T  ^T ` OJQJo(u 4 ^4` OJQJo(l  ^` OJQJo(n  ^` OJQJo(u  ^` OJQJo(l  ^` OJQJo(n  ^` OJQJo(u8^8`o(. \^`\hH) \^`\hH. ` \^` `\hH.  \^ `\hH)  \^ `\hH. L\^L`\hH. \^`\hH) \^`\hH.   ^ ` CJOJQJo(l  ^` OJQJo(n e e^e` OJQJo(u E  E ^E ` OJQJo(l %  % ^% ` OJQJo(n  ^` OJQJo(u  ^` OJQJo(l  ^` OJQJo(n  ^` OJQJo(u8^8`PJo(.  ^` hH0 p ^p` hH. P  ^P ` hH. 0  ^0 ` hH0  ^` hH.  ^` hH.  ^` hH0  ^` hH.hh^h`o(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.9^9`o(() \^`\hH) \^`\hH. a\^a`\hH.  \^ `\hH)  \^ `\hH. M\^M`\hH. \^`\hH) \^`\hH.0^`0o(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.hh^h`PJo(0 H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.JJ^J`PJo(() *\*^*`\hH) \^`\hH. r\r^r`\hH.  \ ^ `\hH)  \ ^ `\hH. ^\^^^`\hH. \^`\hH) \^`\hH.hh^h`o(.  ^` hH0  ^` hH.  ^` hH. `  ` ^` ` hH0 @  @ ^@ ` hH.    ^ ` hH.  ^` hH0  ^` hH. ^` o(hH.  ^` hH0  ^` hH.  ^` hH. `  ` ^` ` hH0 @  @ ^@ ` hH.    ^ ` hH.  ^` hH0  ^` hH.hh^h`o(. ^` 0 ^` . ^` .`  ` ^` ` 0@  @ ^@ ` .   ^ ` . ^` 0 ^` .hh^h`o(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.hh^h`o(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.p^p`PJo(() P\^P`\hH) \^`\hH.  \^ `\hH. < \^< `\hH)  \^ `\hH. \^`\hH. (\^(`\hH) \^`\hH.0^`0PJo(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.^`o(. ^` 0 ^` .   ^ ` .   ^ ` 0v v^v` .V V^V` .6 6^6` 0 ^` .hh^h`o(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.hh^h`PJo(. H\H^H`\hH) \^`\hH. \^`\hH. 4\4^4`\hH)  \ ^ `\hH. | \| ^| `\hH.  \ ^ `\hH) \^`\hH.--^-`o(() ^` 0e e^e` .E  E ^E ` .%  % ^% ` 0 ^` . ^` . ^` 0 ^` .^`PJo(() \^`\hH) @\@^@`\hH. \^`\hH.  \ ^ `\hH) , \, ^, `\hH.  \ ^ `\hH. t\t^t`\hH) \^`\hH.^`PJo(() \^`\hH) %\%^%`\hH.  \ ^ `\hH. m \m ^m `\hH) \^`\hH. \^`\hH. Y\Y^Y`\hH) \^`\hH. ^` PJo(.  ^` hH0  ^` hH.  ^` hH. `  ` ^` ` hH0 @  @ ^@ ` hH.    ^ ` hH.  ^` hH0  ^` hH. ^ `PJo(. d ^d` hH0 D ^D` hH. $  ^$ ` hH.   ^ ` hH0   ^ ` hH.  ^` hH.  ^` hH0  ^` hH. ^` OJPJQJo($   ^` OJQJo(n p ^p` OJQJo(u P  ^P ` OJQJo(l 0  ^0 ` OJQJo(n  ^` OJQJo(u  ^` OJQJo(l  ^` OJQJo(n  ^` OJQJo(u&e;7S&iU`[c"V A5vV %\FR7~}|1nrcr uEq-E;(<0 R Z GA>wl2qS,{cr%.R62>:l@},&&^RJ        Y        N        Lz        U                 |:        Z         TL        ^n                L        m2o                 4S        x,c        *        |d0]        kP                 w                                .#x        ހ        "        Ԙx        V<C qAP k4+>6.} GrP bC ZG_ b*ilbF/x~*0EseWh40p{~,h40+0\Si!xqSwN!EOEb[!.}R"LkW= ,'DZV*KJF4+G4+')Z6.QF.. ^9mMP3go63QF.. 9V* ^9} >:! i:0_LkW=@X](}&>+0'4?WelCc8lEz#3e EOE ,'KJFlbFy`OFG$-_'GZn^wHRM/~aOvRP>\w8QvR(qo.}RuaeMSv }nh2YSRMxKU4+FPhU(}&>seWFPhU uprW8Q')Z}k]DZ>\h2YS@X]uprW}k] 9Zn^i$-_aeMS0_`OFZG_Bv5(a<z#3eb[!We~v\Si> jbc8lEl"v }n(qoHgo>:xq63Gro {u~aOBvi:~v$IlwqAy5(at${z$Ilwo {x~kp{~'4?bSwN!)8|.6 ;4l= e 6?XIWXZy!\0de"S4M;h:C-  ! 5 " $ #: ` %/ u/ @ hn @ _ d9-4bPq9E ;%8<^}1CeUel~ :8HkM$]e3A}89AEEsHT d S>),%o >1 h }p | +!{q!x!1"p"#$A$u|$@C%!S%[d%t%~%0&Ok&l&u&'&S([("v(F|(5)%*E?*p*+ ,\I,- I-4$.9.)/9`/{/-0U0X0_21h1 '2X2!4.4E4)5ua5B5E#6&6]6Z7i8|F8959]>9B9K9e9:`:;=;7 <<B,=I=S=]> > >X>H>X>T,?RG?N^?@@*@+@?@KP@[@e@A&ABAB`B{CD!D{FF`FHIJITIlI 5JMJKlIT}6(+Tln'r^g)m=nqu_)il+g9Yw[Z@w5[[L]=q_^ezt )&;\WXzKo\5bM/' 17<1qm+^\M W&'P\ 3IZ2iIi7vY!U4SdX';DI?VS70^.y&)Opr]x5TAen/t (5:jqs |VCOt"}=TY`ix'x$Y{_ky} n~F %?(.L@f*)WX+Ln_+,9XjV;8?yhx=Cpv7CG*C7}~^c`(7E t :4k |/rSX ]0},~0Gfs*^N+26= {!=2~:) /8 =2;<Er^mUn{2C1Si_ 8FHH9%Z6;?5|x1F}'MnTSy*5O:wm:L{;M4N:YvQfg '56HS^m|}"#9HVhz{f   , 7 8 H b  !!! ! !!*!,!.!0!2!3!c!e!g!k!m!n!u!w!y!{!}!~!!!!!!!!" """"I"U"["g"m"n"""""""# $ $6$S$~$$$$ %%%%% %9%I%U%[%]%_%`%%%%%%%%%%%%%%&7&<&D&I&K&M&N&h&m&u&z&|&~&&&&&&&&& '''''!'"'+';'C'H'J'L'M''''''''(+(Y(i(j(p(|((((((((((( ))) )W)_)h)i)))))))))*** *)*1*:*;*n*v****t2y222222222222 3 3 3 333 3)3-3135363E3\3`3d3h3i3w3333333333333344 4 44>4B4F4J4K4[4444444.52565:5;5L5555555165696=6>6X666666666666666666677 777"797=7A7E7F7V7m7q7u7y7z77777777777777777777"8&8*8.8/8>8U8Y8]8a8b8p88888888888889#9'9+9,9=9O9S9X9\9]9i9{99999999999R:?f*{{{{{{{{{{{{||%|-|5|6|=|E|M|U|]|^|g|o|w||||||||||||||||||}B}Y}Z}n}}}}}}}}}}~(~=~R~S~x~~~~~~~~~~9?Pbcdsx )89P_n}~: .exƌȌ׌ #)79Eirsy&9:<IXetuОў 01IZi{ǟٟ.<=VesàѠ (7FGcpr̡ΡС%2@NOƢԢբ  4BO_noģţP[fr~äѤҤ %&?M[iwxȥ֥إ#%3HI_`acefƦ̦ӦԦ/0N\jz !gtv'Z[\b{|}~ĪƪЪڪ۪&'9:@FGTU\cdst|֫׫./5;<=>?@ASU\bcvx #$*012345678?EFGHIJKsu~ۭܭݭޭ&2345678NOV\]^_`abˮ̮ͮήϮ JKS\]12:DEFGHIJưǰͰӰ԰հְװذٰڰ۰)*+1>OPQRZbcdeq{|}~رٱCDLTUklsz{òIJ̲Բղ =>ELMNOPQRST^hijklmn}~ij˳̳%&,23XY_efvw}ôĴ̴Դմִ״شٴڴ۴ܴ ')19:LMSYZ}~µȵɵԵյݵ!)*+,-./UV`jklmnopǶȶ !+56PQX_`abcders}·÷ɷϷз!"23;CDEFGHIJKU_`abcdefgq{|}&`awm!?@d-.Euv@X&;uvwxy,-./0Gxy  !"#$,-./0123DLT\dfpq"#*+,-./0123GHIJKLSTijklmnvw4CZw *08>FPRSTUVWXYZ[bjrz'(6789:;EFghijklrstuvwxyz{234IWm#$%&'/01234567KLMNOYZ]{|} %-5=GHIJKLMNOlmnopxyz{|}~|ELST{&-456789fpz{,/12MQST'().345=EFGS_`abcdEF_`afklmu}~]cijk BKTUVWXYZbjklmno;DMNOPQRSZabcdef&'()*+;CKLtz~g h v                       @ F M N _ e l m n o p q r z               >"#$L=Zswe8l%['' qG}tYZ7G}t%!A-0!A-0==!77a2@| '!Hvv GHCJCK3]3^33::aaZ  K`@` `@``$@``0@`"`$`&`P@`X`@`\`@`p`@``d@``l@``@` @`` @` @UnknownGz Times New Roman5Symbol3& z ArialKE  DFKai-SBPMingLiU;[SOSimSunC .PMingLiUe0}fԚ9: ZWAdobeF3Times] Times-BoldTimes New Roman_ Times-RomanTimes New RomanUSimSunTimes New Roman?5 .MingLiU0}fԚ;ўSOSimHei?5 z Courier New[DFPFangSongW4-B5PMingLiU?A eckwiSO_GBKўSOGTimes LT Std[SO;Wingdings F!'Q(Q(!xxd**2qHX?O2 2006 ANNUAL RESULTS ANNOUNCEMENTWonderful SkyhggSf&                           ! " # $ % Oh+'0(8 HT t  $2006 ANNUAL RESULTS ANNOUNCEMENTWonderful Sky$generated by an Adobe applicationNormal417Microsoft Office Word@jq@NՀ@D[3-@Fk Q(՜.+,D՜.+,  `h Wonderful Sky'  8@ _PID_HLINKSARF http://www.cninfo.com.cn/V?mailto:xhzy@xhzy.comVOGhttp://www.xhzy.com/VyPmailto:guolei@xhzy.comV  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrtuvwxyz|}~Root Entry F7)Data K1TableMWordDocumentSummaryInformation(sDocumentSummaryInformation8{CompObjm  FMicrosoft Office Word ĵ MSWordDocWord.Document.89q